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III. Abstract / Zusammenfassung 
 
Truncating or nonsense mutations in the ubiquitously expressed tumour suppressor and BAF 
chromatin remodelling complex core subunit gene SMARCB1 cause malignant rhabdoid tumours 
(MRTs) of the brain, the kidney, and the soft tissues. MRTs show a high clinical variance despite a 
simple cancer genome with SMARCB1 being the only gene recurrently mutated in these malignancies. 
MRTs of the brain are called atypical teratoid/rhabdoid tumours (AT/RT) and present a rare, but 
highly aggressive brain tumour entity with poor prognosis that predominantly occurs in very young 
children. In this thesis, diverse constructs for the generation of three-colour reporter cell lines with 
SMARCB1 mutations found in AT/RTs were established and methods required for the 
CRISPR/Cas9-mediated genome engineering using these constructs were optimised. Heterozygous 
missense mutations or small in-frame deletions clustering in the last two exons of the SMARCB1 gene 
are frequently observed in another disease entity, Coffin-Siris syndrome (CSS). CSS is a congenital 
neurodevelopmental disorder characterised by cognitive impairment, microcephaly, coarse facial 
features, and hypoplasia of the fifth finger- and/or toenail as well of the distal phalanx of the fifth 
finger and/or toe. CRISPR/Cas9 constructs for the generation of hiPSC and MCF10A cell lines with 
heterozygous c.1091_1093del AGA SMARCB1 mutation were generated to investigate the cellular 
consequences of this mutation. Comparison of cellular AT/RT and CSS models would contribute to a 
better understanding of how different types of SMARCB1 mutations can lead to two very different 
diseases and how particular mutations affect the gene expression of SMARCB1 itself. 
The recently published mouse model recapitulating SMARCB1-associated features of CSS, which is 
based on a partial loss-of-function of Smarcb1, revealed a diminished pool of neural progenitor cells 
(NPC) in the developing brain of these mice. To test the hypothesis if overexpression of Hes5 can 
rescue the impairment of mouse neural stem cell (NSC) maintenance, a lentiviral system for the 
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SMARCB1 ist ein ubiquitär exprimiertes Tumorsuppressorgen und kodiert eine Kernkomponente der 
chromatinremodellierenden BAF Komplexe. Inaktivierende Mutationen des SMARCB1-Gens sind die 
einzige wiederkehrende genetische Veränderung in malignen rhabdoiden Tumoren (MRT) des 
zentralen Nervensystems, der Niere und weicher Gewebe. MRTs des Gehirns werden atypische 
teratoide/rhabdoide Tumore (AT/RTs) genannt und betreffen vorwiegend sehr junge Kinder. In 
dieser Arbeit wurden verschiedene Konstrukte erstellt um mit Hilfe der CRISPR/Cas9-Technologie 
Zelllinien mit drei Fluoreszenzreportern und Inaktivierung des SMARCB1-Gen zu erstellen. 
Methoden, die für diese CRISPR/Cas9-vermittelten Veränderungen im Genom benötigt werden, 
wurden etabliert und optimiert. Der Austausch oder Verlust einzelner Aminosäuren in der C-
terminalen Region des SMARCB1-Proteins ist mit der Manifestation des Coffin-Siris Syndroms (CSS) 
assoziiert. Das CSS ist eine angeborene Entwicklungsstörung, die durch Verzögerungen in der 
geistigen Entwicklung, Mikrozephalie, und Hypoplasie des Nagels des kleinen Fingers und/oder Zehs 
sowie des letzten Gliedes des kleinen Fingers und/oder Zehs charakterisiert ist. Die am häufigsten 
auftretende Mutation des SMARCB1-Gens bei CSS ist die heterozygote Deletion des Lysin-
codierenden Tripletts an Position 364 (c.1091_1093del AGA). In dieser Arbeit wurden CRISPR/Cas9-
Konstrukte für das Einbringen dieser Mutation in hiPSC und MCF10A-Zellen entwickelt. Mit Hilfe 
dieser Zellmodelle wird es möglich sein, die durch die Mutation des SMARCB1-Gens veränderten 
zellulären Prozesse und deren Auswirkung besser zu untersuchen. Der Vergleich von Zellmodellen 
für AT/RTs und für das CSS kann dazu beitragen, besser zu verstehen wie unterschiedliche 
Mutationen desselben Gens zu verschiedenen Erkrankungen führen können und welchen Einfluss 
diese Mutationen auf die Genexpression von SMARCB1 haben.  
Bei dem kürzlich veröffentlichten Mausmodell, das SMARCB1-assoziierte Charakteristika von CSS 
rekapituliert und auf einem partiellen Funktionsverlust von Smarcb1 beruht, wurde eine reduzierte 
Zahl an neuralen Vorläuferzellen (NPCs) während der Gehirnentwicklung festgestellt. Um zu 
überprüfen, ob die Überexpression von Hes5 die durch Mutation des Smarcb1-Gens verursachte 
Reduktion neuraler Stammzellen (NSCs) ausgleichen kann, wurde ein lentivirales System zur 
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1. Introduction 
 
1.1. The tumour suppressor gene SMARCB1 
SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1 -  
SMARCB1 (also known as BAF47, INI1, SNF5) is a bona fide tumour suppressor gene located on the 
long arm of chromosome 22 (22q11.23), and truncating mutations of the SMARCB1 gene are the main 
recurrent event causing malignant rhabdoid tumours in various organs (Wang, Cote et al. 1996, 
Versteege, Sevenet et al. 1998, Biegel, Zhou et al. 1999, Jackson, Sievert et al. 2009). The gene spans 
approx. 50 kb on Chr.22q11.23 and contains nine exons coding for two isoforms (a 385 amino acids, 
b 376 amino acids) of a ubiquitously expressed nuclear protein of approx. 44 kDa which is highly 
conserved from humans to Caenorhabditi elegans and Drosophila melanogaster (Versteege, Sevenet et al. 
1998). The C-terminal SNF5 domain is even conserved to Saccharomyces cerevisiae (Muchardt, Sardet 
et al. 1995, Wang, Xue et al. 1996).  This conservation led to the identification of the SMARCB1 
protein as a human homolog to yeast Snf5 binding to HIV-1 integrase (Kalpana, Marmon et al. 1994, 
Muchardt, Sardet et al. 1995, Wang, Cote et al. 1996, Wang, Xue et al. 1996, Versteege, Sevenet et al. 
1998). SMARCB1 is a core component of the highly conserved mammalian SWI/SNF or BAF 
chromatin remodeling complexes (Phelan, Sif et al. 1999). SMARCB1 was shown to be essential for 
early development in mice and neural differentiation of human embryonic stem cells (Klochendler-
Yeivin, Fiette et al. 2000, Langer, Ward et al. 2019). The SMARCB1 protein contains a N-terminal 
winged-helix domain, which was originally identified as a putative DNA binding domain, and a C-
terminal domain (CTD), the SNF5 domain, which contains two imperfect tandem repeat domains 
(RPT1 and RPT2), a coiled-coil domain and an arginine and lysine-rich, positively charged region, a 
hot-spot for mutations associated with Coffin-Siris syndrome (CSS) (Kalpana, Marmon et al. 1994, 
Muchardt, Sardet et al. 1995, Morozov, Yung et al. 1998, Tsurusaki, Okamoto et al. 2012, Allen, 
Freund et al. 2015, He, Zhang et al. 2019). CSS-associated mutations mainly affect the arginine and 
lysine residues in this positively charged cluster resulting in a reduction of the positive charge of this 
region, either by amino acid exchanges or a shift in the secondary structure resulting in the burial of 
the positively charged amino acids. This reduction of the positive charge in the C-terminal region of 
SMARCB1 weakens the binding of the SMARCB1 protein to the acidic patch of the nucleosome 
(Valencia, Collings et al. 2019, He, Wu et al. 2020). Figure 1 summarises and graphically depicts the 
structural characteristics of the SMARCB1 gene and protein.  
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Figure 1: Graphical summary of the structural characteristics of the human SMARCB1 gene and protein. (A) The human 
SMARCB1 gene locates to the long arm of chromosome 22 (Chr.22q11.23) and stretches over 50 kb (exons black boxes, introns 
black lines). (B) The nine exons of the coding sequence translate to 385 amino acids in isoform a. Isoform b is generated by 
alternative splicing and lacks nine amino acids at the 3’ end of exon 2 (376 amino acids). Nucleotide positions of each exon’s 
first base are indicated above the coding sequence. (C) The amino acid sequence forms an approx. 44 kDa protein with 
specifically structured N- and C-terminus. N-terminally, human SMARCB1 protein folds into a winged helix and is C-
terminally characterised by two imperfect repeat domains (RPT1 and RPT2) as well as a coiled coil domain which contains a 
lysine and arginine-rich, positively charged cluster (    ). Amino acid positions of each structural component are indicated above 
the SMARCB1 protein depiction. 
 
1.2. BRG1-associated factor (BAF) complexes 
BRG1-associated factor (BAF) complexes are 2.2 MDa ATP-dependent chromatin remodeling 
complexes composed of up to 15 subunits (Wang, Cote et al. 1996, Wang, Xue et al. 1996, Kadoch, 
Hargreaves et al. 2013). BAF complex core subunits show high homology to the nucleosome 
remodeling Swi/Snf complexes originally identified in genetic screens in yeast (Wilson and Roberts 
2011). In these screens several genes were identified, which result in similar phenotypes upon knock-
out. One affected phenotype was the sucrose metabolism and genes causing a sucrose non-fermenting 
phenotype upon knock-out were named Snf genes (Neigeborn and Carlson 1984). The second group of 
knocked out genes were required for the activation of HO for mating type switching in yeast and, thus 
were termed Swi genes (Stern, Jensen et al. 1984). Compared to the mammalian BAF complexes, the 
Swi/Snf complexes are small and their transcription regulatory competences are limited to 
transcriptional activation. The latter is comprehensible considering the remarkably less complex 
regulatory structure of the yeast genome compared to the extent of regulatory elements present in the 
highly repressed mammalian genome. Therefore, the functions of BAF complexes in mammalian cells 
are more diverse than in yeast including transcriptional activation and repression of genes in an 
orchestrated manner (Alfert, Moreno et al. 2019). The subunits of the BAF complexes contain DNA- 
and/or histone-binding domains such as zinc fingers, AT-hooks, chromo- and bromodomains. 
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Therefore, the complexes can recognise binding sites based on DNA sequence, architectural 
characteristics, and pre-existing histone modifications (Alfert, Moreno et al. 2019). The BAF 
complexes couple chromatin state, histone modification, transcription factor binding, and ATP-
dependent chromatin remodeling, mechanisms involved in the regulation of transcription. In general, 
mammalian BAF complexes are composed of more subunits than their yeast counterpart to fulfil these 
diverse functions. Additionally, most of the subunits present in mammalian BAF complexes are 
encoded by gene families, which further increase the observed and assumed diversity of BAF complexes 
found in mammalian cells (Wu, Lessard et al. 2009). So far, three distinct basic BAF complexes have 
been identified in mammalian cells: the canonical BAF complex (cBAF), the polybromo-associated BAF 
complex (PBAF), which is supposed to be highly related to the yeast RSC nucleosome remodeling 
complex, and most recently the non-canonical BAF complex (ncBAF) (Cairns, Lorch et al. 1996, Wang, 
Cote et al. 1996, Xue, Canman et al. 2000, Alpsoy and Dykhuizen 2018, Wang, Wang et al. 2019). 
These complexes differ in their subunit composition. cBAF and PBAF share the highly conserved core 
complex subunits SMARCB1 (BAF47), BAF155 (SMARCC1), and BAF170 (SMARCC2) in 
combination with one of the two mutually exclusive ATPase subunits BRM (BAF190B, SMARCA2, 
homolog of D. melanogaster Brahma) or BRG1 (BRM protein-like 1, BAF190, SMARCA4) 
(Figure 2B, C) (Phelan, Sif et al. 1999). Both complexes also differ in some subunits: PBAF-complexes 
specifically include BAF200 (ARID2), BAF180 (polybromo-BRM1, PBRM1), BAF45a (PHF10), and 
BRD7 subunits (Wang, Cote et al. 1996, Middeljans, Wan et al. 2012, Alfert, Moreno et al. 2019). The 
ncBAF differs more profoundly from cBAF and PBAF. It contains some distinctive subunits such as 
GLSTR1, BRD4 and BRD9, but lacks many of the core BAF subunits as well as some of the PBAF-
specific subunits, namely SMARCB1, BAF57, BAF250, BAF180, BRD7 (Figure 2A) (Alpsoy and 
Dykhuizen 2018, Alfert, Moreno et al. 2019, Wang, Wang et al. 2019). These three basic BAF 
complexes already exemplify how the combinatorial assembly ensures complex variety and specificity 
and by this might allow regulation of mammalian gene expression. It was assumed that expression of 
unique subunits, leading to BAF complexes of diverse composition, represents a major contribution to 
the regulatory process of gene expression by these complexes via the binding to and coordination with 
tissue-specific transcription factors (Alfert, Moreno et al. 2019). 
Indeed, complexes specific to tissues or biological functions have been identified e.g. in the context of 
neural development and function, heart development, muscle development, and maintenance of 
embryonic stem cell pluripotency (Alfert, Moreno et al. 2019). How orchestrated exchange of paralog 
BAF complex subunits changes the cellular properties was intensively studied in neural development, 
and can be used as an example for the epigenetic control of chromatin accessibility and gene expression 
by BAF complexes. In mouse embryonic stem cells (mESCs), the esBAF complex was identified to be 
required for maintenance of pluripotency, proliferation, and self-renewal in the context of a genome 
characterised by a high number of bivalent domains (Figure 2D). Exertion of these cell type-specific 
functions is dependent on the esBAF specific subunits Brg1, BAF250a, and especially a BAF155 
homodimer in mice (Ho, Ronan et al. 2009). In hESCs, a BAF170::BAF155 heterodimer was shown to 
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be required to maintain pluripotency (Zhang, Li et al. 2014). In this latter example also a human to 
mouse species difference in the BAF complexes adds to the general tissue-specific diversity of BAF 
complexes. For the neural development in mice, the commitment of mESCs to neural progenitor cells 
(NPCs) coincides with the initiation of the transcription of Brm and BAF170 (Ho, Ronan et al. 2009, 
Narayanan and Tuoc 2014). In combination with the neural progenitor BAF complex (npBAF) specific 
subunits BAF45a/d (PHF10/DPF3), BAF53a (ACTL6A), and SS18 the self-renewal and proliferation 
of NPCs is maintained (Figure 2E) (Lessard, Wu et al. 2007, Alfert, Moreno et al. 2019). Since the 
NPC population shows heterogeneous molecular characteristics, e.g. differences in gene expression of 
early and late progenitors or NPCs with lower or upper neuronal fate, which are regulated by the 
sequential activation or repression of transcription factors, the combinatorial assembly of BAF 
complexes is also heterogeneous (Narayanan and Tuoc 2014). The npBAF depicted in Figure 2E thus 
is only one of several BAF complex combinations found in NPCs. Mitotic exit of NPCs and thus 
development to post-mitotic neurons is accompanied with the exchange of npBAF-specific subunits 
for their paralogs: BAF45b/c, BAF53b, and CREST to generate the nBAF complex (Figure 2F) 
(Staahl, Tang et al. 2013). The compositional switch in the BAF complex causes a switch in the 
proliferative capacity of the cells further highlighting the role of BAF complex-mediated regulation of 
chromatin and gene expression in neural development (Staahl, Tang et al. 2013).  
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Figure 2: Combinatorial BAF complex composition facilitates tissue-specific regulation of chromatin and gene expression. 
(C) The canonical BAF complex (cBAF) is depicted in the centre. It is highly related to yeast Swi/Snf nucleosome remodeling 
complexes and is considered the basic state of the BAF complex. Alterations in subunit composition in the other BAF 
complexes are highlighted in different colours. Aside from the cBAF complex, there are two other, distinct, basic BAF 
complexes. (A) The non-canonical BAF complex (ncBAF) was recently discovered. Its subunit composition differs remarkably 
from the previously known cBAF and polybromo-associated BAF (PBAF) complexes and lacks several of the cBAF and PBAF 
core subunits. ncBAF complexes contain several new, and ncBAF defining subunits as GLSTR1, BRD4, and BRD9 (light grey 
colour indicates likely incorporated subunits or predicted position of a defining subunit, spaces indicate yet unidentified subunit 
equivalents to the cBAF complex). (B) The polybromo-associated BAF complex (PBAF) was identified early in BAF complex 
research, and is thought to be related to the yeast RSC complex. The PBAF complex contains several defining subunits as 
BAF180 (PBRM1), BRD7, BAF200, and BAF45a. Its assembly is also cell type-specific and thus facilitates specific biologic 
functions (not covered in detail here). (D-F) The mammalian neural development is a well-studied example of how 
specification of BAF complexes is achieved by distinct combinatorial assembly and by this drives the development of a specific 
cellular lineage. Here, the cBAF complex composition of ESCs developing into neuronal cell types is depicted. Upon neural 
cell fate commitment, the esBAF changes to the npBAF complex by incorporation of the SS18 subunit, the paralog exchange 
of BAF60a/b to BAF60c, and for murine development only, the incorporation of BAF170 to form BAF155::BAF170 
heterodimers. Further commitment to neuronal cell types and mitotic exit in post-mitotic neurons is associated with paralog 
exchanges of BAF53b, BAF45b/c, and CREST to generate nBAF complexes from the npBAF. The heterogeneous NPC 
population was also found to express a variety of subtype-specific BAF complexes. The depicted BAF complex assembly in 
neural development is only one example of how BAF complexes facilitate cell type-specific development by gene expression 
control. (Ho, Ronan et al. 2009, Wu, Lessard et al. 2009, Zhang, Li et al. 2014, Kadoch and Crabtree 2015, Michel, D'Avino 
et al. 2018, Alfert, Moreno et al. 2019, He, Wu et al. 2020, Johann 2020) 
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After describing how the different subunits of BAF complexes are associated with cell type-specific 
gene expression, the mechanism of BAF complex-mediated ATP-dependent chromatin remodeling is 
addressed in the following section. In yeast, the nucleosomes are mobilised and moved across DNA to 
activate gene expression (Imbalzano, Kwon et al. 1994, Kwon, Imbalzano et al. 1994). This activity 
was found to be reconstituted in vitro by combination of the BAF core complex consisting of one 
ATPase subunit, SMARCB1, BAF170, and BAF155 (Phelan, Sif et al. 1999). Since BAF complexes 
contain up to 11 more subunits, this mechanism cannot be entirely sufficient to explain all actions 
exerted by mammalian BAF complexes. For BAF complex-mediated chromatin remodeling, two 
different mechanisms were suggested: nucleosome sliding or nucleosome ejection/insertion (Wilson 
and Roberts 2011). ATP-dependent nucleosome sliding is hypothesised to include DNA looping by 
formation of new contacts to histones and sliding of the nucleosome along the DNA via the translocase 
activity of ATPases (Wilson and Roberts 2011, Alfert, Moreno et al. 2019). Recently, the crystal 
structure of the nucleosome-bound human BAF complex was resolved (Figure 2) (He, Wu et al. 2020). 
The nucleosome is sandwiched between the catalytic ATPase subunit and the C-terminal domain of 
SMARCB1 (Han, Reyes et al. 2020, He, Wu et al. 2020). This clasping structure fits well with the 
proposed model of nucleosome sliding and ejection designed by Clapier, Iwasa et al. (2017). In this 
model, the ATPase subunit couples itself to the nucleosome octamer, and the ATPase-translocase 
domain consisting of two RecA-like lobes translocates the DNA one to two basepairs per ATP-
hydrolysis along the surface of the nucleosome. Thereby, DNA tension on both sides of the translocase 
domain is generated which is resolved by sequential nucleosome-DNA contact disruption and 
nucleosome sliding. Ejection of nucleosomes is predicted to take place upon collision of the BAF 
complex-bound nucleosome with an adjacent histone octamer resulting in the DNA being peeled off 
the adjacent octamer. In this scenario, coupling activity to the nucleosome and ATPase activity are 
rather low. However, BAF complexes can also exhibit high coupling and ATPase activity leading to 
efficient and forceful DNA translocation, and eventually resulting in simultaneous rupture of several 
histone-DNA contacts. This rupture destabilises the histone octamer and causes nucleosome ejection. 
In both scenarios, BAF complex targeted regions of the genome potentially get depleted in 
nucleosomes, and thus get accessible for transcription factors or the transcriptional machinery 
resulting in activation of gene expression (Clapier, Iwasa et al. 2017, He, Wu et al. 2020). 
Aside from regulating the accessibility of chromatin, i.e. nucleosome occupation, BAF complexes also 
play a role in the regional regulation of histone methylation. The BAF versus PRC2 (polycomb 
repressive complex 2) opposition is a well-studied example. The PRC2 subunits EZH1 and EZH2 are 
the only mammalian enzymes known to deposit the repressive chromatin mark of trimethylation of 
lysine residue 27 in histone H3 (H3K27me3) (Alfert, Moreno et al. 2019). mESCs show a decrease in 
the H3K27me3 chromatin mark at BAF complex-repressed genes and elevated levels of H3K27me3 
marks at BAF complex-activated genes upon loss of Brg1 or its ATPase domain, while the expression 
of PRC2 and the genome wide H3K27me3 levels remain unaltered. The phenotype caused by loss of 
Brg1 gene expression can be rescued by knock-down of another PRC2 subunit (Ho, Miller et al. 2011). 
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Furthermore, recruitment of BAF complexes to the Oct4 gene locus removes PRC2 complexes and 
H3K27me3 histone marks and vice versa. Thus, the opposition between BAF and PRC2 complexes 
plays an important role in the balance of methylation of histone H3 and, again, chromatin accessibility 
(Wu, Lessard et al. 2009, Helming, Wang et al. 2014, Alfert, Moreno et al. 2019). 
Considering the importance of cell type- and developmental stage-specific BAF complexes in neural 
development the association of mutations in BAF subunit genes with neurodevelopmental disorders is 
plausible (Alfert, Moreno et al. 2019). Additionally, the tissue-specificity of BAF complex assembly 
links the BAF complexes to cancer. Dependent on the affected BAF complex subunit, a variety tissues 
are affected by a distinct subset of cancers (Alfert, Moreno et al. 2019). In total, 20% of human cancers 
harbour mutations in BAF complex subunit genes (Kadoch and Crabtree 2015). 
 
1.3. Diseases associated with mutations affecting the SMARCB1 gene 
As described above, a key role of BAF complexes is to regulate the balance between stem cell states 
and more mature cell states during development (Masliah-Planchon, Bieche et al. 2015). Among the 
BAF complex-regulated genes, many are associated with cancer. BAF complexes, for example, are 
involved in downregulating the expression of the cyclin-dependent kinase inhibitor p16INK4A, in 
repressing RB target genes including the E2F factor, promote c-MYC oncogene-mediated 
transactivation, and in inducing aberrant activation of Sonic Hedgehog (SHH) signalling by 
interaction with GLI1 (Cheng, Davies et al. 1999, Versteege, Medjkane et al. 2002, Isakoff, Sansam et 
al. 2005, Jagani, Mora-Blanco et al. 2010). Additionally, BAF complexes contribute to invasion and 
metastasis by control of genes involved in cellular adhesion and motility (Caramel, Quignon et al. 
2008). The fact that chromatin remodelling by BAF complexes plays a role in many different cellular 
processes is also related to their cooperation with various transcription factors (Masliah-Planchon, 
Bieche et al. 2015). 
Involvement of BAF complexes in tumorigenesis was first observed in malignant rhabdoid tumours 
(MRTs). MRTs are aggressive tumours with an exceptional low mutational burden mainly affecting 
very young children. They were initially histologically defined by the presence of rhabdoid cells and 
of cells of all three germ layers (Figure 3A) (Burger, Yu et al. 1998, McKenna, Sansam et al. 2008). 
Rhabdoid cells possess a prominent nucleolus, uncondensed chromatin, and characteristic cytoplasmic 
eosinophilic inclusions consisting of whorls of intermediate filaments (Masliah-Planchon, Bieche et al. 
2015). MRTs can be found in various organs, e.g. the kidney, soft tissue, liver, or the brain, but are 
considered one tumour entity due to the common histological features as well as loss of expression of 
SMARCB1 (Masliah-Planchon, Bieche et al. 2015). Aside from MRTs, somatic loss of SMARCB1 
expression can give rise to a broader spectrum of tumours, e.g. choroid plexus carcinoma, meningioma, 
ependymoma, malignant glioma, epithelioid malignant peripheral nerve sheath tumours, epithelioid 
sarcomas, sinonasal carcinomas, paediatric hepatoblastomas, or cribriform neuroepithelial tumours 
(CRINET) (Strother 2005, Masliah-Planchon, Bieche et al. 2015). 
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This thesis focuses on MRTs of the central nervous system, so-called atypical-teratoid/rhabdoid 
tumours (AT/RTs). AT/RTs are highly aggressive brain tumours occurring predominantly in very 
young children with 75% of the patients being younger than three years of age at diagnosis (Strother 
2005). They represent only 1 to 2% of paediatric brain tumours, but 10% of tumours of the central 
nervous system (CNS) in infants (Biegel 2006). Despite aggressive therapy approaches and 
advancement in treatment options, the diagnosis of an AT/RT is still fatal for most affected children 
(Schrey, Carceller Lechon et al. 2016). Most AT/RT patients exhibit somatic mutations of both 
SMARCB1 alleles resulting in complete loss of its protein and 25 to 30% of affected children are 
carriers of germline mutations of the SMARCB1 gene (Bourdeaut, Lequin et al. 2011, Eaton, Tooke et 
al. 2011). Most of the germline mutations are de novo mutations linked to gonadal or early post-zygotic 
mosaicism, but there are rare cases of the rhabdoid tumour predisposition syndrome 1 (RTPS1) in 
which families are affected by MRTs and schwannomas due to inherited germline mutations of the 
SMARCB1 gene (Ammerlaan, Ararou et al. 2008, Masliah-Planchon, Bieche et al. 2015, Sredni and 
Tomita 2015). Upon the development of mouse models for AT/RTs, constitutional loss of Smarcb1 
was shown to be early embryonic lethal in mice. Smarcb1+/- mice compensate for the loss of one allele 
by upregulation of the transcription from the remaining wildtype allele of Smarcb1, but are susceptible 
to develop MRTs in soft-tissues or in the head upon loss of the wildtype allele of Smarcb1 (Klochendler-
Yeivin, Fiette et al. 2000, Roberts, Galusha et al. 2000, Guidi, Sands et al. 2001, Guidi, Veal et al. 2004). 
Conditional knock-out of the Smarcb1 gene in Smarcb1flox/- mice by Cre recombination in early 
embryonic development circumvents the embryonic lethality and results in highly penetrant and 
unprecedented rapid tumour formation within 11 weeks (Roberts, Leroux et al. 2002). Timely 
controlled biallelic inactivation of the Smarcb1 gene by Cre recombination upon tamoxifen treatment 
revealed that loss of Smarcb1 expression at an early developmental stage in which stem cells start to 
differentiate into specified progenitors (embryonic day 6 to 10) causes intracranial tumours with 
rhabdoid tumour-like characteristics (Han, Richer et al. 2016). These findings in mice support the 
notion of SMARCB1 being a tumour suppressor gene, and correspond to the rarity of RTPS1, the 
young age of tumorigenesis observed in patients suffering from AT/RTs, and hint to the clinical 
heterogeneity observed in AT/RT cohorts. This heterogeneity is unexpected considering the very 
simple tumour genome observed in AT/RTs with inactivation of SMARCB1 being the only recurrent 
event in these tumours aside from very rare cases with mutations in the ATPase subunit 
BAF190/BRG1 (Fruhwald, Hasselblatt et al. 2006, Hasselblatt, Nagel et al. 2014). Definition and 
characterization of the biological heterogeneity of AT/RTs may help to understand how tumour 
biology shapes the response and treatment outcome of these tumours, and thus to improve the 
currently poor prognosis for AT/RT patients (Ho, Johann et al. 2020). Two groups independently 
analysed AT/RT cohorts and each identified three distinct subgroups of AT/RT based on 
clinicopathological findings, DNA methylation, and gene expression studies (Torchia, Picard et al. 
2015, Han, Richer et al. 2016, Johann, Erkek et al. 2016, Torchia, Golbourn et al. 2016). In order to 
define a standard subgrouping scheme similar to schemes which have been proven beneficial for the 
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treatment of other childhood brain cancers such as medulloblastoma, a meta-analysis of a large cohort 
of individual AT/RT cases was conducted (Ho, Johann et al. 2020). Based on DNA methylation, gene 
expression profiling, and gene set enrichment analyses three distinct subgroups of AT/RT were 
defined: AT/RT-SHH, AT/RT-TYR, AT/RT-MYC (Figure 3B) (Ho, Johann et al. 2020). 
AT/RT-SHH subgroup tumours are characterised by overexpression of SHH and NOTCH pathway 
members (GLI2, PTCHD1, BOC, or ASCL1, HES1, DTX1). Overexpression of the SHH marker genes 
appears to be activated directly or indirectly by loss of SMARCB1 gene expression. The lack of this 
effect in the other subgroups may hint to a different cellular origin of the tumours. This notion is 
supported by AT/RT-SHH tumours showing features of neuronal differentiation while AT/RT-TYR 
and –MYC subgroups show rather mesenchymal characteristics. AT/RT-SHH tumours mostly 
exhibit inactivation of the SMARCB1 gene by heterozygous point mutations and are mainly found in 
patients of an intermediate age group (median age at diagnosis 20 months). DNA methylation analysis 
shows some level of heterozygosity within this subgroup and reveals two subtypes associated with 
either supratentorial or infratentorial tumour localisation. (Ho, Johann et al. 2020) 
The AT/RT-TYR subgroup is mainly characterised by the overexpression of tyrosinase (TYR) and 
the upregulation of components of the melanosomal pathway. Additionally, the bone morphogenetic 
protein pathway (BMP) and developmentally related transcription factors as orthodenticle 
homeobox 2 (OTX2) are upregulated in AT/RT-TYR tumours. Gene set enrichment analyses show 
overexpression of genes of the melanosomal pathway, the tyrosine metabolism, and epithelial 
proliferation indicating a neuroectodermal origin of these tumours. In general, AT/RTs of the 
AT/RT-TYR subgroup affect a younger patient group (median age at diagnosis 12 months) with the 
highest proportion of patients younger than three years. Tumours of the AT/RT-TYR subgroup are 
mostly located infratentorially, and predominantly show whole or partial loss of one copy of 
chromosome 22 in combination with an inactivating e.g. point mutation in the SMARCB1 sequence of 
the second allele. Compared to the other subgroups, and corresponding to the youngest age group 
affected, the tumours show a more open chromatin structure suggesting a more primitive epigenetic 
landscape. Also, CRINETs are reported to exhibit a DNA methylation pattern similar to AT/RT-
TYR and express TYR. This raises the possibility that CRINETs and AT/RT-TYR may be two 
histological variants of a tumour with a common cell of origin. (Ho, Johann et al. 2020)  
Elevated expression of the MYC oncogene as well as overexpression of several HOX cluster genes 
characterizes the AT/RT-MYC subgroup and distinguishes it from the AT/RT-TYR group. 
AT/RT- MYC tumours mainly arise upon a homozygous broad loss of the SMARCB1 gene covering 
several hundred kilobase pairs. Similar to the AT/RT-TYR subgroup, tumours of the AT/RT-MYC 
subgroup appear more mesenchymal, but are found in young and also the oldest patients in the cohort 
(median age at diagnosis 27 months). Most of the AT/RT-MYC tumours were located 
supratentorially, and all spinal tumours were clustered into the AT/RT-MYC subgroup. Also, the 
rare adult cases of AT/RT were assigned to resemble entities of the AT/RT-MYC subgroup. 
Similarities between AT/RT-MYC tumours and extracranial MRTs for example occurring in the 
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kidney were highlighted by recent reports indicating a common cell of origin different from the other 
two identified subgroups of AT/RTs. (Ho, Johann et al. 2020) 
Recently, Fruhwald, Hasselblatt et al. (2019) identified an age at diagnosis of <1 year and a non-




Figure 3: Summary of the main clinical characteristics of AT/RTs. (A) AT/RTs exhibit a heterogeneous histology with regions 
containing the characteristic rhabdoid, round cells with acentric nuclei and cytoplasmic eosinophilic inclusions consisting of 
whorls of intermediate filaments. Areas of rhabdoid cells are present aside regions exhibiting a primitive undifferentiated 
phenotype as well as areas of mesenchymal cells. Adapted from Sredni and Tomita (2015). (B) Summary of the consensus 
AT/RT molecular subgroup-defining properties by Ho, Johann et al. (2020), figure 5. MAD = median age at diagnosis, 
TYR = tyrosinase, TYRP = tyrosinase-related protein, MITF = melano-oncogene, BMP = bone morphogenic protein, 
OTX2 = orthodenticle homeobox 2, PDGFRB = platelet derived growth factor receptor B, SHH = Sonic Hedgehog, GLI2, 
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In summary, each subgroup has specific clinical and molecular characteristics which should be 
considered in the development of targeted therapies. Insights into the inhibition of sensitive processes 
should help to tailor therapy plans for each subgroup to finally improve each patient’s outcome (Ho, 
Johann et al. 2020). By subgrouping it also was highlighted that the kind and extent of mutation 
affecting the SMARCB1 gene may play a role in the phenotypical outcome. In general, mutations of 
the SMARCB1 gene associated with the development of AT/RTs are truncating, nonsense, or 
frameshift mutations resulting in inactivation of both alleles and complete loss of gene expression 
(Versteege, Sevenet et al. 1998, Biegel, Tan et al. 2002). Heterozygous missense mutations of the 
SMARCB1 gene are reported in the context of the neurodevelopmental disorder Coffin-Siris syndrome 
(CSS) (Tsurusaki, Okamoto et al. 2012). These diverse outcomes indicate that a specific type of 
germline mutation of the SMARCB1 gene can lead to distinct disease phenotypes. 
CSS is a rare congenital anomaly syndrome characterised by growth deficiency, intellectual disability, 
microcephaly, coarse facial features, hypoplastic nail of the fifth finger and/or toe, feeding difficulties 
in infancy, and numerous organ abnormalities, i.e. affecting the cardiovascular system, the 
gastrointestinal and genitourinary tract caused by mutations in BAF complex subunits (Figure 4B) 
(Coffin and Siris 1970, Tsurusaki, Okamoto et al. 2014, Alfert, Moreno et al. 2019). Mutations in 
ARID1A (BAF250a), ARID1B (BAF250b), DPF2 (BAF45d), SMARCA4 (BAF190), SMARCE1 
(BAF57), and in SMARCB1 have been identified in patients with CSS (Tsurusaki, Okamoto et al. 2014). 
Mutational analysis of large patient cohorts identified the majority of patients exhibiting pathogenic 
variants in the ARID1B gene (Tsurusaki, Okamoto et al. 2012, Tsurusaki, Okamoto et al. 2014, 
Sekiguchi, Tsurusaki et al. 2019). However, missense mutations and small in-frame deletions in the 
SMARCB1 gene were also observed frequently. Seven of the nine reported pathogenic variants in the 
SMARCB1 gene associated with CSS cluster in exons 8 and 9, especially in the positively charged 
amino acid patch in the C-terminal coiled coil region of the highly conserved SNF5 domain (amino 
acids 363 to 377, Figure 4A). The c.1091_1093del AGA in-frame deletion of lysine residue 364 in exon 8 
of the SMARCB1 gene is the most recurring one of the pathogenic variants observed in CSS patients 
with mutations in the SMARCB1 gene (Table 1) (Tsurusaki, Okamoto et al. 2012, Santen, Aten et al. 
2013, Wieczorek, Bogershausen et al. 2013, Sekiguchi, Tsurusaki et al. 2019).  
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Table 1: Overview of the pathogenic variants of the SMARCB1 gene identified in patients diagnosed with CSS 
GENETIC VARIANT ALTERATION AFFECTED INDIVIDUALS 
c.314G>A 
missense, exon 3 
p.Arg105Gln 1 
(Santen, Aten et al. 2013) 
c.806A>G 
missense, exon 7 
p.His269Arg 1 
(Sekiguchi, Tsurusaki et al. 2019) 
c.1052dup 
frameshift, exon 8 
p.Leu352Thrfs*9 1 
(Sekiguchi, Tsurusaki et al. 2019) 
c.1087A>G 
missense, exon 8 
p.Lys363Glu 1 
(Sekiguchi, Tsurusaki et al. 2019) 
c.1089G>T 
missense, exon 8 
p.Lys363Asn 1 
(Santen, Aten et al. 2013) 
c.1091_1093del AGA 
deletion, exon 8 
p.Lys364del 12 
(Tsurusaki, Okamoto et al. 2012, Santen, Aten 
et al. 2013, Tsurusaki, Okamoto et al. 2014, 
Filatova, Rey et al. 2019, Sekiguchi, Tsurusaki 
et al. 2019) 
c.1096C>T 
missense, exon 8 
p.Arg366Cys 1 
(Wieczorek, Bogershausen et al. 2013) 
c.1096C>G 
missense, exon 8 
p.Arg366Gly 1 
(Sekiguchi, Tsurusaki et al. 2019) 
c.1121G>A 
missense, exon 8 
p.Arg374Gln 4 
(Wieczorek, Bogershausen et al. 2013, Filatova, 
Rey et al. 2019, Sekiguchi, Tsurusaki et al. 
2019) 
c.1130G>A 
missense, exon 9 
p.Arg377His 1 
(Tsurusaki, Okamoto et al. 2012) 
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Figure 4: Anatomical and genetic characteristics of patients affected by CSS-associated mutations in the SMARCB1 gene. 
(A) Graphical overview of the distribution of mutations in the SMARCB1 gene identified in patients diagnosed with CSS on 
the gDNA and protein level. The black bars in the coding sequence of SMARCB1 represent the position and frequency of the 
identified mutation which are specified in Table 1. Magnification of the mutational hot-spot of exon 8 and 9 of the SMARCB1 
gene displays the position, frequency, and type of the observed mutations on the protein level. The majority of the identified 
mutations cluster in the region of the positively charged amino acid patch between amino acid 363 and 377 in the coiled coil 
region of the highly conserved C-terminal SNF5 domain of SMARCB1. Twelve cases of CSS-patients affected by the 
c.1091_1093del AGA mutation in exon 8 (p.Lys364del) were identified in large patient cohorts. It is the most frequently 
recurring variant of SMARCB1 found in CSS-patients. A black cross indicates a frameshift mutation, black circles stand for 
missense mutations, and black triangles represent small in-frame deletions. (B) Representative images of children diagnosed 
with CSS. Both patients carry mutations in the SMARCB1 gene. Patient K2426 (Wieczorek, Bogershausen et al. 2013) is 
affected by the SMARCB1 c.1121G>A (p.Arg374Gln) missense mutation in exon 8, while patient 29 (Tsurusaki, Okamoto et 
al. 2014) carries the recurring in-frame deletion c.1091_1093del AGA (p.Lys364del) in exon 8 of the SMARCB1 gene. Both 
children show the CSS-characteristic facial features (wide mouth with thick, everted upper and lower lips, a broad nasal bridge 
and nasal tip, thick eyebrows and long eyelashes) and hyperplastic finger and toenails as well as hypoplasia of the fifth distal 
phalanx. 
 
Recently, the first mouse model recapitulating features of SMARCB1-associated CSS-like 
neurodevelopmental disorders was published by the Stem Cell and Developmental Biology group of 
the Technical University of Darmstadt (Filatova, Rey et al. 2019). The heterozygous nervous system-
specific partial loss-of-function mutation of the Smarcb1 gene by inversion of exon 1 resulted in a 30% 
decrease of Smarcb1 transcript level, microcephaly, and several anatomical defects of the brain, i.e. 
agenesis of the corpus callosum, and choroid plexus hyperplasia (Filatova, Rey et al. 2019). The 
anatomical aberrations observed in these mutant mice were similar to the brain defects seen in 
magnetic resonance images of CSS-patients with mutations in different BAF complex components 
(Wieczorek, Bogershausen et al. 2013, Filatova, Rey et al. 2019). Comparison of this mouse model with 
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AT/RT mouse models further highlights the differential impact of the type of a germline mutation 
affecting the SMARCB1 gene on brain and tumour development. A congenital complete loss of one 
allele of Smarcb1 predisposes to the development of tumours, which occur upon spontaneous loss of 
the second allele, while partial loss of Smarcb1 protein function by inversion of exon 1 of the Smarcb1 
gene causes severe developmental defects in the brain of affected mice (Guidi, Sands et al. 2001, 
Filatova, Rey et al. 2019). 
   
1.4. CRISPR/Cas9-mediated genome engineering 
The CRISPR/Cas9 genome engineering tool is based on the clustered regularly interspaced 
palindromic repeat (CRISPR)/CRISPR-associated (Cas) type II archaeal and bacterial adaptive defence 
system to protect these organisms from the invasion of foreign plasmid or viral DNA (Horvath and 
Barrangou 2010, Jinek, Chylinski et al. 2012, Wiedenheft, Sternberg et al. 2012). The microbial 
immune response depends on Cas gene operons and CRISPR arrays, genome-targeting sequences 
(protospacers) interspersed with identical repeats. It consists of two phases. In phase one, the 
immunization or adaptive phase, organisms with one or more CRISPR loci respond to the challenge 
of invading nucleic acids by integrating a short fragment of the foreign sequence (protospacer) into 
the CRISPR array on its chromosome. After surviving this first infection, the organism has stored 
some genetic information on its attacker, which will be used to defend itself against a second infection 
in phase two of the bacterial immune response. In the subsequent immunity or expression and 
interference phase (phase two), transcription and processing of the CRISPR locus elements takes place. 
CRISPR RNAs (crRNAs) that guide Cas9 endonucleases to nucleic acid sequences complementary to 
the saved protospacer sequences are generated. In this process, the transactivating-crRNA (tracrRNA) 
hybridises to the repeat regions of the pre-crRNA transcribed from the repeat-protospacer array. In 
the presence of Cas9 this pre-crRNA:tracrRNA hybrid is cleaved by endogenous RNase III, and the 
5’ end of the spacer is removed resulting in a mature crRNA associated with tracrRNA and Cas9 
protein. This ribonucleic protein complex then targets and cleaves complementary protospacer 
sequences in the invading plasmid or viral nucleic acid. Cas9-mediated site-specific cleavage requires 
complementary base-pairing between the mature crRNA and the target protospacer DNA in 
combination with a short, protospacer adjacent motif (PAM) on the target DNA to differentiate 
between self and non-self DNA targets (Figure 5A). Cas9-mediated cleavage of DNA is facilitated by 
the HNH- and RuvC1-homologous domains of the protein (Figure 5). (Horvath and Barrangou 2010, 
Jinek, Chylinski et al. 2012, Wiedenheft, Sternberg et al. 2012, Mali, Esvelt et al. 2013)  
Utilization of this targeted DNA cleavage for genome editing in mammalian, i.e. human, cells was 
achieved by programming the CRISPR/Cas9 system of Streptoccocus pyogenes to target the Cas9 
endonuclease to a specific genomic locus by a chimeric crRNA:tracrRNA hybrid (Jinek, Chylinski et 
al. 2012). This guide RNA (gRNA) is expressed from a human U6 RNA polymerase III promoter and 
combined with a human-codon-optimised Cas9 protein with a nuclear localisation signal (NLS) in a 
mammalian expression system (Figure 5B, C) (Cong, Ran et al. 2013, Mali, Yang et al. 2013). The 
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gRNA consists of the 20 nucleotides targeting protospacer sequence led by a guanine base, fused to a 
gRNA scaffold. In total, this gRNA-gRNA scaffold construct resembles the mature crRNA:tracrRNA 
hybrid necessary for Cas9 targeting and cleavage. With this programmable system, theoretically any 
genomic sequence in the form of 5’ GN19-20 3’ directly followed by the 5’ NGG 3’ PAM sequence of 
S. pyogenes can be targeted (where N is any nucleotide), making the CRISPR/Cas9 system a versatile 
tool for targeted genome engineering in human cells (Mali, Yang et al. 2013, Ran, Hsu et al. 2013). 
 
Figure 5: Graphical overview of the active CRISPR/Cas9 ribonucleic protein complex in microbial immune response and 
programmed for genome editing. (A) Depiction of the mature crRNA base-paired with the tracrRNA in the active Cas9 complex 
after detection of the complementary protospacer sequence in invaded foreign DNA. Scissors indicate the cleavage site of the 
endonuclease domains 3 bp upstream of the PAM. (B) Recombinant chimeric gRNA complexed by Cas9 programmed for 
targeted genome engineering bound to the 20 nt target sequence in the genome. The 20 nt complementary targeting crRNA is 
fused to a gRNA scaffold replacing the base paired region of the crRNA:tracrRNA hybrid connected by a linker loop. 
(C) Graphical summary of the mammalian expression system necessary for programmed CRISPR/Cas9-mediated genome 
engineering in human cells. The human-codon-optimised Cas9 with SV40 nuclear localisation signal (NLS) and polyA tail is 
expressed by a constitutively active cytomegalovirus (CMV) promoter. The gRNA expression cassette is expressed by the 
human U6 RNA polymerase III promoter and contains the variable 20 nt target sequence directly upstream of the gRNA 
scaffold. Adapted from Jinek, Chylinski et al. (2012) and Mali, Yang et al. (2013). 
 
Mechanistically, CRISPR/Cas9-mediated genome editing starts with the binding of a gRNA to the 
primary binding channel of Cas9, activating it to the gRNA-directed target DNA search mode. As 
soon as it has found the target protospacer DNA, the Cas9/gRNA complex binds to the protospacer 
DNA. In cooperation with the PAM interacting domain of Cas9, the gRNA starts interrogating the 
double-stranded DNA by base pairing starting from the PAM proximal position. The primary binding 
channel of Cas9 gradually changes its conformation to bind the gRNA/target DNA heteroduplex, 
while the non-target DNA strand is bound by the minor binding channel of Cas9. As the base-pairing 
process continues to the PAM distal end of the complementary 20 nt target sequence, the HNH 
endonuclease domain of Cas9 turns by 180° until it is perfectly positioned near the third nucleotide 
position of the target DNA strand proximal to the PAM. Meanwhile the RuvC1 domain of Cas9 is 
changed from the buried to the exposed state, and is positioned at the HNH-respective location on the 
non-target DNA strand. Upon correct positioning, the nuclease activity of HNH and RuvC1 domains 
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breaks both strands simultaneously resulting in a blunt ended DNA double strand break (DSB) three 
base pairs upstream of the PAM sequence (Figure 5B) (Zhang, Adikaram et al. 2016). 
The generated DSB activates the cellular DNA damage response and recruits the DNA repair 
machinery (Ran, Hsu et al. 2013). Repair of the DSB promotes gene editing by either of one DNA 
repair pathways. Most DSBs are repaired by the predominant, error prone non-homologous end 
joining (NHEJ) pathway. During NHEJ, the DSB ends are processed by nucleases, and are 
subsequently re-joined by ligase IV (Cahill, Connor et al. 2006, Ran, Hsu et al. 2013). DSB repair via 
NHEJ can result in small insertions or deletions (indel), which can cause the knock-out of the targeted 
gene if the indel leads to a frameshift or a pre-mature stop codon in the coding region of the gene 
(Cong, Ran et al. 2013, Ran, Hsu et al. 2013). In the presence of a sister chromatid or an exogenous 
repair template (plasmid or single-stranded oligonucleotide) in late S/G2-phase of the cell cycle, DSBs 
can also be repaired by the homology directed repair (HDR) pathway (Cahill, Connor et al. 2006). 
During HDR, the processed DSB ends are coated by Rad51 and form double Holliday junctions with 
a homologous repair template to complement the lost genetic information by copying the presumably 
correct sequence (Cahill, Connor et al. 2006, Ran, Hsu et al. 2013). Exploiting this mechanism, the cell 
can be tricked into integrating new sequences, e.g. reporter genes, flanked by sequences homologous 
to the genetic information up- and downstream of the Cas9-mediated DSB resulting in a precisely 
edited knock-in (Ran, Hsu et al. 2013). 
Different studies identified specificity issues when editing a genome by CRISPR/Cas9 due to mismatch 
tolerance in the gRNA sequence (Cong, Ran et al. 2013, Fu, Foden et al. 2013). Even though off-target 
editing events are rare, DSB generation and indel insertion at off-target sites present a major obstacle 
for the use of CRISPR/Cas9 for the generation of specific, single mutation disease models or cell 
therapy applications (Fu, Foden et al. 2013, He, Tan et al. 2016). Point mutations of catalytic residues 
of the Cas9 HNH or RuvC1 endonuclease domain can selectively inactivate one domain leading to a 
DNA single-strand nick upon targeting by a gRNA (Jinek, Chylinski et al. 2012). These nicks are 
predominantly repaired by the high-fidelity base excision repair pathway (Ran, Hsu et al. 2013). 
Combination of two offset gRNAs with a Cas9 nickase containing a p.Asp10Ala (D10A) mutation in 
its RuvC1 endonuclease domain (Cas9n) generates readily repaired single-strand nicks at all off-target 
sides of each gRNA, but a DSB only at the on-target site where both gRNAs bind in close proximity 
(Figure 6) (Ran, Hsu et al. 2013). This DSB then triggers the cellular DNA damage response and is 
repaired either by NHEJ or HDR as described above (Ran, Hsu et al. 2013). 
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Figure 6: Visualization of the DSB generation by a pair of Cas9n/gRNA complexes. D10A mutation of the catalytic aspartic 
acid residue of the RuvC1 domain (grey) of Cas9 diminishes the endonuclease activity of this domain. Thereby, only the 
complementary DNA strand can be cleaved by the HNH domain of Cas9 resulting in a DNA single-strand nick. Combination 
of two offset gRNAs with Cas9n results in a DSB with cohesive ends by simultaneous nicking both DNA strands. gRNA offset 
is defined as the distance between the PAM-distal (5’) ends of the 20 nt targeting sequence of a given gRNA pair. Adapted 
from Ran, Hsu et al. (2013). 
 
Taking these studies into consideration, both, a conventional and a double nicking approach were 
applied for the CRISPR/Cas9-mediated genome editing of hiPSCs and MCF10A cells in this thesis. 
The selection of the gRNA sequences and the design of the HDR construct were based on the 
recommendations made by Ran, Hsu et al. (2013). The HDR construct was optimised to prevent re-
cutting of edited loci (Hendriks, Warren et al. 2016). CRISPR/Cas9-mediated cleavage of DNA was 
shown to be dependent on the presence of the 5’ NGG 3’ PAM sequence (Jinek, Chylinski et al. 2012, 
Zheng, Hou et al. 2017). Silent mutations in the -3 position of the PAM at the 3’ end of the PAM are 
not tolerated and ablate CRISPR/Cas9-mediated DNA cleavage. A silent mutation at this position was 
introduced in the homologous sequences of the HDR constructs to prevent re-cutting after insertion 
(Zheng, Hou et al. 2017). If the introduction of a silent mutation of the -3 position of the PAM was not 
possible, position -2 was mutated guanine to either thymine or cytosine. Both mutations were shown 
to remarkably reduce Cas9 cleavage activity (Zheng, Hou et al. 2017). In some cases, silent mutation 
of the PAM was not possible since base exchange of either guanine residue of the PAM site would 
have resulted in an amino acid exchange. In these cases, the profound compromising effects of 
mismatches in the core sequence of the gRNA (positions +4 to +6/+7, counting 3’ to 5’ starting at the 
PAM proximal position) were exploited (Zheng, Hou et al. 2017). A single mismatch in these bases 
was shown to prevent base-pairing between the gRNA and target DNA, and thus provides three to 
four additional positions for the insertion of a silent mutation to prevent re-cutting after genome 
editing (Zheng, Hou et al. 2017). 
 
1.5. Aim of this thesis 
This thesis had three aims: the establishment and optimisation of methods for the introduction of 
AT/RT and CSS-associated SMARCB1 mutations into human cells by CRISPR/Cas9-mediated 
genome engineering, and the establishment and optimisation of the transduction of mouse 
neurospheres (NSPs) to analyse the effect of overexpression of Hes5 on Smarcb1-mutated neurosphere-
forming cells (NSPs contain neural stem (NSCs) and progenitor cells (NPCs)). 
For the generation of the hiPSC- and MCF10A SMARCB1 mutant cell lines, a strategy for 
CRISPR/Cas9-mediated insertion of promoterless selectable fluorescence reporter cassettes and loxP 
sites co-expressed with mutant SMARCB1 gene variants was established. The MCF10A cell line was 
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chosen to be CRISPR/Cas9-mediated genome engineered at the SMARCB1 locus since MCF10A cells 
are diploid for chromosome 22 while showing higher DNA transfer efficiencies compared to hiPSCs 
and could have represented an adequate intermediate model until the establishment of the hiPSC 
models (Marella, Malyavantham et al. 2009). For the hiPSC line with AT/RT-associated SMARCB1 
mutations, a CRISPR/Cas9(n)-mediated genome engineering strategy to generate cells which co-
express the SMARCB1 gene with three different fluorescence reporters was established and optimised. 
The insertion of loxP sites up- and downstream of the engineered locus allows a removal of the 
complete genomic sequence of SMARCB1 and the flanking reporter genes by Cre recombination. This 
design allows the inactivation of the SMARCB1 gene at any developmental stage upon introduction of 
Cre, e.g. by lentiviral transduction. This inactivation could be homo- or heterozygous, dependent on 
the presence of loxP sites on both or only one allele of SMARCB1 (Figure 7). 
 
Figure 7: Graphical overview of the envisaged CRISPR/Cas9- genome engineered human SMARCB1 locus in the three-colour 
reporter system. (A) The wildtype SMARCB1 locus. (B) The SMARCB1 locus in the AT/RT cell model for homozygous deletion 
of the whole sequence of SMARCB1 and the result of Cre recombination. (C) Mutation of exon 1 (depicted as an example) or 
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In addition to the complete deletion of the SMARCB1 gene, other types of AT/RT-associated 
mutations were included in the SMARCB1 mutated human cell lines. Therefore, HDR constructs were 
generated to facilitate inactivation of SMARCB1 by the combination of the heterozygous loss of the 
complete SMARCB1 coding sequence with the heterozygous inactivation of SMARCB1 by AT/RT-
associated nonsense point mutations in one cell (Figure 7C). Since the insertion of the point mutations 
would also be linked to the insertion of a reporter cassette, the mutations had to be located in the first 
or last exon of the SMARCB1 gene. Literature research identified several cases of AT/RT with the 
c.1148delC mutation in exon 9 of the SMARCB1 gene (Biegel, Tan et al. 2002, Kordes, Gesk et al. 
2010). Additionally, two mutations in exon 1 of the SMARCB1 gene were reported in the germline of 
AT/RT patients (c.20_43delins T, c.93G>C) (Eaton, Tooke et al. 2011). With this array of human cell 
lines with AT/RT-associated SMARCB1 mutations, the genetic background and possibly the different 
tumour subtypes observed in AT/RT patients could be modelled. 
To generate a human cell model for the CSS-associated mutation of the SMARCB1 gene, the frequently 
observed deletion of lysine residue 364 in exon 8 of the SMARCB1 gene (c.1091_1093del AGA) was 
selected (Table 1). This mutation was included in the HDR construct for the insertion of a reporter 
downstream of the native stop codon of the SMARCB1 gene and would be combined with insertion of 
another reporter on the second, wildtype allele of SMARCB1 (Figure 8). These genetic alterations 
were designed to be introduced in hiPSC and MCF10A cells. The hiPSC lines with CSS-associated 
SMARCB1 mutations should be used to better understand the cellular consequences of the 
c.1091_1093del AGA mutation during embryonic organ, i.e. brain, development, which are observed in 
CSS patients and in the mouse model recapitulating SMARCB1-associated CSS.  
 
Figure 8: Graphical depiction of the human SMARCB1 locus after genome engineering to introduce the CSS-associated 
mutation. The c.1091_1093del AGA mutation in exon 8 was introduced into the HDR construct designed for insertion of the 
eGFP::ZeoR reporter cassette. 
 
Both, the hiPSC- and MCF10A cell lines with CSS-associated SMARCB1 mutations could in principle 
be used to analyse the effect of the mutation on the expression of SMARCB1 from each of its alleles by 
e.g. RT-qPCR analysis of the transcription of the co-expressed reporter genes (Figure 9). hiPSC and 
MCF10A cells expressing the SMARCB1 gene with point mutations associated either with AT/RT or 
CSS could help to identify the cellular mechanisms underlying tumour formation and CSS upon specific 
congenital alteration of the SMARCB1 sequence.  
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Figure 9: Primer positioning for the allele-specific RT-qPCR analysis of the expression of each allele of the SMARCB1 gene 
in the engineered locus. The introduction of AT/RT or CSS-specific point mutations allows to analyse the effect of either 
mutation on the expression of the mutated and wildtype allele. 
 
AT/RT-associated inactivation of the SMARCB1 gene by Cre recombinase in MCF10A cells, similar 
to hiPSCs, could also help to understand how cells cope with loss of SMARCB1. Comparison of gene 
expression changes observed in MCF10A cells to the changes observed in hiPSCs upon loss of 
SMARCB1 gene expression could hint to coping mechanisms activated independent of the 
developmental state of the cell, which could present potential targets for tumour treatment. 
 
Another aim of this thesis was the establishment of methods to overexpress Hes5 in neurosphere-
forming cells. Murine NSCs/NPCs isolated from Smarcb1+/inv NesCre+/- mice, the first mouse model 
recapitulating SMARCB1-associated CSS recently published by the Stem Cell and Developmental 
Biology group of the Technical University of Darmstadt, showed diminished sphere forming abilities. 
Neurospheres (NSPs) are three-dimensional floating spheroid cell clusters that arise from NSP-
forming cells, which can be both NSCs or NPCs, isolated from the mammalian CNS (Jensen and 
Parmar 2006, Singec, Knoth et al. 2006, Pastrana, Silva-Vargas et al. 2011). Upon in vitro cultivation, 
the heterogeneity of NSPs increases and aside from proliferative, NSP-forming NSCs and NPCs, also 
post-mitotic neurons and glia cells can be found within one sphere (Jensen and Parmar 2006). 
Nonetheless, NSP culture can be applied as a functional assay and is a useful tool to analyse 
proliferation, self-renewal capacity, and multipotency of the NSP-forming NSCs and NPCs over serial 
clonal passages (Jensen and Parmar 2006). Therefore, a loss of sphere forming ability as observed in 
cells isolated from mutant brains in Filatova, Rey et al. (2019) indicates a lack of cells presenting NSC 
or NPC characteristics in the NSP culture system e.g. due to impairment of NSC maintenance or loss 
of self-renewal in NSCs and NPCs. Additionally, RNA in situ hybridisation analyses revealed reduced 
expression of Hes5 in the radial glia cell (RGC) population of the glial wedge in Smarcb1+/inv NesCre+/- 
brain sections of E15.5 mice (Filatova, Rey et al. 2019). These findings led to the hypothesis that 
overexpression of Hes5 in Smarcb1+/inv NesCre+/- NSCs could potentially rescue their sphere forming 
abilities. Therefore, the transduction of NSP-forming cells isolated from Smarcb1+/inv NesCre-/- mice 
(E15.5), which possess sphere forming abilities, was established and optimised to generate a system in 
which Cre recombinase and Hes5 could be overexpressed to test the hypothesis. Expression of Cre 
recombinase inverts the floxed exon 1 of the Smarcb1 gene in the infected cells. The inversion is 
reversible and continues forth and back as long as Cre is expressed (Filatova, Rey et al. 2019). Thereby, 
some of the NSP-forming cells would exhibit a genotype analogous to the mice in the CSS-model and 
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would be expected to lose their sphere forming abilities. Simultaneous overexpression of Hes5 might 
rescue the partial loss-of-function of Smarcb1 occurring upon heterozygous inversion of exon 1 
(Figure 10).  
 
Figure 10: Experimental design to test the hypothesis if overexpression of Hes5 can rescue the impaired sphere forming ability 
of murine NSP-forming cells upon continuous inversion of exon 1 of the Smarcb1 gene. Smarcb1+/inv NSPs should be 
transduced with lentiviral particles transferring a VenusCre and a Hes5-IRES-mKate2 expression system (Smarcb1+/inv 
VenusCre+ Hes5-IRES-mKate2+ NSPs, red halves on the left). Upon expression of VenusCre, the transduced NSP-forming 
cells would inverse the loxP-flanked exon 1 of the Smarcb1 gene. Smarcb1+/inv VenusCre+ IRES-mKate2+ NSP-forming cells 
(red halves on the bottom, control 1) are hypothesised to lose their sphere forming ability, similar to the Smarcb1+/inv 
NesCre+/- NSCs/NPCs (Filatova, Rey et al. 2019). Overexpression of Hes5 in NSP-forming cells is hypothesised to enhance 
the sphere forming ability of transduced NSPs, resulting in an increase of sphere number, due to its role in the maintenance of 
NSCs (Smarcb1+/inv Venus+ Hes5-IRES-mKate2+ NSPs, red halves on the right, control 2) (Kageyama, Ohtsuka et al. 2008). 
Simultaneous presence of both expression systems is hypothesised to rescue the impairment in sphere formation caused by the 
inversion of exon 1 of the Smarcb1 gene, thereby increasing the number of spheres observed compared to NSP-forming cells 
expressing only VenusCre (Smarcb1+/inv VenusCre+ Hes5-IRES-mKate2+ NSPs, red halves on the left). As control for the 
impact of the effect of the transduction and subsequent overexpression of the fluorescence genes, expression systems only 
encoding eGFP or mKate2, without Cre recombinase or Hes5 coding sequence respectively, are used (Smarcb1+/inv Venus+ 
IRES-mKate2+ NSPs, red halves on the top, control 3).  
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2. Materials and methods 
 
2.1. Molecular biology methods 
2.1.1. Polymerase chain reaction (PCR) amplification of DNA 
Polymerase chain reaction (PCR) is a basic molecular biology method used to amplify specific 
sequences of DNA from different kinds of DNA templates, e.g. genomic, plasmid or bacterial DNA. In 
a thermal cycling reaction DNA polymerase adds free nucleotides to primers, initial building blocks of 
DNA. Primers are short oligonucleotides (typically ≥18 bp) complementary to the 3’ ends of the sense 
and antisense strands of the DNA sequence which is amplified and thus have to be custom-made for 
each sequence. A list of all oligonucleotides ordered at Sigma Aldrich and used in this work can be 
found in the appendix (section 7.1.1). 
In the first step, the PCR reaction is heated to 98° C to initially separate the template’s DNA strands 
(denaturation). After this, the thermal cycling starts. Every cycle is composed of a denaturation step 
(98°C, 10 to 30 seconds), followed by reduction of the temperature allowing primer annealing to the 
template strands (10 to 30 seconds; each primer’s melting temperature has to be identified using the 
IDT OligoAnalyzer, https://eu.idtdna.com/calc/analyzer). The reaction is completed by an extension 
step at 72° C during which the DNA polymerase condenses the 5’-phosphate groups of the free 
deoxyribonucleotide triphosphates (dNTPs) to the 3’-hydroxyl group of the nascent DNA strand. In 
a standard reaction, this thermal cycle is repeated 25 to 35 times before a final extension step (72° C, 
2 to 10 minutes) completes the amplification process.  
For cloning purposes, Phusion or Q5 High-Fidelity DNA polymerases (NEB, M0530 or M0491) were 
used. These DNA polymerases are characterised by fast amplification and extremely low amplification 
error rates. PCR reactions using Phusion or Q5 High-Fidelity DNA polymerases were set up on ice 
following the pipetting scheme of Table 2.  
Table 2: Set up of PCR reactions using Phusion of Q5 High-Fidelity DNA polymerases. 
REACTION COMPONENT FINAL CONCENTRATION VOLUME 
5x Q5 Reaction Buffer OR 
5x Phusion HF Buffer 
1x 10 µL 
5x Q5 GC Enhancer (optional) 1x 10 µL 
10 mM dNTPs (N0446S, NEB) 200 µM 1 µL 
10 µM Forward Primer 0.5 µM 2.5 µL 
10 µM Reverse Primer 0.5 µM 2.5 µL 
Q5 High-Fidelity DNA polymerase 0.02 U1/µL 0.5 µL 
Template DNA 10-100 ng x µL 
Nuclease free water  Add to 50 µL 
 
1 1 Unit of enzyme is defined as the amount of enzyme that will incorporate 10 nmol of dNTP into acid insoluble material in 30 minutes at 
74° C (https://international.neb.com/products/m0491-q5-high-fidelity-dna-polymerase#Product%20Information_Properties%20&%20 
Usage, November 30, 2019) 
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The PCR mixture was placed in a thermal cycler (peqSTAR 2x Universal Gradient, 732-2889DE, 
VWR) running the following programme (Table 3).  
Table 3: Thermal cycling programme for PCR reactions setup with Phusion or Q5 High-Fidelity DNA polymerases. 
PCR STEP TEMPERATURE TIME 
Initial Denaturation 98° C 30 seconds 









Final Extension 72° C 2 minutes 
Hold 15° C ∞ 
 
PCR amplified DNA sequences were analysed by agarose gel electrophoresis (section 2.1.4) and, if 
necessary, purified for further processing. 
 
2.1.2. Purification of DNA samples 
Purification of DNA samples after processing e.g. after PCR or restriction endonuclease digestion is 
necessary to remove salts and enzymes from the mixture yielding pure DNA (A260/A280 > 1.8) which 
can be further used for various downstream applications. 
 
Purification of DNA samples using the Clean & Concentrator-5 Kit (D4004, Zymo Research) 
The Zymo Clean & Concentrator-5 Kit was used to purify processed DNA samples containing only 
one specific DNA sequence. For example, after PCR amplification of a specific sequence or restriction 
endonuclease digestion, yielding only one fragment of DNA as after digestion of a PCR product or 
plasmid linearization. The DNA samples were processed as described in the manufacturer’s handbook3. 
In brief: In a 1.5 mL microcentrifuge tube, five volumes of DNA Binding Buffer were added to each 
volume of DNA sample and mixed briefly by vortexing or pipetting (e.g. 50 µL DNA sample + 250 µL 
of DNA Binding Buffer). The mixture was transferred to an uncapped Zymo-Spin Column in a 
collection tube and centrifuged for 30 seconds at maximum speed (21,700 xg). The flow-through was 
discarded. 200 µL of DNA Wash Buffer (diluted with 100% ethanol) was added to the column and 
centrifuged for 30 seconds at maximum speed. This wash step was repeated once. The column was 
transferred to a sterile 1.5 mL microcentrifuge tube, 15 µL of pre-warmed (55° C) nuclease-free water 
were added directly to the column matrix, and incubated at room temperature for five minutes. Finally, 
the DNA was eluted by centrifugation at maximum speed for 60 seconds. DNA concentration and 
purity were determined using the NanoDrop2000c (software version 1.6, Thermo Scientific) and 1 µL 
of the purified DNA sample. 
 
2 Primer melting temperature as calculated by IDR OligoAnalyzer https://eu.idtdna.com/calc/analyzer 
3 https://files.zymoresearch.com/protocols/_D4003T_D4003_D4004_D4013_D4014_DNA_Clean_Concentrator_-5_ver_1_2_1_LKN-
SW__1.pdf, November 24, 2019 
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Purification of DNA samples using the GeneJET Gel extraction kit (K0692, Thermo Scientific) 
DNA samples containing fragments of different size are separated by agarose gel electrophoresis in 
1x TAE buffer (section 2.1.4). Purification of the separated and excised DNA bands is achieved with 
the GeneJET Gel extraction kit. The excised agarose gel slices are processed as described in the 
manufacturers protocol4. In brief: Binding buffer was added 1:1 to the gel slice (volume:weight, e.g. 
100 µL Binding buffer to each 100 mg of agarose gel) and incubated at 55° C for 10 minutes while 
rapidly shaking. It was ensured that the gel was completely dissolved before proceeding to the next 
step. The solubilised gel solution was transferred to a GeneJET purification column and centrifuged 
at maximum speed (21,700 xg) for 60 seconds. The flow-through was discarded. This step was 
repeated until all solution was passed through the column. 700 µL of Wash Buffer (diluted with 100% 
ethanol) was added to the column, and centrifuged at maximum speed for 60 seconds. The wash step 
was repeated once. The empty column was centrifuged at maximum speed for two minutes to dry the 
column matrix completely. Following this, the column was transferred to a sterile 1.5 mL 
microcentrifuge tube, 25 µL of pre-warmed (55° C) nuclease-free water were added directly to the 
column matrix and incubated at room temperature for five minutes. Finally, the DNA was eluted by 
centrifuging at maximum speed for 60 seconds. DNA concentration and purity were determined using 
the NanoDrop2000c (software version 1.6, Thermo Scientific) and 1 µL of the purified DNA sample. 
 
2.1.3. Restriction endonuclease digestion 
Restriction endonucleases are enzymes which recognise specific sequences of typically six to eight 
bases and cleave the DNA within or close to these recognition sites. Cloning of DNA fragments can 
be achieved by using restriction endonuclease recognition sites present in both the plasmid and insert 
sequences. If specific cloning cannot be achieved by the given recognition sites and their corresponding 
restriction endonucleases, suitable recognition sequences need to be added to the 5’ end of PCR 
primers5. Efficient cleavage close to the ends of the PCR amplified sequences has to be enabled by 
adding sufficient bases 5’ of the recognition sequence. The number of added bases required for efficient 
cleavage of the used New England Biolabs (Masliah-Planchon, Bieche et al.) restriction endonucleases, 
can be found online (https://www.neb.com/tools-and-resources/usage-guidelines/cleavage-close-to-
the-end-of-dna-fragments). 
The NEB restriction endonucleases available in the laboratory are listed in the appendix (section 7.1.2). 
Restriction endonuclease digestion reactions were set up on ice following the scheme of Table 4: 
  
 
4 https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0012661_GeneJET_Gel_Extraction_UG.pdf, November 24, 2019 
5 https://www.neb.com/applications/cloning-and-synthetic-biology/dna-preparation/restriction-enzyme-digestion#tabselect3, 
October 27, 2019 
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Table 4: Reaction setup of restriction endonuclease digestions of DNA. 
REACTION COMPONENT VOLUME, µL 
DNA (up to 10 µg) x µL 
Restriction endonuclease 1, 1 U6/µg of DNA 
(Masliah-Planchon, Bieche et al.) 
0.2-1.5 µL 
Restriction endonuclease 1, 1 U/µg of DNA 
(Masliah-Planchon, Bieche et al.) 
0.2-1.5 µL 
10x Reaction buffer e.g. CutSmart (Masliah-
Planchon, Bieche et al.) 
5 µL 
Nuclease free water Add to 50 µL 
 
The restriction endonuclease reactions were incubated at the appropriate reaction temperature, mostly 
37° C, for 30 minutes to three hours. If applicable, the enzymes were inactivated at the required 
inactivation temperature (section 7.1.2). Subsequently, the DNA sample was purified as described in 
section 2.1.2 to remove the enzymes. 
 
2.1.4. Agarose gel electrophoresis 
Agarose gel electrophoresis is an effective and simple way to separate DNA fragments of different 
sizes. Agarose is a mixture of L- and D-galactose subunits which form non-covalently interacting 
bundles. The density of these bundles and thus, the pore size of the agarose gel depends on the agarose 
concentration. The higher the concentration of agarose in the mixture, the smaller the pores in the 
resulting gel. For separation of smaller DNA fragments, a higher concentration of agarose and for 
larger fragments a lower concentration of agarose is used (Table 5). The agarose gel electrophoresis 
is run in an electrophoresis chamber filled with 1x TAE (Tris-acetate-EDTA, Table 6) buffer. 
Application of an electric current facilitates separation of the DNA sample. Based on the negative 
charge of the phosphate backbone of the DNA, the DNA fragments migrate through the agarose gel 
towards the positively charged anode. The distance migrated in the electric field is inversely 
proportional to the log of the fragments’ molecular weight due to DNA’s uniform mass to charge ratio. 
All samples were supplemented with 1x loading dye (Table 7), applied to the pre-cast wells of the 
agarose gel, and separated at 90 to 120 V for 30 to 60 minutes. For each gel, a DNA standard (N3231 
for 100 bp to 1,517 bp, N3232 500 bp to 10,000 bp, NEB, Figure 11) was added to determine each 
DNA band’s fragment size. The separated DNA fragments were visualised using UV light. Therefore, 
a staining agent that binds to the minor groove of helical nucleic acids and emits a green fluorescent 
light when excited by UV light (Roti-GelStain, 3865, Carl Roth, 1 µL/20 mL of TAE buffer)7 was 
supplemented in the agarose gel.  
 
6 1 U = 1 unit of restriction enzyme completely digests 1 µg of substrate DNA in a 50 µL reaction in 60 minutes, 
https://international.neb.com/protocols/2012/12/07/optimizing-restriction-endonuclease-reactions, October 27, 2019 
7 https://www.carlroth.com/downloads/ba/en/3/BA_3865_EN.pdf, December 10, 2019 
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Table 5: Concentration of agarose recommended for different sizes of DNA fragments. 
AGAROSE CONCENTRATION SIZE OF DNA FRAGMENTS 
1% >1,000 bp 
2% <1,000 bp 
 
Table 6: Formula of 50x Tris-acetate-EDTA (TAE) buffer for agarose gel electrophoresis. 
REAGENT AMOUNT 
Tris base (4855.1, Carl Roth) 121 g 
0.5 M EDTA pH 8.0 (E6758, Sigma Aldrich) 50 mL 
Acetic acid (100063, Merck) 28.55 mL 
Add H2Odest. to 500 mL. 
For agarose gel electrophoresis, a 1X TAE buffer was used. 
 
Table 7: Composition of 6x loading dye for supplementation of DNA samples for agarose gel electrophoresis. 
REAGENT FINAL CONCENTRATION AMOUNT 
Ficoll-400 (CN90.1, Carl Roth) 15% 7.5 g 
1 M Tris-HCl pH 8.0 20 mM 1.0 mL 
0.5 M EDTA 60 mM 6.0 mL 
SDS (1.12533.0250, Merck) 0.48% 0.24 g 
Xylene Cyanol (1.10590.0005, Merck) 0.03% 0.015 g 
Orange G (15925, Merck) 0.12% 0.06 g 
 
 
Figure 11: DNA standards for agarose gel electrophoresis, ref. https://international.neb.com/products/n3232-1-kb-dna-
ladder#Product%20Information;https://international.neb.com/products/n3231-100-bp-dna-
ladder#Product%20Information, January 06, 2020 
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2.1.5. Blunting of cohesive DNA ends 
In some cases, molecular cloning via complementary cohesive 5’ and 3’ DNA overhangs is not possible. 
Thus, the blunting of cohesive DNA ends is adopted in cases in which no restriction endonuclease site 
that generates blunt DNA ends can be used. The cohesive DNA overhangs resulting from restriction 
endonuclease digestion are removed by T4 DNA polymerase (M0203, NEB). T4 DNA polymerase 
exhibits 5’ to 3’ polymerase and 3’ to 5’ exonuclease activity. By these activities, the enzyme fills in 
5’ recessed ends and resects 3’ overhanging bases.8 DNA end blunting reactions were set up on ice as 
follows (Table 8). 
Table 8: Reaction setup of DNA end blunting reactions. 
REACTION COMPONENT VOLUME 
DNA with cohesive end(s) (1 µg) x µL 
100 µM dNTPs (N0446S, NEB) 0.25 µL 
10x NEBuffer 2.1 (B7202, NEB) 2.5 µL 
T4 DNA polymerase, 1 U/µg of DNA (M0203, NEB) 0.25 µL 
Nuclease free water Add to 12.5 µL 
 
The reaction mix was incubated at 12° C for 15 minutes and immediately purified as described in 
section 2.1.2 to avoid extensively recessed ends due to 3’ to 5’ exonuclease activity of the T4 DNA 
polymerase. 
 
2.1.6. Dephosphorylation of DNA ends 
Cleavage of DNA by restriction endonucleases generates 3’-hydroxyl on one and 5’-phosphate residues 
on both sides of the cut. During ligation, both groups are essential to form the phosphodiester bond of 
the DNA backbone linking adjacent plasmid and insert DNA fragments covalently. The 
phosphodiester bond may also be formed between the two adjacent ends of linearised plasmid DNA 
leading to self-ligation of the plasmid and a high number of transformants carrying self-ligated 
plasmid. Dephosphorylation of the digested plasmid was performed using Antarctic phosphatase 
(M0289, NEB) which efficiently hydrolyses the ester bond between the terminal 5’-nucleoside of the 
DNA fragment and its phosphate group, prevents self-ligation of linearised plasmid DNA, and thus 
enhances cloning efficiency.9 Dephosphorylation reactions were set up on ice as described in Table 9. 
  
 
8 https://international.neb.com/products/m0203-t4-dna-polymerase#Product%20Information, January 06, 2020 
9 https://www.neb.com/products/m0289-antarctic-phosphatase#Product%20Information, October 27, 2019 
 
2 Materials and methods       28 
Table 9: Reaction setup of the dephosphorylation of plasmid-backbone DNA. 
REACTION COMPONENT VOLUME 
Linearised plasmid-backbone DNA (1 µg) x µL 
Antarctic phosphatase, 5 U10/reaction (M0289, NEB) 1 µL 
10x Antarctic phosphatase reaction buffer (Masliah-
Planchon, Bieche et al.) 
2 µL 
Nuclease free water Add to 20 µL 
 
The reaction mix was incubated at 37° C for 30 minutes. Subsequently, the thermo-labile phosphatase 
was irreversibly inactivated at 80° C for two minutes and the dephosphorylated DNA was used in 
ligation reactions without any further purification step. The concentration of plasmid DNA for 
subsequent ligation reactions is calculated by dividing the amount of DNA in nanograms by the total 
reaction volume of the dephosphorylation reaction (20 µL). It is recommended to test the efficiency of 
the dephosphorylation reaction by setting up a ligation reaction of the dephosphorylated backbone 
only followed by transformation of chemically competent E. coli. 
 
2.1.7. Ligation of DNA fragments 
Ligation of two adjacent and compatible DNA fragments is the final step in the cloning process of 
recombinant plasmids. During ligation, a covalent bond between the ends of two DNA fragments is 
formed in a three-step process. First, T4 DNA ligase self-adenylates a lysine residue in its active centre 
by reaction with free adenosine triphosphate (ATP). This phospho-adenyl group is then transferred to 
the 5’ end of the DNA, and in a third step, forms the covalent phosphodiester bond with the 3’-hydroxyl 
acceptor group on the adjacent DNA end while releasing adenosine monophosphate (AMP).11 When 
ligating blunt DNA ends, the addition of polyethylene glycol (PEG) is recommended. The 
macromolecule PEG acts as a crowding agent which increases the effective concentration of T4 DNA 
ligase and DNA substrates, and by this increases ligation efficiency.  
For ligation reactions, T4 DNA ligase of Thermo Fisher (5 U/µL12, EL0014) was used. Ratios of 1:3, 
1:5, and 1:10 of plasmid to insert DNA were applied. The amount of DNA necessary for each ligation 
ratio was calculated using the NEBioCalculator based on 50 ng of plasmid DNA 
(https://nebiocalculator.neb.com/#!/ligation). The reactions for cohesive end ligation were set up on 
ice as follows (Table 10). 
 
10 1 U = 1 unit is defined as the amount of enzyme that will dephosphorylate 1 µg of pUC19 vector DNA cut with a restriction endonuclease 
generating 5’ recessed ends in 30 minutes at 37° C; https://international.neb.com/products/m0289-antarctic-
phosphatase#Product%20Information_Properties%20&%20Usage; October 27, 2019 
11 https://international.neb.com/tools-and-resources/video-library?term=ligase, January 06, 2020 
12 One Weiss unit is equivalent to approximately 200 cohesive end ligation units (CEU). 1 Weiss Unit = 200 CEU. One CEU is defined as 
the amount of enzyme required to give 50% ligation of HindIII fragments of lambda DNA in 30 minutes at 16°C. 
https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0011987_T4_DNA_Ligase_5_Weiss_1000_Weiss_U_UG.pdf, 
January 06, 2020 
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Table 10: Ligation reaction setup for joining of cohesive ends using T4 DNA ligase of Thermo Fisher. 
REACTION COMPONENT VOLUME 
Prepared plasmid-backbone DNA 50 ng 
Prepared insert DNA Amount as calculated 
T4 DNA ligase (EL0014, Thermo Fisher, 5 U/µL) 1 µL 
10x T4 DNA ligase buffer (Thermo Fisher) 1 µL 
Nuclease free water Add to 10 µL 
 
The ligation reaction was incubated at 16° C for 15 hours or at 22° C for two hours and inactivated at 
65° C for 10 minutes before transforming chemically-competent E. coli. A ligation of only plasmid 
backbone DNA was always included as a control to determine the rate of self-ligation of the plasmid. 
When ligating blunt ends, 5 µL of T4 DNA ligase per 20 µL reaction was used, the mixture was 
supplemented with 2 µL of 50% PEG-4000, and the inactivation step of T4 DNA ligase had to be 
skipped. 
 
2.1.8. Generation of chemically-competent Escherichia coli   
Amplification of ligation products is performed in bacteria. Treatment of bacteria with Calcium (Cas2+) 
ions in combination with cold temperatures and a heat pulse can confer the bacteria the competence to 
take up DNA. Calcium chloride (CaCl2) treatment of the cells allows exogenous DNA to attach to the 
bacterial cell membrane. A subsequent heating pulse renders the bacteria transiently permeable by 
opening pores in the cell membrane. Treatment of the cells with a mixture of CaCl2, magnesium 
(Mg2+), manganese (Mn2+), and rubidium (Rb+) or potassium (K+) ions can further stimulate the 
transfer efficiency (Hanahan 1983). 
There are different laboratory strains of Escherichia coli (E. coli) which are optimised for cloning 
purposes and commonly used. The strain E. coli DH5α is a non-pathogenic laboratory strain of E. coli. 
Its genome contains two defining mutations which allow for optimal plasmid stability and DNA yield 
upon purification. A mutation in recA1 disables the cell’s recombinase and inactivates homologous 
recombination, mutation of endA inactivates the intracellular endonuclease and prevents plasmid 
degradation. By the lacZM15 mutation, this strain is also compatible with blue/white screening.13 
E. coli Stbl3 is another non-pathogenic laboratory strain which allows for the cloning and propagation 
of unstable DNA, e.g. DNA for packaging in lentiviral particles with flanking long terminal repeats 
(LTRs).14  
The chemically-competent bacteria used here were originally obtained from Thermo Fisher (DH5α 
18265017, Life Technologies; Stbl3 10193952, Fisher Scientific). From these commercial aliquots, 
 
13https://www.thermofisher.com/de/de/home/life-science/cloning/competent-cells-for-transformation/competent-cells-strains/dh5a-
competent-cells.html, January 06, 2020 
14https://www.thermofisher.com/order/catalog/product/C737303?SID=srch-srp-C737303#/C737303?SID=srch-srp-C737303, 
January 06, 2020 
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fresh stocks of chemically-competent E. coli were prepared using the rubidium chloride (RbCl) method 
adapted from Green and Rogers (2013). 
 
Generation of chemically-competent E. coli DH5α or Stbl3 – RbCl method: 
On day one, a 5 mL Luria Broth (LB (Lennox), X.964.2, Carl Roth) pre-culture of the desired E. coli 
strain was inoculated from its glycerol stock using a sterile inoculation loop and incubated at 37° C 
and 220 rpm overnight. 
On day two, two times 100 mL of pre-warmed LB were inoculated with 2 mL of pre-culture each and 
incubated at 37°C, 220 rpm until the culture reached an optic density of 0.4 to 0.5 at 550 nm (approx. 
2.5 hours of incubation). The cells were then abruptly cooled down in ice water for 10 minutes. 100 mL 
of culture were harvested in 50 mL aliquots in pre-cooled tubes by centrifuging the cell suspension at 
4° C and 5,000 xg for 15 minutes. Each bacterial pellet was carefully re-suspended in 30 mL of pre-
cooled (4° C) TfBI buffer (Table 11). The suspension was incubated on ice for 15 minutes to 1.5 hours 
and harvested again by centrifuging the tubes at 4° C and 5,000 xg for 15 minutes. The supernatant 
was discarded, and each pellet carefully re-suspended in 4 mL of ice-cold TfBII buffer (Table 12). 
Finally, 50 µL of the chemically-competent bacteria were aliquoted to -80° C pre-cooled 1.5 mL 
microcentrifuge tubes and flash frozen in liquid nitrogen. The aliquots were stored at -80° C for further 
use. 
Table 11: Transformation buffer I (TfBI) for the generation of chemically-competent E. coli using the RbCl method. 
COMPONENT CONCENTRATION MASS 
RbCl (83980, Fluka) 100 mM 1.21 g 
MnCl2*4H2O (5927.0100, Merck) 50 mM 0.989 g 
CaCl2*2H2O (1.02383.0250, Merck) 100 mM 0.147 g 
KAc (1.04820.1000, Merck-
Millipore) 
30 mM 0.29 g 
100% glycerol (7530.4, Carl Roth) 15% 18.9 g 
All components were dissolved in H2Odest. in a graduated measuring cylinder. While stirring, the 
buffer’s pH was adjusted to 5.8 (S20 SevenEasy pH, 51302803, Mettler Toledo) by adding 0.2 M acetic 
acid. After removing the magnetic stir bar, the volume was filled up to 100 mL with H2Odest. The buffer 
was sterile filtered into a sterile glass bottle and stored at 4° C. 
Table 12: Transformation buffer II (TfBII) for the generation of chemically-competent E. coli using the RbCl method. 
COMPONENT CONCENTRATION MASS 
MOPS (6979.2, Carl Roth) 10 mM 0.105 g 
RbCl (83980, Fluka) 10 mM 0.06 g 
CaCl2 (C-2661, Sigma Aldrich) 75 mM 0.55 g 
100% glycerol (7530.4, Carl Roth) 15% 9.45 g 
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All components were dissolved in H2Odest. in a graduated measuring cylinder. While stirring, the 
buffer’s pH was adjusted to 7.0 (S20 SevenEasy pH, 51302803, Mettler Toledo) by adding 0.2 M 
NaOH. The magnetic stir bar was removed, and the volume filled up to 50 mL with H2Odest. After 
sterile filtering the buffer into a sterile glass bottle, it was cooled to 4° C and used immediately. 
 
2.1.9. Transformation of Escherichia coli DH5α and Stbl3 
Transformation of chemically-competent bacteria describes the transfer of exogenous DNA, e.g. 
plasmid DNA, into competent bacteria in the presence of calcium ions (Ca2+) in combination with cold 
temperatures and a heat pulse.  
For the transfer of ligation product into E. coli laboratory strains DH5α or Stbl3, one aliquot of 
chemically-competent bacteria per ligation reaction was thawed on ice. Per aliquot, 5 µL of ligation 
reaction were added and mixed well by flipping the tube. This bacteria-DNA suspension was incubated 
on ice for 30 minutes. During this incubation time 250 µL of SOC (Super Optimal broth with Catabolite 
repression, Table 13) medium, and two LB agar (X965.2, Carl Roth) plates with suitable antibiotic 
supplementation (200 µg/mL ampicillin K029.1, Carl Roth; 50 µg/mL kanamycin T832.1, Carl Roth) 
were pre-warmed to 37° C. After 30 minutes, the transformation reactions were heat-pulsed at 42° C 
for 30 to 45 seconds and immediately put back on ice for two minutes to open the cell membrane’s 
pores, transfer the DNA, and allow the pores to close again. 250 µL of SOC medium was added to each 
reaction, and the bacteria were incubated at 37° C for one hour while shaking. Finally, 60 µL and 
200 µL of the final transformation reaction were plated on LB agar plates and incubated at 37° C for a 
maximum of 18 hours (overnight). Resulting colonies were analysed by colony PCR (section 2.1.10). 
Table 13: Preparation of SOC medium. 
COMPONENT CONCENTRATION AMOUNT PER L 
Tryptone (8952.2, Carl Roth) 2% 20 g 
Yeast extract (9213.0500, Chemsolute) 0.5% 5 g 
NaCl (3957.2, Carl Roth) 10 mM 2 mL of a 5 M stock 
KCl (6781.1, Carl Roth) 2.5 mM 2.5 mL of a 1 M stock 
MgCl2*6H2O (2189.1, Carl Roth) 10 mM 10 mL of a 1 M stock 
MgSO4*7H2O (5886.1000, Merck) 10 mM 10 mL of a 1 M stock 
All components were dissolved in H2Odest., and the medium’s pH was adjusted to 7.0 (S20 SevenEasy 
pH, 51302803, Mettler Toledo) by adding NaOH. The medium was sterilised by autoclaving 
(121° C, 20 minutes). Sterile filtered glucose ((D+) Glucose monohydrate 1.08342.1000, Merck) was 
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2.1.10. Colony PCR 
Colony PCR is a standard polymerase chain reaction with bacterial colony material as template and is 
used to identify bacterial colonies which replicate the cloned recombinant plasmid (positive colony). 
Identification of positive colonies works best when the PCR’s primers are selected in a way that 
excludes false positives. One primer complementary to the plasmid-backbone sequence close to the 
plasmid-insert junction and the other one complementary to the insert-sequence close to the same 
junction are desirable. Ideally, the fragment amplified with these primers does not exceed 1,000 bp. 
The colony PCR is an analytical tool only and does not require the reading accuracy of PCR 
amplifications for cloning purposes. Therefore, a non-commercial Taq polymerase and a cost-effective 
commercial PCR buffer can be used. The colony PCR was set up as described in Table 14. 
Table 14: Colony PCR setup using a non-commercial Taq polymerase. 
REACTION COMPONENT FINAL CONCENTRATION VOLUME 
10x PCR buffer (10390885, Fisher 
Scientific) 
1x 2.5 µL 
10 mM dNTPs (N0446S, NEB) 200 µM 0.5 µL 
10 µM Forward Primer 0.2 µM 0.5 µL 
10 µM Reverse Primer 0.2 µM 0.5 µL 
Non-commercial Taq polymerase  0.3 µL 
Nuclease free water  20.7 µL 
 
Some bacterial colony material was picked from the transformation plate with a sterile 10 µL pipette 
tip, a replica plate (LB agar plate with suitable antibiotic supplementation, incubation at 37° C 
overnight) was inoculated, and the remaining colony material from the tip was re-suspended in the 
PCR mixture. A positive control with 1 µL of ligation product was included. The PCR mixtures were 
placed in a thermal cycler (peqSTAR 2x Universal Gradient, 732-2889DE, VWR) running the 
following programme (Table 15).  
Table 15: PCR programme for colony PCR using a self-made Taq polymerase. 
PCR STEP TEMPERATURE TIME 
Initial Denaturation 95° C 5 minutes 









Final Extension 72° C 2 minutes 
The PCR products were analysed by Agarose gel electrophoresis (section 2.1.4). Colonies which 
yielded a PCR product of the expected size were picked from the replica plate to inoculate 5 mL 
overnight cultures (LB medium supplemented with antibiotics, incubated at 37° C and 220 rpm for a 
 
15 Primer melting temperature as calculated by IDR OligoAnalyzer https://eu.idtdna.com/calc/analyzer 
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maximum of 16 hours). The next day, these cultures were used to purify plasmid DNA and analyse the 
replicated plasmid DNA sequence in detail (section 2.1.11). 
 
2.1.11. Plasmid DNA preparations 
Recombinant plasmids are replicated in bacteria. For further analysis and use of the plasmid, the 
plasmid DNA has to be purified from the cells. The most common method for the extraction of plasmid 
DNA from bacteria is alkaline lysis. In a first step, the cells are re-suspended in a buffer containing 
EDTA to complex divalent cations, thus inactivating DNases. Secondly, lysis buffer containing sodium 
hydroxide (NaOH) and sodium dodecyl sulphate (SDS) is added to the cell suspension. SDS solubilizes 
the cell membrane and denatures most of the cells’ proteins. NaOH helps to break down the bacterial 
cell wall and disrupts the hydrogen bonds between the two complementary DNA strands. The lysis 
buffer thus opens the cells and denatures double-stranded DNA to single-stranded DNA. In a third 
step, the lysis reaction is neutralised by decreasing the alkalinity of the mixture. This allows the re-
establishment of hydrogen bonds between complementary DNA strands to form double-stranded 
DNA. Since hybridisation of small DNA fragments is much more efficient compared to longer DNA 
fragments, the small plasmid DNA rings are hybridising while the bacterial genomic DNA remains 
single-stranded. The double-stranded plasmid DNA is soluble in aqueous solutions while cellular 
proteins, single-stranded genomic DNA, and SDS are precipitated. Finally, the plasmid DNA can be 
purified from the solution, e.g. using a silica-based membrane. Depending on the DNA quality required 
and the purpose of the purified plasmid DNA, different plasmid DNA purification kits were used.  
 
E.Z.N.A. Plasmid DNA Mini Kit (D6943-02, VWR): 
For purification of DNA for the final restriction endonuclease analysis and sequencing of newly cloned 
recombinant plasmids, the E.Z.N.A. Plasmid DNA Mini Kit of Omega Bio-Tek (D6943-02, VWR) was 
used according to the manufacturer’s handbook.16 In brief: colonies which were tested positive in 
colony PCR (section 2.1.10) were used to inoculate 5 mL overnight cultures of LB medium with 
antibiotic supplementation (200 µg/mL ampicillin K029.1, Carl Roth; 50 µg/mL kanamycin T832.1, 
Carl Roth) and incubated at 37° C, 220 rpm for a maximum of 16 hours. Turbid cultures were used to 
prepare glycerol stocks of the bacteria for future propagation of the recombinant plasmid by combining 
400 µL of a sterile 1:1 solution of LB medium and glycerol (7530.4, Carl Roth) and 600 µL of the 
overnight culture. The remaining bacterial suspension was harvested in two combining steps of 2 mL 
at 10,621 xg at 4° C for one minute in 2 mL microcentrifuge tubes. The resulting bacterial pellet was 
re-suspended in 250 µL of Suspension I supplemented with RNaseA by vortexing. Lysis was initiated 
by adding 250 µL of Solution II to the cell suspension. The tube was inverted three times to thoroughly 
mix the suspension and incubated at room temperature for three minutes to completely lyse the sample. 
Afterwards, 350 µL of Solution III was added and mixed immediately by inverting the tube to stop the 
lysis reaction. At this point a white, flocculent precipitate formed which contained all cellular 
 
16 E.Z.N.A. Plasmid DNA mini Kit – manual available at https://www.omegabiotek.com/product/e-z-n-a-plasmid-mini-kit-i-q-spin/ 
 
2 Materials and methods       34 
components except for the plasmid DNA. The precipitate was pelleted by centrifugation at maximum 
speed for 10 minutes and 850 µL of the cleared supernatant were transferred to a HiBind DNA mini 
column in a collection tube. Centrifugation at maximum speed for one minute passed the supernatant 
through the membrane, allowing the DNA to bind to it. The flow-through was discarded. A first wash 
step with 500 µL of HBC buffer diluted with 100% isopropanol was performed (maximum speed for 
one minute), followed by two washing steps with 700 µL of Washing buffer diluted with 100% ethanol 
each (maximum speed for 30 seconds). Every flow-through was discarded. Afterwards, the empty 
column was spun at maximum speed for two minutes to completely dry the matrix. Following this, 
the dried column was transferred to a sterile 1.5 mL microcentrifuge tube, 50 µL of pre-warmed (55° C) 
nuclease-free water were added directly to the membrane, and the column was incubated at room 
temperature for five minutes. Finally, the bound DNA was eluted by centrifuging the column at 
maximum speed for one minute. DNA concentration and purity were determined using the 
NanoDrop2000c (software version 1.6, Thermo Scientific) and 1 µL of the purified DNA sample. 
500 ng of the obtained plasmid DNA were subjected to a restriction endonuclease digestion 
(section 2.1.3) which gave a first indication of the plasmid’s identity by a characteristic pattern of bands 
in agarose gel electrophoresis. 
 
E.Z.N.A. Plasmid DNA Midi Kit (D6904-03, VWR): 
Transfection of HEK293T cells for the production of lentiviral particles requires larger amounts of 
plasmid DNA. For this purpose, the E.Z.N.A. Plasmid DNA Midi Kit of Omega Bio-Tek (D6904-03, 
VWR) was used according to the manufacturer’s instructions.17 In brief: 50 mL of LB medium with 
antibiotic supplementation (200 µg/mL ampicillin, or 50 µg/mL kanamycin) were inoculated from a 
bacterial glycerol stock using a sterile inoculation loop or with 100 µL of a previous overnight culture. 
The culture was incubated at 37° C, 220 rpm for a maximum of 16 hours and subsequently harvested 
in a 50 mL conical tube by centrifugation at 6,000 xg and 4° C for 15 minutes. Afterwards, the pellet 
was re-suspended in 2.25 mL of Solution I with RNaseA by vortexing. When the pellet was re-
suspended completely, 2.25 mL of Solution II were added and the tube was slowly inverted for 
two minutes to completely lyse the sample. By addition of 3.2 mL of Solution III the lysis reaction was 
stopped and a white flocculent precipitate formed. The precipitate was pelleted at 10,000 xg for 
20 minutes. The cleared supernatant was transferred to a HiBind DNA midi column in a tube in 3.5 mL 
steps and centrifuged at 4,000 xg for three minutes in a swinging bucket rotor. The flow-through was 
discarded. This step was repeated until all supernatant was passed through the column. Next, 3 mL of 
HBC buffer diluted with 100% isopropanol were added and the column centrifuged at 4,000 xg for 
three minutes. The flow-through was discarded. Remaining salts were washed from the membrane 
with two washing steps using 3.5 mL of Wash buffer diluted with 100% ethanol each. The flow-
through was discarded, and the empty column centrifuged at 4,000 xg for five minutes to completely 
dry the membrane. The dried column was transferred to a sterile 15 mL conical tube, 500 µL of pre-
 
17 E.Z.N.A. Plasmid DNA Midi Kit – manual available at https://www.omegabiotek.com/product/e-z-n-a-plasmid-midi-kit/ 
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warmed (55° C) nuclease-free water were added to the matrix and incubated at room temperature for 
five minutes. Finally, the bound DNA was eluted by centrifugation at 4,000 xg for five minutes. To 
increase the DNA-yield, the eluate was used for a second elution step. The sample was transferred to 
a sterile 1.5 mL microcentrifuge tube, and DNA concentration as well as purity were determined using 
the NanoDrop2000c (software version 1.6, Thermo Scientific) and 1 µL of the purified DNA sample. 
500 ng of the obtained plasmid DNA were subjected to a restriction endonuclease digestion 
(section 2.1.3) which verified the plasmid’s identity by a characteristic pattern of bands in agarose gel 
electrophoresis. 
 
Plasmid DNA purification using the HiSpeed Midi Kit (12643, QIAGEN): 
Plasmid DNA used for transfection of hiPSCs has to be of high purity and quality. These requirements 
are only met using plasmid DNA purification kits of QIAGEN. The HiSpeed Midi Kit was used as 
described in the manual.18 In brief: 50 mL of LB medium with antibiotic supplementation (200 µg/mL 
ampicillin, or 50 µg/mL kanamycin) were inoculated from a bacterial glycerol stock using a sterile 
inoculation loop or 100 µL of a previous overnight culture. The culture was incubated at 37° C, 
220 rpm for a maximum of 16 hours and subsequently harvested in a 50 mL conical tube at 6,000 xg 
and 4° C for 15 minutes. After harvesting, the pellet is re-suspended in 6 mL of Buffer P1 supplemented 
with RNaseA and LyseBlue reagent by vortexing. Lysis was initiated by the addition of 6 mL of Buffer 
P2 followed by mixing through inversion and incubating the lysis reaction at room temperature for 
five minutes. Complete mixing of the solution was indicated by a uniform blue colouring of the mixture. 
During this incubation time, a QIAGEN filter cartridge was prepared by screwing a cap to the outlet 
nozzle. Addition of 6 mL of pre-cooled Buffer P3 and mixing by inversion stopped the lysis reaction, 
decoloured the solution, and formed a white flocculent precipitate. The lysate was poured into the 
prepared filter cartridge’s barrel immediately and was incubated undisturbed at room temperature for 
five minutes. During this incubation time, a HiSpeed Midi tip was equilibrated by adding 4 mL of 
Buffer QBT to the membrane and allowing the column to empty by gravity flow. The cap was removed 
from the outlet nozzle of the filter cartridge, and the plunger was inserted to filter the lysate onto the 
HiSpeed Midi tip. The filtered lysate was allowed to enter the resin by gravity flow. After a gravity 
flow washing step using 20 mL of Buffer QC, the bound DNA was eluted into a sterile 15 mL tube 
using 5 mL of Buffer QF. Next, the eluted DNA was precipitated by the addition of 3.5 mL 
(0.7 volumes) of 100% isopropanol and incubation at room temperature for 10 minutes. A QIAGEN 
precipitator module was attached to the barrel of a 20 mL syringe, and the precipitated 
eluate/isopropanol mixture was poured into the barrel. By applying constant pressure, the eluate was 
filtered through the module. Two washing steps using 2 mL of 70% ethanol each were performed using 
the same 20 mL syringe. The precipitator module was dried by pressing air through the module using 
the 20 mL syringe and tapping the outlet nozzle with absorbent paper. After drying the membrane 
 
18 Plasmid DNA HiSpeed Midi Kit (QIAGEN) – manual available at https://www.qiagen.com/ca/resources/resourcedetail?id=5a63b6b2-
7fd7-4fbf-b3cd-e50d8270fea1&lang=en 
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completely, a new 5 mL syringe-barrel was attached to the precipitator module, 500 µL of pre-warmed 
(55° C) nuclease-free water were applied, and incubated at room temperature for five minutes before 
inserting the plunger and eluting the DNA into a sterile 1.5 mL microcentrifuge tube. To increase the 
DNA-yield, the eluate was used for a second elution step. DNA concentration and purity were 
determined using the NanoDrop2000c (software version 1.6, Thermo Scientific) and 1 µL of the 
purified DNA sample. 
500 ng of the obtained plasmid DNA were subjected to a restriction endonuclease digestion 
(section 2.1.3) which verified the plasmid’s identity by a characteristic pattern of bands in agarose gel 
electrophoresis. 
 
2.1.12. Sanger sequencing of DNA samples 
Sequencing is used as a final verification of the successful cloning of the recombinant plasmid of 
interest. Plasmid DNA which showed the expected pattern of bands in agarose gel electrophoresis 
upon digestion with restriction endonuclease(s) was sent for sequencing to Microsynth Seqlab. 
Sequencing reactions were composed of 800 to 1200 ng of DNA in a total volume of 12 µL and three 
microliters of a 10 µM sequence specific primer which ideally binds 50 bp upstream of the site to be 
sequenced. The tube was labelled with a registered Barcode EasyRun label and deposited in the Seqlab 




TA-cloning is a fast and simple cloning technology based on the ligation of complementary A- and T-
overhangs at plasmid and insert DNA ends. Blue-white selection of the transformants allows for direct 
visual identification of recombined colonies. The components needed for TA-cloning are pBluescript 
(plasmid #80) or any other backbone plasmid with a LacZ gene for blue-white screening, suitable blunt 
restriction endonuclease recognition site, and a 
Taq polymerase which adds single-base 
overhangs to the 3’ end of DNA due to its 
transferase activity. First, pBluescript was 
linearised via the EcoRV restriction 
endonuclease recognition site within the LacZ 
gene, and the digested DNA was purified using 
the Clean&Concentrator-5 kit (section 2.1.2). 
The desired insert was PCR amplified using a proof-reading DNA polymerase as described in 
section 2.1.1. Using the Taq polymerase JumpStart Taq (D9307, Sigma) and dATP or dTTP, 3’ A- or 
T-overhangs were added to the insert’s or plasmid’s blunt DNA ends, respectively (Figure 12 and 
Table 16).  
Figure 12: TA-Cloning. Schematic overview of the addition of 
3' A- or T-overhangs to insert or plasmid DNA, respectively. 
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Table 16: Setup of the addition of 3' A-/T- overhangs to blunt DNA ends for TA-cloning. 
REACTION COMPONENT FINAL CONCENTRATION VOLUME 
Blunt ended DNA (insert/plasmid) 600 ng to 1 µg 2.5 µL 
dATP/dTTP (R0441/R0171, Life 
Technologies) 
2 mM 0.5 µL 
10x JumpTaq Buffer 1x 0.5 µL 
JumpStart Taq (D9307, Sigma) 2.5 U 0.5 µL 
Nuclease free water  Add to 50 µL 
 
The reaction mix was incubated at 68° C for 20 minutes, and the processed DNA fragments were 
purified using the Clean&Concentrator-5 Kit (Zymo, section 2.1.2). Subsequently, plasmid and insert 
were ligated as described in section 2.1.7 and transformed into chemically-competent E. coli 
(section 2.1.9). To initiate the blue-white selection, 40 µL of Isopropyl β-D-thiogalactopyranoside 
(IPTG, 20 mg/mL in water, 05684, Biomol) and 40 µL of 5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside (X-Gal, 25 mg/mL in DMSO, BIO-37035, Bioline) were added to the 
transformation mix prior to plating. Transformants with an intact LacZ gene, without the insert, 
metabolize the chromogenic β-galactosidase substrate X-Gal producing galactose and 5-bromo-4-
chloro-3-hydroxyindole. The latter spontaneously dimerises and is oxygenised into 5,5'-dibromo-4,4'-
dichloro-indigo, an insoluble intense blue compound responsible for the blue colour of the negative 
colonies. Transformants with a disturbed LacZ gene, due to integration of the insert, cannot 
metabolize X-Gal and remain white. After overnight incubation of the transformation plates, it was 
necessary to incubate the plates at 4° C for two to four hours until the blue colour of the negative 
transformants becomes observable. Two to four white colonies were then used to inoculate LB-cultures 
and incubated at 37° C overnight for plasmid DNA isolation and a detailed analysis of the obtained 
plasmid (section 2.1.11). 
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2.1.14. Overlap extension method 
Introduction of small insertions, deletions or point 
mutations into sequences close to suitable restriction 
endonuclease recognition sites is possible by the mutation 
of the oligonucleotide primer’s sequence used for PCR 
amplification of the sequence of interest. If mutations are 
to be introduced which are located more distant to a 
restriction endonuclease recognition site, the overlap 
extension method can be applied for site-directed 
mutagenesis (Heckman and Pease 2007). 
The overlap extension method for mutation of DNA 
sequences requires four oligonucleotide primers and three 
separate PCRs. Since the final PCR product will be used 
for cloning, the use of a proof-reading DNA polymerase 
like Phusion DNA polymerase is recommended 
(section 2.1.1). In the first round of PCR, the mutation is 
introduced to the 5’ or 3’ terminus of two independent 
DNA fragments, respectively. A “sense” mutated primer is 
combined with an “anti-sense” flanking primer and vice 
versa (Figure 13, adapted from Heckman and Pease 
(2007)). The purified PCR products are then used in a 1:2 
mass ratio based on fragment size (100 ng of total DNA 
mass) as a template in the second round of PCR. In this 
last reaction, the “sense” and “anti-sense” flanking primers are used to amplify the mutated fragment 
and to add suitable restriction endonuclease recognition sites to the 3’ and 5’ end of the PCR product. 
Subsequently, the mutated PCR product can be cloned into the desired backbone plasmid via 
restriction endonuclease cloning (sections 2.1.3 and 2.1.7).  
The mutated primers have to be designed to be fully complementary containing the desired mutation 
in the sequence’s centre. Due to the extensive overlap of the primers, also a chimeric gene product by 
artificial splicing can be generated. In this case, the “mutated” primers do not carry a mutation of the 
sequence but are half upstream and half downstream sequence of the chimeric gene product (10 bp 
each) generating a 20 bp overlap for the second round of PCR. 
  
Figure 13: Schematic overview of the overlap 
extension method to introduce mutations into DNA 
sequences. Site directed mutagenesis is achieved by 
using the mutation-containing primers b and c and 
the flanking primers a and d to generate PCR 
products AB and CD. In a second round of PCR the 
PCR products AB and CD are combined in a 1:2 
mass ratio and PCR product AD is amplified using 
the flanking primers a and d. (Heckman and Pease 
2007) 
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2.1.15. Cloning of guide RNA sequences into multiplex CRISPR/Cas9(n) plasmids 
Target-specific sequences were cloned into the multiplex all-in-one plasmid system described by 
Sakuma, Nishikawa et al. (2014) (CRISPR/Cas9 Assembly System Kit #1000000055, Addgene, 
Figure 14). 
 
Figure 14: Schematic overview of the cloning of all-in-one multiplex CRISPR/Cas9n plasmids as described in Sakuma, 
Nishikawa et al. (2014). Annealed and phosphorylated sequences targeting the gene of interest are cloned into pX330A-1x2 or 
pX330S via BbsI. Subsequently, Golden Gate assembly using BsaI combines the sense and antisense gRNA expression 
cassettes in the pX330A backbone. AmpR, β-lactamase confers resistance to ampicillin. SmR, aminoglycoside 
adenylyltransferase confers resistance to spectinomycin. Adapted from Sakuma, Nishikawa et al. (2014). 
Suitable sequences for targeting using the Cas9 nickase were identified using the CRISPR designing 
tool of MIT (http://tools.genome-engineering.org). For each targeting sequence, two 
oligonucleotides (forward and reverse) were ordered. To meet the requirements of the CRISPR/Cas9 
Assembly kit overhangs complementary to the pX330 plasmids were added 5’ to the oligonucleotides 
(5’ CACCG to the forward, and 5’ AAAC to the reverse oligonucleotide). The oligonucleotides were 
annealed and phosphorylated, as stated in Table 17. 
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Table 17: Reaction setup for the annealing and phosphorylation of oligonucleotides. 
REACTION COMPONENT VOLUME, 10 µL REACTION 
Forward oligonucleotide, 100 µM 1 µL 
Reverse oligonucleotide, 100 µM 1 µL 
10x T4 DNA Ligase Buffer (B0202S, NEB) 1 µL 
Nuclease free water 6.5 µL 
T4 Polynucleotide Kinase (M0201S, NEB) 0.5 µL 
 
The reaction mix was incubated at 37° C for 30 minutes, followed by 95° C for five minutes. Starting 
from 95° C, the reaction was cooled down to 25° C at a reduction rate of 5° C per minute. The annealed 
and phosphorylated oligonucleotides were diluted 1:250 in nuclease-free water and cloned into the 
pX330 plasmids.  
As a first step in the cloning of the multiplex all-in-one plasmid system, a digestion and ligation 
reaction of the annealed targeting oligonucleotides and the pX330 plasmids using BbsI were prepared 
(Table 18, Figure 14). In general, the sequence targeting the sense strand of the gene of interest was 
cloned into pX330A-1x2 (plasmid #120, #217, #219, or #220) and the sequence targeting the 
antisense strand of the gene of interest was cloned into pX330S-2 (plasmid #145). 
Table 18: Digestion and ligation reaction setup for the cloning of targeting sequences into pX330 plasmids. 
REACTION COMPONENT VOLUME 
pX330A-1x2/pX330S-2 100 ng 
Annealed and phosphorylated oligonucleotide, 1:250 2 µL 
10x Tango Buffer (BY5, Thermo Fisher) 2 µL 
dTTP, 10 mM (R0171, Life Technologies 1 µL 
dATP, 10 mM (R0441, Life Technologies) 1 µL 
BbsI-HF (R3539S, NEB, 20,000 U/mL) 0.5 µL 
T4 DNA ligase (EL0014, Thermo Fisher, 5 U/µL) 0.5 µL 
Nuclease free water Add to 20 µL 
 
The reaction mix was placed in a thermal cycler (peqSTAR 2x Universal Gradient, 732-2889DE, 
VWR) programmed with six cycles of incubation at 37° C for five minutes, followed by incubation at 
23° C for five minutes. After transforming chemically-competent E. coli and plating them on LB-plates 
appropriately supplemented with antibiotics (pX330A-1x2 200 µg/mL ampicillin, pX330S-2 
100 µg/mL spectinomycin PHR1441, VWR, section 2.1.9), two colonies per plasmid were picked, 
propagated, and plasmid DNA was analysed by BbsI digestion (section 2.1.11). Clones which inserted 
the targeting oligonucleotide will not be cut by BbsI as the restriction endonuclease’s recognition site 
will be lost.  
In a second step, the gRNA expression cassettes of pX330A-gRNA sense and pX330S-gRNA antisense 
were combined in the pX330A backbone using Golden Gate assembly via BsaI (Table 19, Figure 14).  
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Table 19: Golden Gate assembly of CRISPR/Cas9n multiplex plasmids. 
REACTION COMPONENT VOLUME 
pX330A-gRNA sense 100 ng 
pX330S-gRNA antisense 150 ng 
10x Tango Buffer (BY5, Thermo Fisher) 2 µL 
dTTP, 10 mM (R0171, Life Technologies 1 µL 
dATP, 10 mM (R0441, Life Technologies) 1 µL 
BsaI-HF (R3733S, NEB, 20,000 U/mL) 0.5 µL 
T4 DNA ligase (EL0014, Thermo Fisher, 5 U/µL) 0.5 µL 
Nuclease free water Add to 20 µL 
 
The reaction mixture was placed in a thermal cycler (peqSTAR 2x Universal Gradient, 732-2889DE, 
VWR) programmed with six cycles of incubation at 37° C for five minutes, followed by incubation at 
23° C for five minutes each. E. coli DH5α were transformed with 5 µL of the Golden Gate reaction and 
supplemented with IPTG and X-Gal for blue/white screening (section 2.1.9). Up to ten white colonies 
were analysed by colony PCR using the oligonucleotides #666 and #667 (section 2.1.10). The forward 
primer #666 was binding the U6 promoter. Thus, two fragments of 1,000 bp and 500 bp were expected 
upon assembly of both gRNA expression cassettes in the pX330A backbone. Colonies showing both 
bands in colony PCR were propagated for plasmid DNA purification and analysed by BsaI digestion. 
Upon successful assembly, the BsaI restriction endonuclease recognition site will be lost, and positive 
clones will not be cut. 
 
2.1.16. Gateway cloning 
Gateway cloning was performed according to Katzen (2007). For this work, only the integrating LR 
reaction for the transfer of the gene(s) of interest from a donor plasmid (pENTR4, plasmid #174) to a 
lentiviral recipient plasmid (e.g. pLenti-UbC, plasmid #160) was required. 
The LR reaction was set up on ice from the LR clonase II mix of Invitrogen (11791019, Thermo 
Fisher) according to the following scheme (Table 20). 
Table 20: Reaction set up of the LR reaction in the Gateway Cloning process. 
REACTION COMPONENT VOLUME 
Entry clone 150 ng 
Recipient plasmid 150 ng 
5x LR clonase enzyme mix 2 µL 
TE buffer pH 8.0 Add to 10 µL 
 
The reaction mix was incubated at 25°C for one hour. 1 µL of proteinase K was added, mixed, and 
incubated at 37° C for 10 minutes. Subsequently, E. coli Stbl3 were transformed with 5 µL of reaction 
mix and incubated at 30° C overnight to suppress any residual recombination activity (section 2.1.9). 
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2.1.17. RNA isolation 
Cell samples for RNA isolation were obtained by detaching the cells from their culture flask’s surface 
using the appropriate detaching agent and incubation time (section 2.3). Detached cells were harvested 
by centrifugation in a microcentrifuge tube at 200 xg for three minutes and washed in 500 µL of 
Dulbecco’s Phosphate Buffered Saline (DPBS) twice to allow efficient lysis of the cells. The obtained 
pellet was either flash-frozen in liquid nitrogen for storage at -80° C or directly used for RNA isolation 
using the GenElute Total Mammalian RNA Miniprep Kit (RTN350, Sigma Aldrich). 
 
GenElute Total Mammalian RNA Miniprep Kit 
RNA was isolated from harvested, and DPBS washed cell pellets using the GenElute Total 
Mammalian RNA Miniprep Kit (RTN350, Sigma Aldrich) according to the manufacturer’s 
instructions. In brief: 10 µL of β-mercaptoethanol (4227, Carl Roth) was added per 1 mL of lysis 
solution to achieve effective degradation of RNases present in the sample. 250 µL of lysis solution was 
used for samples containing less than 5x106 cells, and 500 µL of Lysis solution was used for samples 
of 5x106 to 1x107 cells. The appropriate amount of lysis solution was added to the sample, and the cells 
were disrupted by vortexing vigorously for one minute. All samples containing more than 1x106 cells 
had to be passed through a GenElute Filtration Column after lysis by centrifugation at maximum 
speed for two minutes. An equal volume of 70% ethanol was added to the flow-through and mixed well 
by pipetting. Up to 700 µL of this sample was transferred to a GenElute Binding Column and 
centrifuged at maximum speed for 15 seconds. The flow-through was discarded, and the binding step 
repeated until the complete sample was passed through the binding column. After a first wash step 
using 250 µL of Wash Solution I (centrifuged at maximum speed for 15 seconds), on-column DNaseI 
digestion was performed to remove all contaminating traces of DNA present in the sample. For 
DNaseI digestion, 10 µL of DNaseI stock was diluted in 70 µL of Buffer RDD (RNase free DNase Set, 
79254, QIAGEN) by gently pipetting up and down. The complete 80 µL of DNase I reaction mix were 
applied to the binding column by directly pipetting it onto the membrane and incubated at room 
temperature for 15 minutes. Following, the binding column was washed to remove all remaining salts 
from the RNA sample. First, 250 µL Wash Solution I were added to the DNase I solution on the 
column and centrifuged at maximum speed for 15 seconds. The flow-through was discarded and the 
column placed in a new collection tube. Secondly, two subsequent wash steps using 500 µL of Wash 
Solution II and centrifugation for 15 seconds at maximum speed each were performed. The flow-
through was discarded and the empty column centrifuged at maximum speed for one minute to 
completely dry the membrane. Finally, the column was placed in a new collection tube, 30 to 50 µL of 
nuclease-free water were applied to the column matrix, incubated at room temperature for five minutes, 
and the RNA was eluted by centrifuging the column at maximum speed for one minute. Eluted RNA 
was put on ice immediately. RNA concentration and purity were determined using the 
NanoDrop2000c (software version 1.6, Thermo Scientific), and RNA was stored at -80° C. 
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2.1.18. cDNA synthesis 
Complementary DNA (cDNA) is used for different applications like the cloning of coding-sequences 
of interest in recombinant plasmids or as a template for the quantification of the gene of interest’s 
transcript via PCR. cDNA is reversely transcribed from RNA and contains coding sequences of the 
gene locus. The enzymes catalysing the reverse transcription are reverse transcriptases (RTs), which 
use a random hexamer primer or a short primer complementary to the 3’ end of RNA to prime the 
synthesis of first strand cDNA. The first strand cDNA can directly be used as a template in a PCR 
reaction during which it will be complemented to double-stranded cDNA and thus can be used for 
cloning of the gene of interest into recombinant plasmids.  
In this thesis, the reverse transcriptase (RT) from the Moloney Murine Leukemia Virus (M-MuLV) 
was used. The enzyme is genetically optimised to be more thermostable than the wild-type form, lacks 
a 3’ to 5’ exonuclease activity and exhibits a reduced RNase H activity specific to RNA in RNA-DNA 
hybrids compared to other RTs. cDNA syntheses were set up on ice as follows (Table 21). 
Table 21: Reaction setup cDNA synthesis - part I. 
REACTION COMPONENT VOLUME 
Total RNA 1 µg 
Random Hexamer Primer, 100 µM (SO142, Thermo Fisher) 1 µL 
Nuclease free water Add to 12.5 µL 
 
The reaction was mixed, incubated at 65° C for five minutes in a thermal cycler (peqSTAR 
2x Universal Gradient, 732-2889DE, VWR), and immediately put on ice. 7.5 µL of RT-reaction mix 
was added to each sample (Table 22), mixed and incubated in a thermal cycler at 25° C for 10 minutes, 
followed by incubation at 42° C for one hour. The enzyme was inactivated at 70° C for 10 minutes. 
5 to 10 µL aliquots were prepared from the 20 µL reaction and stored at -20° C. 
Table 22: Reaction setup cDNA synthesis - part II. 
REACTION COMPONENT VOLUME 
5x RT reaction buffer 4 µL 
10 mM dNTPs (N0446S, NEB) 2 µL 
RiboLock RNase Inhibitor (40 U/µL, EO0382, Thermo Fisher) 0.5 µL 
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2.1.19. Quantitative reverse transcription PCR (RT-qPCR) 
Real-time or quantitative PCR (qPCR) is a method to measure the amplification of a DNA fragment 
as the reaction takes place. If RNA or complementary DNA (cDNA) is used as a template, the method 
is called quantitative reverse transcription PCR (RT-qPCR). Using RNA/cDNA as a template allows 
the indirect quantification of RNA and by this, the expression of a specific gene of interest.  
The template’s amplification is measured via the fluorescent dye SYBRGreen which weakly binds to 
single stranded nucleic acids like RNA or cDNA but emits a strong fluorescent signal as it binds to 
double-stranded DNA after PCR amplification. As soon as a signal intensity stronger than the 
background fluorescence is detectable, a quantification cycle or cT (threshold) value is determined. The 
cT value reflects the number of cycles necessary to reach a fixed signal threshold. With these values 
the target’s relative abundance between two or more samples can be evaluated. cT values thus allow to 
evaluate the effect of a treatment on gene expression of a gene of interest. Normalization to a gene, 
whose expression is not expected to vary within cell cycle or upon the treatment (housekeeping or 
reference gene), serves as a control for differences in RNA extraction, RNA quality, and efficiency of 
reverse transcription. Subtraction of the gene of interest’s cT from the housekeeping gene’s cT value 
gives the normalised expression value ∆cT. The difference of ∆cT values of different samples (∆∆cT) 
expresses the direction and size of the change in gene expression between these samples. ∆∆cT is the 
logarithm of the ratio of concentrations of cDNA or the log fold-change. Usually, the relative 
quantification RQ is blotted when analysing RT-qPCR data. RQ is the square of the negative ∆∆cT 
and reflects the mean expression level of the gene of interest. The extending bars in these blots do not 
reflect error bars but represent the lowest and highest values of expression level of the gene of interest 
based on cT values.  
The StepOnePlus system of Applied Biosystems (4376600, Thermo Fisher) in combination with the 
PowerUp SYBRGreen Master Mix of Applied Biosystems (15320929, Fisher Scientific) and low profile 
96-well microtitre plates (732-3221, Peqlab brand VWR) was used for RT-qPCR analysis. Primers 
used for RT-qPCR were validated against a relative standard curve prior to gene expression analyses. 
Amplification efficiency of 95 to 105% at the given primer annealing temperature was accepted for 
further experiments. RT-qPCR reactions were set up as described in Table 23. 
Table 23: Setup of RT-qPCR reactions. 
REACTION COMPONENT VOLUME 
PowerUp SYBRGreen Master Mix (15320929, Fisher Scientific) 12.5 µL 
10 µM Forward Primer 0.5 µL 
10 µM Reverse Primer 0.5 µL 
Nuclease-free water 7.5 µL 
Template cDNA 4  µL 
 
Three technical replicates per sample and gene analysed were set up in a 96-well plate. All reaction 
components except for the cDNA were prepared as a master mix and stored on ice. The final reaction 
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was composed of the 4 µL template cDNA which were pipetted first into each well and 21 µL of the 
master mix which were added last. Each well was mixed by pipetting up and down three times. Finally, 
the microtitre plates were sealed with self-adhesive foil (BRND701367, VWR), and the contents were 
collected by centrifugation. The PCR was run in a StepOnePlus thermal cycler with the programme 
described in Table 24. 
Table 24: RT-qPCR thermal cycler programme. 
STAGE TEMPERATURE TIME 









Melt curve stage 95° C 
2055-60° C 







After the run, data was collected from the machine and analysed using StepOne Software (Version 2.3) 
and Microsoft Excel. The ∆∆cT method was applied as described above and calculated RQ values were 




19 Primer melting temperature as calculated by IDR OligoAnalyzer https://eu.idtdna.com/calc/analyzer 
20 Primer melting temperature as calculated by IDR OligoAnalyzer https://eu.idtdna.com/calc/analyzer 
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2.2. Biochemical methods 
2.2.1. Protein sample preparation and protein concentration measurement 
Samples for protein analyses by immunoblotting were harvested in Lämmli buffer (Table 25). An 
appropriate volume of Lämmli buffer (e.g. 150 to 200 µL per well of a 6-well plate) was added directly 
to the DPBS-washed, adherent cells which were detached using a cell scraper (3008, Costar, Corning). 
Alternatively, dissociated or sorted cells were washed in DPBS, and an appropriate volume of Lämmli 
buffer was added. The cells in Lämmli buffer were then heated to 95° C for five minutes, cooled down 
on ice, and subsequently sonicated (one minute, intervals of five seconds) to efficiently extract and 
denature the sample’s proteins. The so prepared protein samples were stored at -20° C or directly used 
for protein concentration measurement. 
Table 25: Composition of the protein extraction buffer after Lämmli (Lämmli buffer). 
COMPONENT FINAL CONCENTRATION AMOUNT 
1 M Tris-HCL, pH 7.5 10 mM 1 mL 
SDS (112533, Merck) 2% 2 g 
EGTA (108435, Merck) 2 mM 0.076 g 
NaF (P756.1, Roth) 20 mM 0.084 g 
All components were added to a graduated measuring cylinder, and dissolved in approx. 60 mL of 
MilliQ H2O while stirring. As soon as all components were dissolved, the stirring bar was removed, 
and the volume was filled up to 100 mL with MilliQ H2O. 
 
Protein concentration measurement was performed using the DC protein assay of Bio-Rad (500-0116). 
This assay is based on the biuret reaction of the Lowry assay but optimised to show a faster and more 
stable colour reaction. The colorimetric assay relies on the reaction of proteins with an alkaline copper 
tartrate solution (reagent A) and a Folin reagent (reagent B). Colour development takes place in two 
steps: first, the proteins in the sample react with the copper in alkaline medium to form cuprous ions. 
Secondly, the Folin reagent interacts with these cuprous ions and side chains of tyrosine, tryptophan, 
and cysteine amino acid residues. Thus, the Folin reagent is reduced to several possible reduced species 
which emit the characteristic blue colour with a maximum absorbance at 750 nm. 
For protein concentration measurements, the protein samples were thawed and centrifuged at 
18,000 xg for three minutes. 25 µL of the sample in an appropriate dilution (1:5 in Lämmli buffer) was 
prepared in two technical replicates in spectrophotometer cuvettes (613101, semi-micro, Greiner 
bio- one). 25 µL of Lämmli buffer were prepared to serve for background measurement (Ostrom, de 
Blank et al.). To prepare the working reagent A’, 20 µL of reagent S were added per 1 mL of reagent 
A. 125 µL of working reagent A’ were then added to the protein dilution, and mixed with 1 mL of 
reagent B in the cuvette. The reaction was incubated in the dark for 15 minutes before measuring the 
absorbance at 750 nm in a spectrophotometer (Spectronic BioMate 3, 335904, Thermo). The measured 
absorbance values were compared to a protein concentration standard to determine the sample’s 
concentration. 
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Based on these calculations, protein samples of equal protein concentration (10 to 15 µg) were prepared 
in 4x loading buffer to a final volume of max. 40 µL (Table 26) for the SDS PAGE. The calculated 
sample volume was supplemented with 4x protein loading buffer to a final concentration of 1x, and 
diluted with Lämmli buffer. The sample was mixed by vortexing. After incubating the prepared sample 
at 95° C for 10 minutes and cooling it down on ice, the sample was directly loaded onto the SDS-
containing polyacrylamide gel or stored at -20° C. 
Table 26: Composition of 4x protein sample buffer for SDS PAGE and immunoblotting. 
COMPONENT FINAL CONCENTRATION AMOUNT 
1 M Tris-HCL, pH 6.8 200 mM 1.6 mL 
10% SDS (from 112533, Merck) 4% 4 mL 
100% Glycerol (7530.4, Roth) 2 mM 2 mL 
Bromphenol blue (11746, Merck) 0.02% 1.9 mg 
MilliQ H2O  1.9 mL 
250 µL aliquots of the sample buffer were prepared and stored at -20° C. Prior to use, 1 µL of 
β- mercaptoethanol (4227.3, Roth) were added per 50 µL of sample buffer. 
 
2.2.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) is a denaturing method to 
separate proteins according to their mass due to an overall negative charge imparted on the denatured 
proteins by the bound SDS detergent.  
Polyacrylamide is a mixture of acrylamide and bisacrylamide which forms a cross-linked polymer 
network when the polymerizing agent ammonium persulfate (APS) is added. The polymerisation 
reaction is catalysed by tetramethylethylenediamine (TEMED) which promotes the production of free 
radicals by APS. For protein separation, two polyacrylamide gels with different characteristics are 
combined. The protein sample is concentrated in the stacking gel before entering the resolution gel. 
The stacking gel contains a lower concentration of polyacrylamide, therefore exhibits a larger pore 
size, has a lower pH, and a different ionic content compared to the resolution gel allowing the sample 
to move through it quickly and to be concentrated directly above the resolution gel. This concentration 
ensures optimal resolution of the proteins present in the sample.21  
In this thesis, a discontinuous buffer system based on tris-glycine base of the Lämmli system was used 
to separate proteins in SDS PAGE prior to immunoblotting in the Mini Trans-Blot Electrophoretic 
Transfer cell (1703930, Bio-Rad). The SDS-containing polyacrylamide gels were always cast freshly 
prior to use. To cast the gel, two glass slides (1.5 mm) were cleaned with 70% EtOH and delicate task 
wipers, and fastened together with the casting clamp. The casting clamp was then fixed onto its holder 
to lay plane on the bottom. First, the resolution gel was prepared according to Table 27. For the 
 
21 https://www.thermofisher.com/de/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-
library/pierce-protein-methods/overview-western-blotting.html, May 03, 2020 
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analysis of proteins larger than 50 kDa, 8% polyacrylamide gels, for the analysis of proteins smaller 
than 50 kDa, 12% polyacrylamide gels were cast. Upon addition of APS and TEMED, the gel 
components were mixed quickly and completely by inversion, and the mixture was directly poured in 
between the glass slides to approx. ¾ of the volume. The polymerizing gel was immediately overlaid 
by 100% isopropanol to prevent drying. During the 30 minutes’ polymerisation, the stacking gel was 
prepared according to Table 28. Before adding APS and TEMED, the isopropanol layer on the 
resolution gel was removed completely by pouring it from the gel and absorbing the remaining fluid 
with strips of Whatman paper. Upon addition of APS and TEMED, the gel components were mixed 
quickly and completely by inversion and the mixture was directly poured in between the glass slides 
till an upper meniscus formed atop of the glass slides. A 10- lane comb (1.5 mm) was carefully pushed 
into the polymerizing stacking gel without any bubbles. After 30 minutes, the polymerised gel between 
the glass slides was carefully removed from the holder and two gels were fixed into the electrophoresis 
holder. After testing for leaks with running buffer (Table 31), the electrophoresis holder was placed in 
the electrophoresis chamber. The chamber was filled with the indicated amount of running buffer, the 
combs were removed, and each well of the gels was rinsed with running buffer to remove gel residues. 
Per gel, at least one well was loaded with 7 µL of pre-stained PageRuler (26616, Thermo Fisher), the 
remaining wells were loaded with the prepared protein samples (section 2.2.1). The samples were 
concentrated through the stacking gel right above the resolution gel by applying 80 V for 
15 to 20 minutes. As soon as the samples formed a tight line above the resolution gel and the protein 
standard had started to move into the resolution gel, the voltage was increased to 130 V. 
Electrophoresis was run until the protein standard indicated an appropriate separation (approx. 
60 minutes). For the analysis of SMARCB1 protein, the SDS PAGE was run until the 25 kDa band of 
the protein standard had moved to the lower edge of the gel to ensure separation of both isoforms of 
SMARCB1 while keeping the GAPDH reference on the gel. 
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Table 27: Composition of polyacrylamide gels for protein separation in a SDS PAGE (resolution gel). Volumes are sufficient 
for casting one gel in 1.5 mm slides. Polyacrylamide gels with 8% acrylamide were used to separate proteins larger than 50 
kDa, 12% polyacrylamide gels were used to separate proteins smaller than 50 kDa. APS and TEMED were added last, and the 
gel was cast quickly upon addition of APS and TEMED. 
COMPONENT FINAL CONCENTRATION AMOUNT 
MilliQ H2O  4.65 mL 
Resolution gel buffer (Table 29)  2.6 mL 
30% Acrylamide solution (3029.2, Roth) 8% 2.7 mL 
10% APS (9592.2, Roth) 0.01% 100 µL 
TEMED (2357.1 Roth)  5 µL 
 
COMPONENT FINAL CONCENTRATION AMOUNT 
MilliQ H2O  3.5 mL 
Resolution gel buffer (Table 29)  2.6 mL 
30% Acrylamide solution (3029.2, Roth) 12% 4 mL 
10% APS (9592.2, Roth) 0.01% 100 µL 
TEMED (2357.1 Roth)  5 µL 
 
Table 28: Composition of the polyacrylamide gels for sample concentration in a SDS PAGE (stacking gel). Volumes are 
sufficient for casting one gel in 1.5 mm slides. APS and TEMED were added last and the gel was cast quickly upon addition 
of APS and TEMED. 
COMPONENT FINAL CONCENTRATION AMOUNT 
MilliQ H2O  3.05 mL 
Stacking gel buffer (Table 30)  1.3 mL 
30% Acrylamide solution (3029.2, Roth) 0.4% 0.65 mL 
10% APS (9592.2, Roth) 0.005% 50 µL 
TEMED (2357.1 Roth)  5 µL 
 
Table 29: Composition of the resolution gel buffer required to prepare the resolution gel for SDS PAGE. 
COMPONENT FINAL CONCENTRATION AMOUNT 
Tris Base (4855.2 Roth) 1.5 M 18.17 g 
20% SDS (from 112533, Merck) 0.4% 2 mL 
Tris base was dissolved in 60 mL of MilliQ H2O in a graduated measuring cylinder. The pH of the tris 
buffer was adjusted to pH 8.8 (S20 SevenEasy pH, 51302803, Mettler Toledo) by adding 5 M 
hydrochloric acid (HCl). SDS was added, and the volume filled up to 100 mL with MilliQ H2O. The 
buffer was used immediately for preparation of the SDS-containing polyacrylamide resolution gel to 
ensure optimal resolution and sharp protein bands. 
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Table 30: Composition of the stacking gel buffer required to prepare the stacking gel for SDS PAGE. 
COMPONENT FINAL CONCENTRATION AMOUNT 
Tris Base (4855.2 Roth) 0.5 M 6.06 g 
20% SDS (from 112533, Merck) 0.4% 2 mL 
Tris base was dissolved in 50 mL of MilliQ H2O in a graduated measuring cylinder. The pH of the tris 
buffer was adjusted to pH 6.8 (S20 SevenEasy pH, 51302803, Mettler Toledo) by adding 5 M 
hydrochloric acid (HCl). SDS was added, and the volume filled up to 100 mL with MilliQ H2O. The 
buffer was used immediately for preparation of the SDS-containing polyacrylamide resolution gel to 
ensure optimal resolution and sharp protein bands. 
Table 31: Composition of 10x running buffer for SDS PAGE. 
COMPONENT FINAL CONCENTRATION AMOUNT 
Tris Base (4855.2 Roth) 250 mM 60.6 g 
Glycine (3790.2, Roth) 2 M 288 g 
SDS (112533, Merck) 1% 20 g 
Tris base, glycine, and SDS were dissolved in two litres of MilliQ H2O and stored at room temperature. 
For SDS PAGE, the 10x running buffer was diluted 1:10 in MilliQ H2O. 
 
2.2.3. Immunoblotting 
Immunoblotting, in general, describes the transfer of biologic samples from a gel to an adhesive 
membrane and subsequent qualitative or semi-quantitative detection of the sample on the membrane’s 
surface by specific antibody-antigen interaction. For the purpose of this thesis, wet immunoblotting 
was used to identify target proteins in a sample after separation of the proteins using SDS PAGE. 
For the transfer of the separated proteins from the polyacrylamide gel to a polyvinylidene difluoride 
(PVDF) membrane, the gel has to be in direct contact with the membrane’s surface. Therefore, the 
polyacrylamide gel and the PDVF membrane were sandwiched between Whatman paper and foam 
pads soaked in transfer buffer in a transfer clamp in the following order: starting on the clear side of 
the transfer clamp, one foam pad, three pieces of transfer buffer-soaked Whatman paper (approx. 
8.5x10.5 cm, 5421836, Opti-lab), the methanol-activated and hydrophilised PVDF membrane 
(3010040001, Sigma Aldrich), the SDS-containing polyacrylamide gel, three pieces of transfer buffer-
soaked Whatman paper (approx. 8.5x10.5 cm), and one foam pad were stacked in transfer buffer 
(Table 33). Trapped air bubbles were removed by rolling a 15 mL tube over the stack, before tightly 
closing the clamp. The sandwich was inserted into the transfer holder with the black side of the 
sandwich facing the black side of the holder (black = negatively charged cathode). The transfer holder 
with the sandwich was then put in the electrophoresis chamber and placed on a stirring plate 
(preferably in a 4° C room). Transfer buffer was added up to the transfer mark on the electrophoresis 
chamber and an electric current of 300 V/250 mA was applied per sandwich inserted. The protein 
transfer was run for 1.5 hours. After the transfer, the membrane was washed twice in tris-buffered 
saline with Tween-20 (TBS-T, Table 34) for 10 minutes while shaking. To reduce the background due 
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to unspecific binding of the secondary antibody, the membrane surface was blocked with 5% milk in 
TBS-T (T145.2, Roth) for one hour at room temperature while shaking. Before probing the blocked 
membrane with the primary antibody to detect the gene of interest, it was cut to the area where the 
protein of interest was expected (for SMARCB1 and GAPDH protein the membrane was cut between 
the 70 and 55 kDa band and the 34 and 26 kDa band of the protein standard) to save on primary 
antibody. The cut membrane was placed in a small plastic dish and probed with the primary antibody 
in 5% milk in TBS-T (Table 32), and incubated overnight at 4° C while shaking. Afterwards, the 
membrane was washed three times in TBS-T for 10 minutes while shaking to remove any unbound 
antibody residues. For detection of the probed protein, a horse radish peroxidase (HRP)-coupled 
secondary antibody was diluted 1:2,000 in 5% milk in TBS-T, and incubated on the membrane for one 
hour at room temperature while shaking. Finally, the membrane was washed three times in TBS-T for 
15 minutes while shaking and put into TBS for imaging. Imaging was performed using the Fusion FX 
device and Fusion Capt Advance software of Vilber at the laboratory of the Löbrich group in serial 
mode and the enhanced chemo-luminescence (ECL) reagent of Pierce (10455145, Thermo Fisher). The 
protein standard was detected in auto mode to verify the size of the detected protein. 
Detection of GAPDH protein as a loading control required removal of the antibodies used to detect 
the gene of interest. Therefore, the membrane was incubated in glycine stripping buffer (Table 35) for 
one hour at room temperature, rinsed three times with TBS-T, and was re-blocked in 5% milk in 
TBS- T for 30 minutes to one hour at room temperature. Primary antibody probing against GAPDH 
was performed as described above with a shortened incubation time of one hour at room temperature.  
Table 32: Summary of primary and complementary secondary antibodies used for immunoblotting. 
1° ANTIBODY DILUTION  2° ANTIBODY 
α SMARCB1 (rabbit monoclonal, D8M1X, CST) 1:80,000 Goat α rabbit (HRP) 
111-035-003, Dianova 
α GAPDH (mouse monoclonal, Sc_47724, Santa 
Cruz) 
1:2,000 Goat α mouse (HRP) 
115-035-003, Dianova 
 
Table 33: Composition of 10x immunoblotting transfer buffer. 
COMPONENT FINAL CONCENTRATION AMOUNT 
Tris Base (4855.2 Roth) 250 mM 30.3 g 
Glycine (3790.2, Roth) 2 M 144 g 
Both components were dissolved in 1 L of MilliQ H2O to obtain a 10x concentrated transfer buffer 
stock. For protein transfer, the 10x stock was diluted in 1.4 L MilliQ H2O and 0.4 L of methanol 
(4627.5, Roth). The 1x transfer buffer can be filtered after each transfer and used three to four times. 
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Table 34: Composition of 10x Tris buffered saline (TBS) to prepare 1x TBS and 1x TBS-T for immunoblotting. 
COMPONENT FINAL CONCENTRATION AMOUNT 
Tris Base (4855.2 Roth) 200 mM 24.2 g 
NaCl (3957.2, Roth) 1.4 M 80 g 
Both components were dissolved in 1 L of MilliQ H2O for the 10x TBS stock. 100 mL of 10x TBS 
stock were diluted in 900 mL of MilliQ H2O to obtain the 1x TBS buffer. To obtain the 1x TBS-T 
working buffer, 0.1% of Tween-20 (9127.2, Roth) were added to 1x TBS (1 mL of Tween-20 per 1 L 
of 1x TBS). 
Table 35: Composition of the glycin stripping buffer. 
COMPONENT FINAL CONCENTRATION AMOUNT 
Glycine (3790.2, Roth) 200 mM 1.5 g 
Tween-20 (9127.2, Roth)  0.05% 50 µL 
The glycine was dissolved in a graduated measuring cylinder in approx. 70 mL of MilliQ H2O, the pH 
was adjusted to 2.5 (S20 SevenEasy pH, 51302803, Mettler Toledo) with 1 M HCl, then Tween-20 
was added. The volume was filled up to 100 mL. The buffer may be stored at room temperature for up 
to four weeks. 
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2.3. Cell culture methods 
Mammalian cells have to be handled in designated laboratories under a laminar flow hood to ensure a 
sterile working environment. All cell lines were kept in an all copper carbon dioxide (CO2) incubator 
at 37° C, 5% CO2, and 85-95% humidity. Whenever an exact cell number had to be plated, 100 µL of 
cell suspension in 10 mL of CASYton (5651808, OLS) were counted using the CASY Model TT Cell 
Counter & Analyser (OLS) with the appropriate settings. All waste generated during the work with 
mammalian cells was collected and sterilised in an autoclave at 121° C for 20 minutes. 
 
2.3.1. Cultivation and transfection of the human embryonic kidney cell line HEK293T  
Human embryonic kidney 293 (HEK293) cells were first established in 1973 and are now a widely used 
immortalised cell line for scientific research. The derivative HEK293T cell line expressed a mutant 
version of the SV40 Antigen T and was used in this thesis (Stepanenko and Dmitrenko 2015). 
HEK293T cells were grown in HEK293T growth medium composed of Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 4,500 mg/L glucose (DMEM-high glucose, D5671, Sigma 
Aldrich), 10% fetal calf serum (FCS, F7524, Sigma Aldrich), 2 mM L-Glutamine (G7513, Sigma 
Aldrich), 100 Units Penicillin, and 100 µg Streptomycin (P/S, P0781, Sigma Aldrich). 
When the cells grew to 70 to 90% confluency, HEK293T cells were passaged. After washing the T75 
culture flask (83.3911.002, Sarstedt) with 10 mL of sterile Dulbecco’s phosphate buffered saline (DPBS, 
D8537, Sigma Aldrich), 2 mL of Trypsin/EDTA solution (T3924, Sigma Aldrich) were rinsed over 
the cells and incubated at 37° C for three to five minutes. The detached cells were dissociated by 
pipetting up and down and were collected in at least 4 mL of HEK293T growth medium to inactivate 
the trypsin reaction. The cell suspension was centrifuged at 200 xg for three minutes, the supernatant 
was aspirated, and the cell pellet re-suspended in an appropriate volume, e.g. 5 mL, of growth medium. 
Depending on the number of cells required and the timing of the next experiment, HEK293T cells 
were re-seeded at a ratio of 1:5 to 1:100 in a T75 culture flask containing 10 mL of HEK293T growth 
medium. 
Transfection of HEK293T cells was performed using polyethylenimine (PEI), a stable cationic 
polymer that complexes DNA into positively charged particles which can bind negatively charged cell 
membranes. These PEI-DNA complexes enter the cell via endocytosis where the DNA is released into 
the cytoplasm (Boussif, Lezoualc'h et al. 1995, Sonawane, Szoka et al. 2003). The protocol applied for 
transfection of HEK293T cells was adapted from Longo, Kavran et al. (2013). In brief: One day prior 
to transfection, HEK293T cells were seeded at 0.4x106 cells per well of a 6-well cell culture plate 
(83.3920.500, Sarstedt) in 2 mL of HEK293T growth medium. Late in the afternoon of the day of 
transfection, the transfection mix was prepared. Two microcentrifuge tubes were needed per 
transfection. Tube I contained 100 µL of DMEM-high glucose and two to four micrograms of purified 
plasmid DNA (section 2.1.11). In tube II 100 µL of DMEM-high glucose were combined with PEI 
(1 µg/µL, 23966-1, Polyscience Inc.) at a ratio of 1:4 of DNA to PEI (e.g. 2 µg of DNA and 6 µg of 
PEI). Both tubes were mixed thoroughly by vortexing and incubated at room temperature for 
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five minutes. The contents of both tubes were combined in one, mixed thoroughly by vortexing, and 
incubated at room temperature for 10 minutes. During this incubation time, the cells to transfect were 
prepared for transfection. The cells’ medium was changed to 1.8 mL of pre-warmed HEK293T growth 
medium with 12% of FCS to account for the medium’s dilution upon addition of the transfection mix. 
The transfection mix was slowly pipetted up and down before adding it dropwise to the prepared 
HEK293T cells. The well’s contents were mixed by cross-shaking the plate and the transfection was 
incubated at 37° C for a maximum of 16 hours. To stop the transfection, the medium was changed to 
HEK293T growth medium. Already 24 hours after addition of the transfection mix, expression of the 
transferred genes could be observed. If larger culture vessels than 6-wells were transfected, the 
experiment was scaled up linearly. 
Table 36 summarizes the concentrations of selection agents used for the selection of HEK293T cells 
expressing the respective resistance genes. 
Table 36: Selection agents and their concentrations used to select HEK293T cells expressing the respective resistance genes. 




Blasticidin (ant-bl, invivogen) 10 mg/mL 10 µg/mL 
Puromycin (P8833, Sigma Aldrich) 10 mg/mL 1 µg/mL 
Zeocin (ant-zn, invivogen) 100 mg/mL 200 µg/mL 
 
2.3.2. Cultivation and transfection of human induced pluripotent stem cells (hiPSC) 
Human induced pluripotent stem cell clone #33 (hiPSC#33) was derived from normal fibroblasts from 
a healthy, male donor and re-programmed using Sendai viruses by Nils Offen. hiPSC#33 were 
cultivated in a feeder-free culture system on Vitronectin-coated culture vessels (VTN, A14700, Life 
Technologies) with StemMACS iPSBrew XF Medium and Supplement (130-104-368, Miltenyi 
Biotech).  
Culture vessels were coated with VTN at 5 µg/mL in a 1:100 dilution of VTN in DPBS (D8537, Sigma 
Aldrich) and incubated at room temperature for one hour prior to detachment of the cells. As soon as 
the hiPSC#33 grew to dense colonies, non-enzymatic passaging was performed. The culture medium 
was aspirated, and the cells were washed with DPBS once. After washing, 2 mL of 0.5 mM EDTA in 
DPBS (15575020, Life Technologies) was added and incubated at room temperature for four minutes. 
The EDTA solution was aspirated and the cells detached as small clumps by rinsing the vessel with 
an appropriate volume of StemMACS iPSBrew XF Medium and Supplement. Depending on the 
subsequent experiment, cells were plated at a ratio of 1:2 to 1:8 onto the VTN-coated 60 millimetres 
dishes containing 3 mL of StemMACS iPSBrew XF Medium and Supplement.  
Single-cell seeding of hiPSC#33 was performed for transfection or transduction experiments. One day 
prior to the experiment hiPSC#33 were detached using 2 mL of accutase (A6964, Sigma Aldrich) at 
37° C for three minutes. Repeated pipetting of the cell suspension with a 1 mL tip as well as passing 
the cells through a 40 µm cell strainer (732-2757, VWR) ensured single cell dissociation. The single-
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cell suspension was diluted in pre-warmed DMEM/F12 (51445C, Sigma Aldrich), the cells were 
counted and collected at 200 xg for three minutes. Pelleted cells were re-suspended in an appropriate 
volume of StemMACS iPSBrew XF Medium and Supplement enriched with 1x RevitaCell (A2644501, 
Life Technologies) and seeded to VTN-coated culture vessels containing StemMACS iPSBrew XF 
Medium and Supplement enriched with 1x RevitaCell. 
Transfection of hiPSC#33 was performed using five microliters of Lipofectamine Stem Reagent 
(STEM00015, Life Technologies) and 1.25 µg of DNA per well of a 6-well culture plate according to 
the manufacturer’s instructions.22 In brief, 125 µL of DMEM/F12 and 1.25 µg of DNA in tube I are 
added to tube II containing 125 µL of DMEM/F12 and 5 µL of Lipofectamine Stem reagent. The 
transfection reaction is mixed well by pipetting and incubated at room temperature for 10 minutes. 
The mixture was added drop-wise to one 6-well containing 3x105 hiPSC#33 which were seeded 
24 hours prior to transfection and were incubated with fresh StemMACS iPSBrew XF Medium and 
Supplement enriched with 1x RevitaCell for at least one hour prior to transfection. 
Table 37 summarizes the concentrations of selection agents used for the selection of hiPSC#33 cells 
expressing the respective resistance genes. 
Table 37: Selection agents and their concentrations used to select hiPSC#33 cells expressing the respective resistance genes. 




Blasticidin (ant-bl, invivogen) 10 mg/mL 3-5 µg/mL 
Puromycin (P8833, Sigma Aldrich) 10 mg/mL 150 ng/mL 
Zeocin (ant-zn, invivogen) 100 mg/mL 150 ng/mL 
 
2.3.3. Cultivation and transfection of the human breast epithelial cell line MCF10A 
The MCF10A cell line is a spontaneously immortalised line of mammalian breast epithelial cells which 
contains a normal chromosome set except for triploidy of chromosome 8 (47 chromosomes in total) 
(Marella, Malyavantham et al. 2009). 
An aliquot of these cells was obtained from Alexander Löwer at Technical University of Darmstadt 
and cultured in MCF10A growth medium composed of DMEM/F12 (21041-025, Life Technologies), 
5% horse serum (16050-122, Life Technologies), 20 ng/mL epidermal growth factor (EGF, AF-100-
15, Preprotech), 0.5 µg/mL hydrocortisone (H0888, Sigma Aldrich), 100 ng/mL Cholera toxin 
(C8052, Sigma Aldrich), 10 µg/mL Insulin (I9278, Sigma Aldrich), 2 mM L-Glutamine (G7513, Sigma 
Aldrich), 100 Units Penicillin, and 100 µg Streptomycin (P/S, P0781, Sigma Aldrich). 
Upon reaching 80 to 90% confluency, the cells were washed once with DPBS (D8537, Sigma Aldrich), 
detached using 2 mL of Trypsin/EDTA solution (T3924, Sigma Aldrich) per 10 cm dish (83.3902, 
Sarstedt) which was incubated on the cells at 37° C for 20 minutes. The detached cells were then 
 
22 Lipofectamine Stem Reagent user guide available at: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0017080 
LipofectamineStem_UG.pdf 
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dissociated to single cells using a 1 mL tip and pipetting the suspension up- and down 30 times. To 
stop the trypsin-reaction, the cell suspension was diluted in at least 4 mL of MCF10A resuspension 
medium (DMEM/F12, 20% horse serum, 100 Units Penicillin, and 100 µg Streptomycin). If an exact 
cell number was required, 100 µL of the diluted cell suspension were counted using CASY cell counter 
before collecting the cells by centrifugation at 200 xg for 3 min. The cell pellet was then re-suspended 
in an appropriate volume of MCF10A growth medium and seeded in the required density.  
Transfection of MCF10A was either performed using linear polyethylenimine (PEI) as described for 
HEK293T cells in section 2.3.1 or using Lipofectamine 3000 reagent (L3000001, Thermo Fisher) 
according to the manufacturer’s instructions23. In brief: 125 µL of DMEM/F12 were mixed with 7.5 µL 
of Lipofectamine 3000 reagent in a microcentrifuge tube (tube 1). In another microcentrifuge tube, 
125 µL of DMEM/F12 were mixed with 5 µL of P3000 reagent, and 2.5 µg of plasmid DNA (tube 2). 
The contents of tube 2 were then added to tube 1 and mixed well. After an incubation at room 
temperature for five minutes, the transfection mix was added drop-wise to MCF10A cells in one well 
of a 6-well plate containing 1.8 mL of MCF10A growth medium. For either method PEI or 
Lipofectamine 3000, MCF10A cells were seeded at a density of 0.3x106 cells per well of a 6-well plate 
in 2 mL of MCF10A growth medium. 
Table 38 summarizes the concentrations of selection agents used for the selection of MCF10A cells 
expressing the respective resistance genes. 
Table 38: Selection agents and their concentrations used to select MCF10A cells expressing the respective resistance genes. 




Blasticidin (ant-bl, invivogen) 10 mg/mL 7.5 µg/mL 
Puromycin (P8833, Sigma Aldrich) 10 mg/mL 0.75 µg/mL 
Zeocin (ant-zn, invivogen) 100 mg/mL 400 µg/mL 
 
2.3.4. Cultivation of mouse neural stem and progenitor cells as neurospheres (NSPs) 
Mouse neural stem/progenitor cells (NSCs/NPCs) were isolated from embryonic mouse brains by 
Alina Filatova. NSCs/NPCs were cultured as free floating spheres (NSPs) in full NSP medium (NSPM) 
composed of DMEM/F12 (21041-025, Life Technologies), 1x B27 supplement (17504-044, Life 
Technologies), 30 mM HEPES Buffer (12509079, Fisher Scientific), 100 Units Penicillin, and 100 µg 
Streptomycin freshly supplemented with 20 ng/mL Epithelial Growth Factor (EGF, 236-EG-200, 
R&D) and 20 ng/mL basic Fibroblast Growth Factor (bFGF, 233-FB-025, R&D). The spheres were 
dissociated when they reached approximately 100 µm of diameter. This was done by collecting the 
NSPs by centrifugation at 200 xg for three minutes, aspiration of the supernatant, and careful 
resuspension of the NSPs in 1 mL of accutase solution. After an incubation at 37° C for 15 minutes, 
the spheres were dissociated to single cells by slowly pipetting up and down the suspension with a 
 
23 Lipofectamine 3000 user guide available at: https://tools.thermofisher.com/content/sfs/manuals/lipofectamine3000_protocol.pdf 
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1 mL tip for at least 20 times and passing it through a 40 µm cell strainer (732-2757, VWR). The 
suspension was diluted in at least 9 mL of DMEM/F12 and seeded at 0.1x106 cells/mL for stock or at 
0.5x106 cells per millilitre in preparation for experiments in T25 cell culture flasks (83.3910.002, 
Sarstedt). 
 
2.3.5. Flow Cytometry analysis and sort (FACS) 
Flow cytometry can be used to analyse the expression of different, antibody-fluorescent labelled 
markers or transgenes in single cells. A single cell solution is run through the flow cytometer, focused 
by a sheath flow, and each single cell passes a laser which excites the expressed fluorescent proteins 
or fluorophores attached to staining antibodies. The emitted light is detected and recorded to analyse 
the rate of cells expressing the gene of interest. All cells passing the laser are analysed in real-time, 
which allows for sorting of the cells with the desired characteristics, e.g. the expression of a fluorescent 
transgene into multi-well plates or tubes.  
FACS was used in this work to analyse and enrich HEK293T cells subjected to CRISPR/Cas9-
mediated introduction of fluorescent reporter cassettes into the SMARCB1 gene locus. For this 
purpose, HEK293T cells were transfected with Cas9(n) and gRNA plasmids targeting the desired 
genomic region and suitable HDR constructs in a 1:4 mass ratio using PEI (section 2.3.1). 60 hours 
after transfection, the cells were dissociated using trypsin/EDTA and collected in FACS tubes 
(55.526.006, Sarstedt, section 2.3.1). After inhibition of the trypsin reaction, the cells were washed once 
in 1 mL of cold DPBS (vortexing, followed by centrifugation at 200 xg, 3 minutes), and twice in cold 
FACS buffer (Table 39). After the last wash, the cells were re-suspended in the FACS buffer that 
remains in the FACS tubes after discarding the supernatant. The cell suspension was then analysed 
using an Aria III FACS device (BD-Biosciences). For the detection of fluorophores, control samples of 
HEK293T cells transfected with plasmids carrying the same fluorophores as the samples were used to 
set the cytometer settings and define the necessary gates. mTagBFP(2) expression was analysed in the 
Pacific Blue channel, eGFP expression in the FITC channel, mKate2 expression in the PE-Cy5 
channel, and SytoxRed staining in the APC channel. 
For cell sorting, the 100 nm nozzle was used. The cells were either sorted into FACS tubes or into 
multi-well plates containing cold HEK293T medium. Populations that were to be subjected to 
RT- qPCR expression analyses were sorted into 96-well plates containing 20 µL of lysis buffer 
(500 to 1000 cells/96-well, Table 40).  
After the sort, multiple wells containing the same cell populations were pooled in a 1.5 mL 
microcentrifuge tube, and lysis was supported by carefully pipetting the suspension. After incubation 
on ice for more than 10 minutes, the lysate was centrifuged at 13,000 xg and 4° C for 10 minutes, 
transferred to a new microcentrifuge tube, and stored at -80° C. Per cDNA synthesis reaction, 12 µL 
of lysate were used as RNA input (section 2.1.18). The synthesised cDNA was then used for RT-qPCR 
analyses (section 2.1.19).  
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Table 39: FACS buffer composition. 
COMPONENT CONCENTRATION VOLUME 
HEPES (1 M, 12509079, Fisher Scientific) 25 mM 12.5 mL 
EDTA (0.5 M, 15575020, Life Technologies) 2 mM 20 mL 
Bovine Serum Albumin (BSA, A8022, Sigma 
Aldrich) 
1% 5 g 
P/S (P0781, Sigma Aldrich) 1%  5 mL 
DPBS (D8537, Sigma Aldrich)  500 mL 
All components were mixed and dissolved in MilliQ H2O. After sterile filtering into a sterile bottle, 
the buffer was stored at 4° C. 
Table 40: Lysis Buffer composition for the lysis of FAC-sorted cells. 
COMPONENT CONCENTRATION VOLUME 
NP-40 Alternative (4%, IGEPAL, US1492016-
100ml, Merck) 
0.4% 100 µL 
RiboLock RNase Inhibitor (40 U/µL, EO0382, 
Thermo Fisher) 
0.5 U/µL 12.5 µL 
Nuclease-free water  887.5 µL 
The NP-40 Alternative was added to the water, and shook for 30 minutes to one hour to completely 
dissolve it. The basic buffer was cooled down on ice before the RNase inhibitor was added. 
 
All FACS experiments were performed in together with Alina Filatova or Nils Offen. The method of 
cell lysis upon sorting was established by Nils Offen. 
 
2.3.6. Electroporation of human cell lines 
Electroporation is a method of transfection which utilizes high voltage electric shocks to transiently 
open pores in mammalian cell membranes to allow DNA to be introduced into the cell (Potter and 
Heller 2011). Upon electroporation, DNA is directly introduced into the nucleus which is 
advantageous for CRISPR/Cas9-mediated genome engineering, and renders electroporation also 
applicable to non-dividing cells (Cao, Xie et al. 2010).  
Another advanced method of electroporation is nucleofection. It combines the electric shocks to open 
pores in the cell’s membrane with cell type-specific reagents to transfer DNA directly into the 
nucleus.24 In both methods, the cells to be electroporated need to be prepared as a single cell solution 




24 https://bioscience.lonza.com/lonza_bs/SE/en/nucleofector-technology, April, 22 2020 
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Preparation of the cells: 
The cells to be electroporated were cultured until they reached 70 to 80% confluency. HiPSCs were 
pre-treated with 1x RevitaCell supplement (A2644501, Life Technologies) one to three hours prior to 
dissociation to inhibit dissociation-induced apoptosis. The cells were dissociated as described in 
sections 2.3.1, 2.3.2, and 2.3.4 to obtain single cell suspensions in a high volume of dilution medium. 
After determination of the cell number using the CASY cell counter, the cell pellet (200 xg, 
three minutes) was washed with 1 mL of cold DPBS (D8537, Sigma Aldrich) twice before re-
suspending the cells in an appropriate volume of electroporation/nucleofection buffer.  
 
Electroporation in self-made electroporation buffer in the Amaxa Nucleofector 2b device 
(AAB-1001, Lonza): 
Per electroporation experiment 106 cells in 100 µL of the self-made electroporation buffer (Table 41) 
were transferred to a 1.5 mL microcentrifuge tube and mixed with DNA (up to 10 µg). This mixture 
was then transferred into an electroporation cuvette (Z706086, Sigma Aldrich). The Nucleofector 2b 
device was kindly provided by the research group of Markus Löbrich. Upon completion of the 
electroporation, 900 µL of pre-warmed growth medium (e.g. StemMACS iPSBrew XF Medium and 
Supplement (130-104-368, Miltenyi Biotech) supplemented with 1x RevitaCell for hiPSC#33) were 
added to the cell suspension in the cuvette, and the cells were carefully seeded to a culture vessel of 
appropriate size (e.g. 106 hiPSC#33 to one to two wells of a 6-well plate coated with VTN (A14700, 
Life Technologies)). 24 hours after electroporation the cells were analysed for reporter gene 
expression. 
Table 41: Composition of the self-made electroporation buffer used with the Amaxa Nucleofector 2b device. 
COMPONENT CONCENTRATION AMOUNT 
KCl (P9541, Sigma Aldrich) 5 mM 0.037 g 
MgCl2 (Hexahydrat) (H9272, Sigma Aldrich) 15 mM 0.310 g 
1 M Na2HPO4/NaH2PO4, pH 7.2 * 120 mM 12 mL 
Mannitol (M9546, Sigma Aldrich) 50 mM 0.910 g 
All components were combined in a graduated measuring cylinder, and the volume filled up to 100 mL 
with MilliQ-water to dissolve all solid components. The buffer was stored at 4° C after sterile filtering. 
 
* For 100 mL of 1 M Na2HPO4/NaH2PO4, pH 7.2 prepare 100 mL of 1 M Na2HPO4 (1.06580.1000, 
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Electroporation using the Neon transfection system (MPK5000, MPP100, Thermo Fisher): 
The Neon transfection system of Thermo Fisher is an electroporation device in a tip-cuvette format. 
Therefore, pipetting steps to transfer the cell suspension into and from the cuvette are performed with 
the cuvette itself. In this work, the 10 µL tip system was used to electroporate hiPSC#33 (MPK1025, 
Thermo Fisher, kindly provided by the research group of M. Cristina Cardoso and Thermo Fisher). 
Prior to transfection, the VTN coated 6-well plates for seeding were prepared with 1 mL of 
StemMACS iPSBrew XF Medium and Supplement supplemented with 1x RevitaCell and 25 mM 
HEPES Buffer (12509079, Fisher Scientific) per well and put into the incubator to adjust to the cell’s 
growth conditions. The prepared single cell dilution was then re-suspended in R buffer of the Neon 
kit to 107 cells per millilitre. 10 µL of the cell suspension were mixed with an appropriate amount of 
DNA and aspirated with the Neon Pipette and 10 µL tip. The Neon Pipette and tip were then placed 
in the Neon Device, and the experiment’s parameters were set. See 
https://tools.thermofisher.com/content/sfs/manuals/neon_device_man.pdf for the parameters to 
test when establishing transfection of a cell line. Upon electroporation, the cell suspension was directly 
seeded to one well of the prepared plate and incubated for 24 hours before analysing the cells for 
expression of the fluorescence reporter. 
 
Nucleofection using the Amaxa Nucleofector 4D System (AAF-1002X, AAF-1002B, Lonza) and 
the P3 Kit (V4XP-3024, Lonza): 
Similar to the Neon procedure, the Amaxa Nucleofector 4D System (kindly provided by Julia Weigand 
of the Süß research group) was only used for the transfection of hiPSC#33 and the plates required for 
seeding of the cells were prepared in advance (VTN coated 24-well plates, 500 µL of StemMACS 
iPSBrew XF Medium and Supplement supplemented with 1x RevitaCell).  
After DPBS wash, the cell pellet was re-suspended in P3 solution to 0.6x106 cells per 100 µL. Per 
reaction, 100 µL of cell suspension were transferred to a microcentrifuge tube. DNA (molar mass) was 
added to be equal to 2 µg of pMAX-GFP (plasmid #376) and the mixture was pipetted into an Amaxa 
4D Nucleocuvette. After nucleofection using the programme CB-150, 200 µL of pre-warmed 
StemMACS iPSBrew XF Medium and Supplement supplemented with 1x RevitaCell were 
added directly to the Nucleocuvette and the complete volume was transferred to one well of the 




2 Materials and methods       61 
2.3.7. Generation and concentration of lentiviral particles 
The transfer of plasmid DNA, especially of large plasmids, into cells can be very inefficient. 
Introduction of DNA into cells via viral transduction offers higher transfer efficiencies. Lentiviruses 
are a subgroup of retroviruses. Both virus groups contain single-stranded RNA as their genome but 
only lentiviral particles can infect dividing and non-dividing cell types. The generation of lentiviral 
particles requires three different components. The transfer plasmid carries the gene(s) to be transferred 
flanked by long terminal repeats (Cheng, Davies et al.) and is packed by a packaging system consisting 
of a packaging plasmid coding for the viral genes Gag, Rev, Pol, and Tat, and the envelope plasmid 
coding for the coating glycoprotein of the Vesicular Stomatitis Virus (VSV-G). All three plasmids have 
to be transfected into the packaging cell line HEK293T at once.  
Depending on the cell type to be infected different packaging and VSV-G envelope plasmids were used. 
Generally, 0.4x106 HEK293T cells per 6 well or 4x106 HEK293T cells per T75 flask were seeded one 
day prior to transfection (section 2.3.1). Late in the afternoon, the cells were transfected using PEI: 
per 6-well 700 ng transfer plasmid are combined with 700 ng of packaging and envelop plasmid each. 
For T75 flasks, 7,000 ng transfer plasmid are combined with 7,000 ng of packaging and envelop 
plasmid each. The transfection was performed as described in section 2.3.1. From the start of the 
transfection on the experiment was classified as biological safety group S2 and the required safety 
standards were met. 16 hours post addition of the transfection mix the medium was changed to 
HEK293T growth medium or the growth medium of the cells which were to be transduced. The cells 
were incubated for another 48 hours at 37° C before the lentivirus-containing supernatant was 
harvested. Cellular debris was removed from the supernatant by centrifugation at 200 xg for 
three minutes. Sterile filtering of the supernatant through a 0.2 µm PVDF syringe filter (SLGV033RS, 
Merck Chemicals) is optional, but recommended. The cleared supernatant was directly used for 
transduction or was concentrated to obtain higher viral titers and/or change of the medium system.  
 
One way of concentration of lentiviral particles is ultracentrifugation. For this purpose, 30 mL of 
cleared lentivirus-containing supernatant were transferred to UV-sterilised screw-cap polycarbonate 
tubes (355618, Beckman Coulter) and balanced to 0.01 g with the counterweight. The 
ultracentrifugation was run at 55,000 xg and 4° C for two hours in an LM-8 Ultracentrifuge (Beckman 
Coulter). Before removing the tubes from the rotor type 70Ti (337922, Beckman Coulter), the 
outward-facing side of the tube, where the virus pellet was expected, was marked. The supernatant 
was completely removed and the virus pellet re-suspended in 125 µL of sterile-filtered DMEM 
supplemented with 1% of Bovine Serum Albumin (BSA, A8022, Sigma Aldrich) at 4° C for 10 to 
15 minutes. Careful pipetting dissolved the pellet. The virus solution was directly used for 
transduction or aliquots of 10 to 20 µL were stored at -80° C. 
 
Concentration of lentiviral particles over a sucrose cushion at speeds below ultracentrifugation is 
gentler and reduces the risk of damaging the particles compared to ultracentrifugation. According to 
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Jiang, Hua et al. (2015), lentivirus containing supernatant was harvested 48 hours after the stop of PEI 
transfection, and laid over a 10% sucrose buffer (Table 42) at a 5:1 v/v ratio in a 50 mL conical tube. 
For concentrating the virus in the sucrose layer, the tube was centrifuged at 10,000 xg and 4° C for 
four hours. After centrifugation, the lentiviral particles were visible as a white pellet in the sucrose 
layer, and the supernatant was removed carefully. The empty tube was then placed upside down on 
paper for three minutes to dry. For reconstitution, 1/50 of the original supernatant volume in DPBS 
was added to the pellet, and the tube was kept at 4° C overnight. The next day, the loosened pellet was 
carefully re-suspended by pipetting and used for transduction. 
Table 42: Composition of sucrose-containing buffer for concentration of lentiviral particles. 
COMPONENT CONCENTRATION VOLUME 
Sucrose 10% 10 g 
Tris-HCl pH 7.4 (1 M,  50 mM 5 mL 
NaCl 100 mM 0.584 g 
EDTA (0.5 M, 15575020, Life Technologies) 0.5 mM 100 µL 
All components were dissolved in Milli-Q water to 100 mL, sterile filtered, and stored at 4° C. 
 
2.3.8. Transduction of mammalian cell lines 
DNA transfer into difficult to transfect cells like NSP-forming cells was facilitated using lentiviral 
particles. The efficiency of viral infection was increased by supplementing the transduction mixes with 
the cationic polymer hexadimethrine bromide (polybrene, H9268, Sigma Aldrich). HEK293T cells 
were used as transduction controls. 500 µL to 1 mL of cleared virus-containing supernatant 
supplemented with 6 µg/mL polybrene was directly added to 0.4x106 HEK293T cells per well of a 
6- well plate seeded one day ahead of transduction. The cells were incubated with the transduction 
mix at 37° C for 24 hours. 
For the transduction of NSPs, 0.5x106 NSCs were seeded per millilitre of NSPM one day ahead. The 
next day NSPs were transduced with 1 mL of virus-containing supernatant made from NSPM and 
supplemented with 6 µg/mL polybrene, 20 ng/mL EGF and bFGF in one well of a 6-well plate. 
24 hours after addition of the transduction mix, the NSPs were collected at 200 xg for three minutes 
and re-suspended in full NSPM.  
Cell health and expression of the transgenes was monitored after the transduction.  
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3. Results 
 
3.1. Design and generation of constructs for CRISPR/Cas9-mediated genome engineering 
of the SMARCB1 locus in human cells 
A fluorescence-based reporter approach was chosen for CRISPR/Cas9-mediated genome engineering 
of the SMARCB1 locus in human cells. Guide RNA (gRNA)-Cas9 expression plasmids, which facilitate 
the co-expression of Cas9 and a fluorescence gene were used so that a direct fluorescent readout for 
transfection and expression of the Cas9 endonuclease was possible. The constructs applied as a 
template for homology-directed repair (HDR construct) encoded for a promoterless fluorescent 
reporter which was only expressed upon directed integration into the genome. In this way, upon 
genome engineering, the SMARCB1 alleles should be co-expressed with three different fluorescence 
genes. Upstream of the native start codon of the SMARCB1 gene, a loxP site and a mTagBFP2 
reporter cassette were introduced, linked by a T2A sequence. Downstream of the stop codon of the 
SMARCB1 gene, either an eGFP or a mKate2 reporter cassette and a loxP site was inserted, linked by 
an IRES sequence (Figure 7). CRISPR/Cas9-mediated introduction of all three HDR constructs 
results in a sophisticated three-colour reporter system. This system not only allows the rapid 
identification of recombined cells by the expression of the fluorescence reporter genes – which would 
be time and cost intensive if the insertion of a loxP site or point mutation alone had to be verified – 
but also indicates the deletion of each marked allele of SMARCB1 by loss of the fluorescence signal 
upon Cre recombination. Additionally, the insertion of the fluorescence reporters facilitates the 
differentiation between the two SMARCB1 alleles. Therefore, differences in the gene expression from 
either allele can be detected by RT-qPCR analysis of the fluorescence genes’ transcripts even though 
the sequence differences, e.g. due to point mutations, are too subtle to be recognised by primers 
(Figure 9). 
HDR constructs homologous either to the sequences flanking the start (exon 1 HDRs) or stop (exon 9 
HDRs) codon of SMARCB1 were generated. Therefore, genomic sequences of SMARCB1 up- and 
downstream of the Cas9 cleavage site were cloned up- and downstream of the reporter sequences to 
be introduced. The homologous sequences selected to edit the genome at chromosome 22q11 were 
1.5 to 1.7 kb long and were referred to as homology arms. The homology arm upstream of the reporter 
was termed “left” homology arm (HL), the genomic sequence downstream of the reporter was termed 
“right” homology arm (HR). All cloning steps were performed using a restriction endonuclease-based 
cloning approach. According to Zhang, Ge et al. (2014), Zheng, Hou et al. (2017), protospacer adjacent 
motif (PAM) sites and/or bases essential for gRNA-target pairing were mutated in the cloned 
homology arms to prevent Cas9-mediated cleavage of the HDR constructs and excision after 
integration. The sequence changes were chosen to be silent base exchanges and are labelled in the 
sequences (Figure 31 and Figure 32) The functionality of the CRISPR/Cas9 approach using the 
generated constructs was tested in HEK293T cells (section 3.2). Based on these test results, the 
 
3 Results       64 
CRISPR/Cas9 strategy was adapted further to optimise the gene editing process or outcome. The 
characteristics of all constructs generated can be found in the appendix (section 7.1.6). 
As mentioned before, mutations of the tumour suppressor gene SMARCB1 may cause either the 
neurodevelopmental syndrome Coffin-Siris (CSS) or can lead to aggressive rhabdoid tumours 
dependent on the type of mutation and if SMARCB1 is altered hetero- or homozygously. The 
developmental timing and the type of mutation appears to be of decisive importance for the phenotypic 
outcome (Han, Richer et al. 2016, Filatova, Rey et al. 2019). In most cases, CSS is caused by germline 
heterozygous non-truncating missense mutations or small in-frame deletions in exons 8 or 9 of the 
SMARCB1 gene (Tsurusaki, Okamoto et al. 2012). Germline mutations causing the rhabdoid tumour 
predisposition syndrome (RTPS1) usually are heterozygous truncating loss-of-function mutations or 
large deletions that can occur in several exons of the SMARCB1 gene (Sevenet, Sheridan et al. 1999, 
Sredni and Tomita 2015). Importantly, RTPS1 individuals carrying such heterozygous germline 
mutations do not show any neurodevelopmental phenotypes. For the rhabdoid tumour-associated 
germline mutations, a complete loss of gene expression is observed upon spontaneous 
mutation/deletion of the second allele of SMARCB1.  
Germline mutations of the SMARCB1 gene, either causing CSS or RTPS1 were selected to analyse 
the effect of each mutation on the expression of the gene on mRNA and protein level. Germline 
mutations of the SMARCB1 gene reportedly predisposing to AT/RTs and located close to the start or 
stop codon of the gene were selected. Three mutations were identified from Eaton, Tooke et al. (2011). 
The AT/RT predisposing nonsense mutation c.20_43delins T which leads to several pre-mature 
termination codons in exon 1 of the SMARCB1 gene and thus to a loss of the protein, and the predicted 
splice-site mutation c.93G>C at the border of exon and intron 1 of SMARCB1 were cloned into the 
SMARCB1 e1 HDR constructs. The heterozygous CSS-associated missense mutation of SMARCB1 
selected was c.1091_1093del AGA, one of the most common CSS-associated SMARCB1 (Tsurusaki, 
Okamoto et al. 2012, Kosho, Okamoto et al. 2014). Additionally, the reported AT/RT-associated 
somatic SMARCB1 mutation c.1148delC in exon 9 of the gene was included in the analysis as there 
were no AT/RT-associated germline mutations in exon 8 or 9 of the SMARCB1 gene reported so far 
(Biegel, Tan et al. 2002, Kordes, Gesk et al. 2010). 
Therefore, constructs to generate human cell lines with a reporter cassette upstream and downstream 
of the coding sequence of SMARCB1 with and without AT/RT- or CSS-related mutations in the 
coding sequence of SMARCB1 were established. 
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3.1.1. Design and generation of constructs for CRISPR/Cas9-mediated genome 
engineering of human cell lines with AT/RT-associated SMARCB1 mutations 
HDR constructs to insert a reporter cassette downstream of the stop codon of the SMARCB1 gene 
were generated as described in the following. The initial plasmid (plasmid #83) was a pBluescript 
(pBS) backbone containing a T2A peptide, an in frame enhanced green fluorescent-zeocin resistance 
fusion gene (eGFP::ZeoR), and a loxP site, the T2A peptide was optimised for optimal self-cleavage 
upon translation (Chng, Wang et al. 2015). Oligonucleotides of the T2A peptide sequence, a 5’ Glycine-
Serine-Glycine (GSG) linker, and 5’ Acc65I/ 3’ AvrII-specific cohesive ends (oligonucleotides #743, 
#744) were cloned into plasmid #83. Insertion of the HR corresponding to the sequence upstream of 
the stop codon of the SMARCB1 gene was achieved by PCR amplification (1.6 kb, oligonucleotides 
#317, #318) from hiPSC#33 genomic DNA (gDNA) while adding PspXI and EcoRI restriction 
endonuclease recognition sites. The HL was generated by PCR amplifying the sequence downstream 
of the stop codon of the SMARCB1 gene from hiPSC#33 gDNA (1.7 kb, oligonucleotides #315, #316), 
followed by insertion into pBluescript (plasmid #80) via TA-Cloning. Subsequently, the HL was 
transferred to the target plasmid via the PsiI and BsrGI restriction endonuclease recognition sites 
which were added by the PCR primers. Figure 15 schematically depicts the cloning steps leading to 
the resulting plasmid SMARCB1 e9 HDR T2A-eGFP::ZeoR (plasmid #226). 
 
Figure 15: Schematic overview of the cloning steps leading to SMARCB1 e9 HDR T2A-eGFP::ZeoR, plasmid #226. The left 
and right homology arms, corresponding to the sequences up- and downstream of the stop codon of SMARCB1 were amplified 
from gDNA and cloned into the final plasmid using the restriction endonuclease recognition sites PsiI/BsrGI or PspXI/EcoRI, 
respectively. The left homology arm covers the sequence of the NCBI reference genome NG_009303.1 positions 50,538 to 
52,218. The right homology arm covers the sequence of NCBI reference genome NG_009303.1 positions 52,219 to 53,787, 
directly adjacent. 
 
After testing in HEK293T cells (section 3.2.1), the T2A peptide linking gene expression of SMARCB1 
and the eGFP::ZeoR reporter was exchanged for an internal ribosomal entry site (IRES). 
Multicistronic expression of genes linked by an IRES is facilitated by the additional binding of 
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ribosomes to IRES on the complete mRNA of the linked genes (Jang, Krausslich et al. 1988). Cloning 
of the exon 9 HDR construct with IRES was achieved via the pBS-IRES-eGFP::ZeoR-loxP 
intermediate. The IRES2 sequence (IRES, oligonucleotides #890, #891) and the eGFP::ZeoR-loxP 
sequence (oligonucleotides #892, #893) were PCR amplified from plasmid #128 and #83, respectively. 
Restriction endonuclease digestion of #80 and the PCR amplicons generated compatible cohesive ends 
which were ligated to combine the intermediate pBS-IRES-eGFP::ZeoR-loxP (plasmid #227). The 
homology arms of SMARCB1 exon 9 HDR were PCR amplified from gDNA similarly to plasmid #226 
(oligonucleotides HL #315, #887; HR #888, #889). The cloning steps for the generation of SMARCB1 
e9 HDR IRES-eGFP::ZeoR (plasmid #243) are summarised in Figure 16. 
 
Figure 16: Schematic overview of the cloning steps required to generate SMARCB1 e9 HDR IRES-eGFP::ZeoR, plasmid #243. 
The left and right homology arms, corresponding to the sequences up- or downstream of the stop codon of SMARCB1 were 
PCR amplified from gDNA and cloned into the target plasmid via PsiI/SalI or EcoRI/XbaI, respectively 
 
Based on plasmid #243, the selectable fluorescence reporter eGFP::ZeoR was exchanged for the far-
red fluorophore mCardinal by SalI/EcoRI restriction endonuclease digestion of plasmid #272 and 
cloning of the IRES-mCardinal cassette (SMARCB1 e9 HDR IRES-mCardinal, plasmid #277, 
Figure 33). 
The SMARCB1 exon 9 HDR construct was further optimised with the exchange of mCardinal for the 
smaller far-red fluorescence gene mKate2. mKate2 was PCR amplified (oligonucleotides #1137, 
#1107) from plasmid #311, and cloned into plasmid #243 via plasmid #227 (SMARCB1 e9 HDR 
IRES-mKate, plasmid #318, Figure 33). 
Optimisation of the identification and isolation of successfully genome-engineered cells was achieved 
by adding a T2A-linked blasticidin resistance cassette downstream of the mKate2 sequence in the 
HDR construct. The eGFP::ZeoR-loxP reporter cassette of plasmid #227 was exchanged for an IRES-
mKate2-T2A sequence, resulting in intermediate plasmid #385. For this purpose, mKate2 was PCR 
amplified (oligonucleotides #1137, #1105) from plasmid #318 and the T2A sequence was annealed 
from oligonucleotides #982, #983. Subsequently, the blasticidin resistance gene (BSD) and a loxP site 
were PCR amplified (oligonucleotides #1440, #1441) from plasmid #355 and inserted into 
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plasmid #385. The IRES-mKate2-T2A-BSD-loxP reporter cassette was cloned into plasmid #318 
(SMARCB1 e9 HDR IRES-mKate2-T2A-BSD, plasmid #386, Figure 17). 
 
Figure 17: Schematic overview of the cloning steps required to obtain the plasmid SMARCB1 e9 HDR IRES-mKate2-T2A-
BSD. mKate2 with NcoI restriction endonuclease recognition sites at the 3’ and 5’ end of the sequence was amplified from 
plasmid #318. The T2A sequence was annealed from oligonucleotides #982, #983 and was flanked by NcoI and EcoRI 
restriction endonuclease recognition sites. The final selectable reporter cassette IRES-mKate2-T2A-BSD-loxP was cloned into 
plasmid #318 via SalI and compatible SmaI/EcoRV DNA ends, resulting in plasmid #386. 
 
The cloning of the SMARCB1 exon 1 HDR constructs was performed analogously to the exon 9 HDR 
constructs. The homology arms comprising the sequences up- and downstream of the native start 
codon of SMARCB1 were cloned into a pBluescript backbone containing a loxP-eGFP::ZeoR-T2A 
cassette to facilitate co-expression of the reporter and the SMARCB1 gene. To fit into the three-colour 
reporter strategy and to take differences in observed fluorescence intensity of different fluorophores 
into account, the encoded reporter upstream of the HR was exchanged to mTagBFP2. A depiction of 
the cloning steps to generate the SMARCB1 e1 HDR constructs is provided in Figure 34. Regarding 
the decision for which of the three selected fluorescence genes to include in which HDR construct, the 
differences in signal brightness were considered (brightness according to https://www.fpbase.org/). 
E.g. eGFP is brighter than mKate2, which is also brighter than mTagBFP2. Tests in HEK293T cells 
showed that fluorescence genes linked downstream of the SMARCB1 coding sequence via an IRES 
result in a weaker signal compared to the same fluorescence gene co-expressed upstream to the coding 
sequence of SMARCB1 (data not shown, compare section 3.2.1 and 3.2.2). Similar to the exon 9 HDR 
constructs, a selectable marker was added to the exon 1 HDR constructs to allow enrichment of 
successfully engineered cells. A more complex cloning strategy with two intermediates was necessary 
to obtain the wildtype exon 1 HDR construct SMARCB1 e1 HDR PuroR-P2A-mTagBFP2-T2A 
(plasmid #380) containing a Puromycin resistance cassette (PuroR, Figure 35). 
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HDR constructs to insert a AT/RT-associated point mutation into the coding sequence of SMARCB1 
and a reporter cassette upstream of the start codon/downstream of the stop codon of the SMARCB1 
gene were generated applying a similar strategy for genome engineering as described above 
(Figure 7C). In a literature-based research, three different (germline) mutations which were observed 
in more than one AT/RT case in exon 1 or exon 9 of the SMARCB1 sequence were identified (Eaton, 
Tooke et al. 2011). Due to the use of a reporter for the selection of successfully engineered cells, the 
mutations to be introduced needed to be located at either the 3’ or 5’ end of the coding sequence of 
SMARCB1. 
Based on the HDR construct SMARCB1 e9 HDR IRES-eGFP::ZeoR (plasmid #243), the somatic 
single base deletion at position 1148 (c.1148delC) was introduced into exon 9 of the SMARCB1 
sequence in the left homology arm. Using an oligonucleotide primer containing the c.1148delC 
mutation, the mutated HL was PCR amplified (oligonucleotides #315, #1309) and cloned into the pBS-
IRES-eGFP::ZeoR-loxP-HR intermediate via PsiI and SalI restriction endonuclease sites (Figure 18). 
The final product SMARCB1 c.1148delC e9 HDR IRES-eGFP::ZeoR, plasmid #363 was used for 
further experiments.  
 
Figure 18: Schematic overview of the cloning of SMARCB1 c.1148delC e9 HDR IRES-eGFP::ZeoR, plasmid #363. The left 
homology arm containing the mutation c.1148delC was PCR amplified using plasmid #243 and subsequently cloned into 
plasmid #243 via PsiI and SalI restriction endonuclease cloning. 
 
The second and third AT/RT-associated germline mutations of the SMARCB1 gene were cloned into 
SMARCB1 e1 HDR mTagBFP2-T2A, plasmid #346 (Figure 34) The replacement of 23 bp for a 
single T in exon 1 (c.20_43delins T) was achieved by PCR amplification of the mTagBFP2 sequence 
and the mutated part of the right homology arm using plasmid #346 and applying an oligonucleotide 
primer containing the mutation (oligonucleotides #1207, #1381). Finally, the amplicon was cloned 
into plasmid #346 via ClaI, PvuII and PciI restriction endonuclease sites, resulting in SMARCB1 
c.20_43delins T HDR mTagBFP2-T2A, plasmid #379 (Figure 34).  
The splice site mutations c.93G>C in intron 1 of the SMARCB1 gene was introduced via the overlap 
extension method (section 2.1.14). Fragment A (mTagBFP2-c.93G>C HR) was PCR amplified 
(oligonucleotides #1207, #1314) and combined with fragment B (oligonucleotides #1315, #988) to 
amplify the final fragment C containing the c.93G>C mutation in the HR of the e1 HDR construct 
(oligonucleotides #1207, #988). Fragment C (mTagBFP2-c.93G>C HR) was then cloned into plasmid 
#346 via ClaI and PciI restriction endonuclease sites, resulting in SMARCB1 c.93G>C HDR 
mTagBFP2-T2A, plasmid #378 (Figure 34). Insertion of the PuroR selection cassette was achieved 
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by replacing the original mTagBFP2-T2A fluorescence reporter cassette in plasmids #378 and #379 
for the complete PuroR-P2A-mTagBFP2-T2A reporter cassette of SMARCB1 e1 HDR PuroR-P2A-
mTagBFP2-T2A (plasmid #380) to obtain SMARCB1 c.93G>C HDR PuroR-P2A-mTagBFP2-T2A, 
plasmid #381 and SMARCB1 c.20_43delins T HDR PuroR-P2A-mTagBFP2-T2A, plasmid #382 
(Figure 35). 
 
3.1.2. Design and generation of constructs for CRISPR/Cas9-mediated genome 
engineering of human cell lines with CSS-associated SMARCB1 mutations 
Starting from plasmid #243, the c.1091_1093del AGA mutation of the SMARCB1 gene was inserted 
into the HDR construct’s left homology arm. For this purpose, the HL was divided into two parts. An 
upstream mutated part from the 3’ end to the BssSαI restriction endonuclease recognition site in 
exon 8 of the SMARCB1 gene and a downstream wildtype part from the BssSαI recognition site to the 
5’ end of the sequence of the HL (Figure 19). The mutation was introduced into the upstream portion 
of the HL by PCR using a mutated oligonucleotide for amplification (oligonucleotides #928, #929). 
Restriction endonuclease digestion of #243 using BssSαI and SalI yielded the second, wildtype portion 
of the HL. Both parts of the HL were ligated and cloned into pBluescript and from there transferred 
into plasmid #243 to generate the CSS HDR construct plasmid #253 (SMARCB1 CSS e9 HDR IRES-
eGFP::ZeoR, Figure 19).  
 
Figure 19: Schematic overview of the cloning steps to generate the c.1091_1093del AGA HDR construct to introduce a CSS-
specific mutation into exon 8 of the SMARCB1 gene. The mutation was introduced by using a mutated oligonucleotide primer 
for PCR amplification of the HL. The complete c.1091_1093del AGA HL sequence was sub-cloned into pBluescript plasmid 
#80 as an intermediate before inserting the complete HL sequence into the SMARCB1 wildtype HDR construct plasmid #243 
to generate SMARCB1 CSS e9 HDR IRES-eGFP::ZeoR, plasmid #253. 
 
Similar to the HDR construct for the insertion of a reporter gene downstream of the stop codon of 
SMARCB1, the plasmid was optimised to encode the IRES-mKate2-T2A-BSD reporter. For this 
purpose, the left homology arm carrying the c.1091_1093del AGA mutation was cloned into 
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3.1.3. Design and generation of gRNA and Cas9 expression plasmids for CRISPR/Cas9-
mediated genome engineering of the SMARCB1 locus in human cells 
gRNA and Cas9 nickase (Cas9n) expression plasmids were obtained using the Multiplex CRISPR/Cas9 
Assembly System Kit from Addgene (Kit #1000000055). An approach with Cas9n and two targeting 
gRNAs per cleavage site was chosen for genome editing of the genomic sequence of SMARCB1. 
Fluorescence reporter cassettes linked to Cas9n via a T2A sequence were inserted into the pX330A-1x2 
plasmid (plasmid #131). Proceeding from plasmid #120 which encoded an eGFP::ZeoR reporter linked to 
Cas9n via T2A, the self-cleavage of the T2A peptide was optimised by insertion of a GSG-linker upstream 
of the T2A sequence and subsequently, mCardinal, dsRedExpress2, and mTagBFP sequences were cloned 
into Cas9n plasmids separately (Chng, Wang et al. 2015). In each case, the fluorescence gene was PCR-
amplified with AvrII and ClaI restriction endonuclease recognition sites added 5’ or 3’ of the sequence, 
respectively (Figure 36). Table 43 gives and overview of the oligonucleotides used for amplification and 
the identification numbers of the resulting plasmids. 
Table 43: Summary of fluorescence reporter genes inserted into the original pX330A-1x2 Cas9 plasmid. 
PLASMID  FLUORESCENCE REPORTER OLIGONUCLEOTIDES USED 
#216 mCardinal Restriction endonuclease cloning  
#217 GSG-T2A-mCardinal #745, #746 
#219 mTagBFP #668, #669 from plasmid #215 
#220 dsRedExpress20 #787, #801 from plasmid #128 
 
The gRNA sequences targeting the sequence flanking the stop codon of the SMARCB1 gene were 
selected using the CRISPR designing tool of the MIT (http://tools.genome-engineering.org) 
according to Ran, Hsu et al. (2013). Cloning of sequences encoding the selected gRNA pairs into 
pX330A-1x2 Cas9n expression constructs was performed according to Sakuma, Nishikawa et al. 
(2014), section 2.1.15. Figure 31 in the appendix shows the exact position and cleavage sites of the 
selected gRNAs. Figure 20 depicts the cloning of the gRNA pairs D1, D2, and D3 targeting the 
genomic region flanking the Stop codon of the SMARCB1 gene into multiplex Cas9n plasmids. 
Table 44 summarises the oligonucleotides (oligo) used to generate the gRNAs required for the 
targeting of the sequences flanking the stop codon of the SMARCB1 gene. 
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Figure 20: Schematic overview of the cloning of the sequences encoding gRNA pairs D1, D2, and D3 targeting the genomic 
region flanking the SMARCB1 gene into multiplex Cas9n expression plasmids. As described in section 2.1.15, the 20 nt 
targeting sequence of the gRNAs were annealed from ordered oligonucleotides carrying overhangs at their 5’ and 3’ ends 
complementary to the overhangs generated by cleavage of the plasmid using BbsI. The annealed and phosphorylated 
oligonucleotides were first cloned into the original pX330 plasmids: The sense gRNAs into plasmid #219, the antisense gRNAs 
into plasmid #145. Combinatorial Golden Gate cloning via BsaI yielded Cas9n plasmids with both gRNA expression cassettes 
of one pair (plasmids #221-223). Later in the project, another fluorescence reporter was required. Thus, the mTagBFP sequence 
was exchanged for the mCardinal sequence from plasmid #126 via AvrII and ClaI/BstBI cloning (plasmid #339). 
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Table 44: Oligonucleotides annealed to generate the double-stranded sequences encoding for the gRNAs targeting the genomic 
sequence flanking the Stop codon of the tumour suppressor gene SMARCB1. The 5’ overhangs required for the Golden Gate 
cloning into the Cas9 plasmids are highlighted in green. 
gRNA NAME gRNA SEQUENCE, 5’→3’ OLIGO  





















Transfer of large plasmids as the Cas9n plasmids into hiPSCs and other difficult to transfect cell lines 
is challenging. To overcome this limitation, the Cas9n sequence was removed from plasmid #221 to 
obtain the gRNA-only plasmid #310 which was co-delivered with recombinant, purified Cas9(n) 
protein (Figure 37). 
Further optimisation of the genome engineering of the SMARCB1 gene in hiPSCs required the cloning 
of wildtype Cas9 (Cas9) plasmids. The Cas9 plasmids #03 and #07 were completed with the sequence 
of antisense gRNA D3 (plasmid #388 and #387, respectively; Figure 38). The highest scoring gRNA 
targeting the sequence flanking the SMARCB1 stop codon selected in the original gRNA search. 
Additionally, the Cas9n sequence of plasmid #221 was exchanged for the wildtype Cas9 sequence via 
AgeI and EcoRV restriction endonuclease recognition sites, resulting in a construct with two gRNAs 
that target wildtype Cas9 molecules to exon 9 of the SMARCB1 gene thus increasing cleavage 
efficiency of the targeted region (plasmid #408, Figure 38). 
 
The gRNA sequences targeting the sequence flanking the start codon of the SMARCB1 gene were 
also selected using the CRISPR designing tool of the MIT (http://tools.genome-engineering.org) 
according to Ran, Hsu et al. (2013). Cloning of sequences encoding the selected gRNA pairs into 
pX330A-1x2 Cas9n expression constructs was performed according to Sakuma, Nishikawa et al. 
(2014), section 2.1.15. The gRNA pair C3 was designed to target the region flanking the start codon 
of SMARCB1. Figure 31 and Figure 32 show the exact position and cleavage sites of the selected 
gRNA sequences targeting the genomic regions flanking the start and stop codon of the tumour 
suppressor gene SMARCB1. The sequences encoding gRNA pair C3 were cloned into the multiplex 
gRNA and Cas9n plasmids #220 (dsRedExpress reporter) and #218 (mTagBFP reporter) analogously 
to pairs D1-D3 (Figure 20). The resulting plasmids were named pX330A_D10A-dsRedExpress 
SMARCB1 gRNA pair C3  and pX330A_D10A-mTagBFP SMARCB1 gRNA pair C3 (#256). 
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Analogous to SMARCB1 gRNA pair D1, the coding sequence of Cas9n was removed from plasmid 
#256 generating a gRNA pair C3 and mTagBFP reporter plasmid which was co-transfected with 
recombinant Cas9 protein (plasmid #309, compare to Figure 37). Table 45 summarises the 
characteristics of the oligonucleotides used to generate sense and antisense gRNA C3 sequences. 
Table 45: Overview of the gRNA sequence pairs selected to target the region flanking the native start codon of the human 
SMARCB1 gene. 
gRNA NAME gRNA SEQUENCE, 5’→3’ OLIGO  
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3.2. Establishment and optimisation of CRISPR/Cas9-mediated genome engineering 
methods in HEK293T cells 
HEK293T cells were used as a system to test the functionality of all generated plasmids for the genome 
editing of the SMARCB1 gene locus. HEK293T cells are easy to transfect and appeared to be rather 
readily genome engineered, probably due to their tetraploidy (Stepanenko and Dmitrenko 2015). 
 
3.2.1. Establishment and optimisation of the CRISPR/Cas9-mediated genome 
engineering of the SMARCB1 locus in HEK293T cells using the generated AT/RT-
associated constructs 
The first approach of CRISPR/Cas9-mediated engineering included a Cas9 nickase in combination 
with one of three pairs of gRNA sequences targeting the genomic region flanking the native stop codon 
of SMARCB1 (gRNA pairs D1, D2, D3, section 7.1.3) and a HDR construct to insert a co-expressed 
eGFP-zeocin resistance (eGFP::ZeoR) cassette as well as a loxP site downstream of the stop codon of 
SMARCB1 (compare to Figure 7B). Co-expression was facilitated by deletion of the native stop codon 
of SMARCB1 and in-frame addition of a T2A sequence with flexible glycine-serine-glycine linker 
(plasmid #226, Figure 15). Flow cytometry analysis showed similar recombination efficiencies for all 
three of the gRNA pairs tested to insert the eGFP::ZeoR reporter cassette downstream of the native 
SMARCB1 stop codon. The portion of eGFP positive cells within the Cas9n/gRNA expressing BFP-
positive population was similar for either of the gRNA pairs used (Figure 21). For further experiments 
only the gRNA-Cas9 plasmid expressing the targeting sequence of gRNA pair D1 was used.  
Engineered HEK293T cells were enriched by zeocin selection, and the engineered cell population was 
analysed for growth rate and for synthesis of the SMARCB1 protein. Due to the nature of the self-
cleavage of 2A peptides, 22 amino acids are added to the protein expressed upstream of the linker 
peptide. As expected, this was observed by a shift of the SMARCB1/T2A protein band to 46.4 kDa in 
protein samples of engineered HEK293T cells (Figure 22C). In addition to the altered C-terminus of 
the SMARCB1 protein, HEK293T cells engineered to co-express eGFP::ZeoR downstream of the 
SMARCB1 gene also showed a significantly reduced growth rate compared to HEK293T wildtype 
control cells (Figure 22A, B). Since only little is known about the folding of the SMARCB1 protein, 
the impact of the additional 22 amino acids added by T2A self-cleavage cannot be assessed, but may 
interfere with the binding of the nucleosome by the BAF complex (He, Wu et al. 2020). Due to the 
observed growth retardation, an alternative approach for the co-expression of the reporter cassette 
was designed, namely the co-expression of the SMARCB1 gene and the fluorescence reporter linked 
by an IRES.  
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Figure 21: All three gRNA pairs targeting the region flanking the native stop codon of the SMARCB1 gene show equivalent 
CRISPR/Cas9n-mediated genome engineering efficiencies in HEK293T cells. (A) Flow cytometry analysis showed 35% of 
mTagBFP positive cells, indicating a transfection efficiency of 35% for the gRNA and Cas9n plasmids #221, #222, #223. Each 
expressing one pair of gRNAs (pair D1, D2, and D3, respectively. Representative FACS plots are shown). (B) Analysis of three 
technical replicates per plasmid showed similar transfection efficiencies for all three plasmids. The percentage of eGFP positive 
cells within the mTagBFP population was similar for all three gRNA and Cas9n plasmids. This indicates a similar efficiency 
in facilitating CRISPR/Cas9n-mediated genome engineering since an eGFP signal was only expected upon targeted insertion 
of the eGFP::ZeoR reporter cassette from the co-transfected HDR plasmid #226. Sample size per condition was n = 3. Normal 
distribution of the results was verified by the Anderson-Darling test. Student’s t-test did not reveal significant differences 
between transfection of genome engineering efficiencies facilitated by either of the three gRNA and Cas9n plasmids. 
 
In this approach, HEK293T cells were genome-engineered using the nickase approach with the same 
three pairs of gRNAs but in combination with a different HDR construct facilitating co-expression of 
the SMARCB1 gene and the eGFP::ZeoR reporter via an IRES sequence (plasmid #243, Figure 7B 
and Figure 16). Due to the direct binding of the ribosome to the IRES, no amino acids are added to 
the co-expressed genes. However, the protein coded downstream of the IRES is reported to be 
expressed at a lower rate (Trichas, Begbie et al. 2008). Flow cytometry analyses showed that genome 
engineering of the SMARCB1 gene using the IRES strategy was similarly efficient compared to the 
T2A approach (Figure 22A). Western Blot analyses showed a protein band of SMARCB1 at the 
expected size of 44 kDa (data not shown, compare Figure 24). In growth analyses, HEK293T cells 
engineered to express the SMARCB1-IRES-eGFP::ZeoR transgene grew at even lower rates than 
HEK293T cells co-expressing the reporter via a T2A sequence (Figure 22B). However, the resulting 
protein was not altered, which was evaluated to be advantageous. The IRES co-expression approach 
was selected to be the method of choice for the genome editing of the SMARCB1 gene.  
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Tests of different fluorophores in HEK293T cells showed that the expression of a fluorescence reporter 
alone was not sufficient to ensure enrichment of successfully engineered cells. Introduction of only a 
fluorescence reporter co-expressed with SMARCB1 resulted in only temporary expression of the 
fluorescence reporter hampering the isolation of successfully engineered cells and diminishing the 
advantages of the multi-colour system (data not shown, section 3.1). Thus, the final chosen second 
fluorophore, mKate2, was linked to a blasticidin resistance cassette (plasmid #386, Figure 7B and 
Figure 17). 
 
Figure 22: Analysis of the impact of the insertion of a T2A or IRES linked eGFP::ZeoR reporter downstream of the native stop 
codon of the SMARCB1 gene. (A) Cell growth was monitored over 48 hours after seeding 0.2x106 HEK293T cells per well of 
a 6-well plate. Already 24 hours post seeding, the cell density in the wells with either the cells engineered to express SMARCB1-
T2A-eGFP::ZeoR (T2A operon) and the cells engineered to express SMARCB1-IRES-eGFP::ZeoR (IRES operon) was lower 
compared to the wells with wildtype HEK293T cells (left panel). The eGFP expression in the engineered cells was detected by 
fluorescence microscopy 48 hours after seeding (right panel). (B) Every 24 hours, three wells per condition were detached 
using Trypsin/EDTA solution and counted using CASY cell counter. The cell count per millilitre was blotted for each condition. 
Already at 24 hours a slight decrease in cell count was observed for the IRES operon cells compared to T2A operon or wildtype 
HEK293T cells. At 48 hours, a significant decrease in cell count per millilitre was observed for both, the T2A and IRES operon 
cells which is more pronounced for IRES operon cells. (C) SMARCB1 protein analysis by Western blotting showed a size 
difference due to the addition of 22 amino acids to the C-terminus of SMARCB1 by self-cleavage of the T2A peptide. Per 
condition and time point, three wells were analysed. Scale bars in A represent 100 µm. Normal distribution of cell count data 
was verified by the Anderson-Darling test. Statistical analysis was performed using Student’s t-test. * p < 0.05, ** p < 0.001. 
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The reporter co-expression via an IRES was considered to be the favoured approach and was thus 
further developed to allow the introduction of the CSS-associated mutation c.1091_1093del AGA in 
exon 8 of the SMARCB1 gene as well as to express different fluorophores (Figure 8, section 3.1.2).  
 
The CRISPR/Cas9 engineering of the regions flanking the start codon of SMARCB1 was tested in 
HEK293T cells as described above. Here, a T2A sequence was used to link a fluorophore reporter with 
the SMARCB1 gene to ensure approximately native expression rates of the SMARCB1 gene 
(Figure 7B). 2A peptides are preferable to IRES sequences for this purpose, since the gene downstream 
of the IRES was shown to be expressed at lower rates (Szymczak and Vignali 2005). Additionally, the 
T2A sequence is much shorter (63 bp) than the IRES sequence (587 bp), resulting in an overall smaller 
HDR construct (Szymczak and Vignali 2005). The effect of the insertion of the reporter cassette 
upstream of the start codon of SMARCB1 on the HEK293T cell growth was analysed. There was no 
negative impact on cell growth of HEK293T cells engineered to express the eGFP::ZeoR-T2A 
reporter cassette upstream of the native start codon of SMARCB1 compared to wildtype control 
HEK293T cells observed. As expected, protein analysis of SMARCB1 showed only a slight increase 
in protein size due to the addition of three amino acids upstream of the first methionine of SMARCB1 
resulting from T2A self-cleavage in the genome engineered sequence (Figure 23). 
Again, different fluorophores were tested as co-expressed reporters and mTagBFP2 was chosen to fit 
into the three-colour reporter scheme. A Puromycin resistance gene was added upstream of the 
fluorescence gene, linked by P2A (plasmid #380, Figure 7B and Figure 35) to prevent homologous 
recombination and genetic instability due to repetitive sequences as in case of a second T2A sequence 
and to allow efficient enrichment of successfully engineered cells (Luke and Ryan 2018). 
 
 
3 Results       78 
 
Figure 23: The addition of a T2A linked eGFP::ZeoR reporter upstream of the native start codon of the SMARCB1 gene in 
genome engineered HEK293T cells did not reduce the growth rate of HEK293T cells. (A) Cell growth was analysed for 
48 hours after seeding 0.1x106 HEK293T cells per well of a 6-well plate. For both time points analysed, no alteration in cell 
growth could be observed (left panel). The expression of eGFP was detected by fluorescence microscopy (right panel). 
(B) Every 24 hours, three wells per condition were detached and counted using CASY cell counter. The cell count per millilitre 
was blotted for both samples. There also was no difference observed between the eGFP::ZeoR-T2A-SMARCB1 engineered 
compared to the wildtype cells in cell counting analysis. (C) SMARCB1 protein analysis by Western blotting showed the 
expected size of 44 kDa for SMARCB1 protein extracted from the wildtype control cells. For the eGFP::ZeoR-T2A-SMARCB1 
engineered cells, a slight increase in protein size probably due to the addition of three amino acids upstream of the first 
methionine residue of the SMARCB1 protein was observed. Per condition and time point, three wells were analysed, scale bars 
in A represent 100 µm. Normal distribution of cell count data was verified by the Anderson-Darling test. Statistical analysis 
was performed using Student’s t-test. There was no significant difference observed. 
 
HEK293T cells expressing a c.1148delC mutated allele of SMARCB1 (plasmid #363, Figure 18) could 
be detected and enriched by the expressed eGFP::ZeoR reporter (data not shown). However, this was 
not the case for the cells engineered to express a SMARCB1 allele with AT/RT-associated nonsense 
mutations in exon 1 (c.20_43delins T, c.93G>C, Figure 7C). The emerging pre-mature stop codons 
introduced by the mutations prevent the expression of SMARCB1, probably by rendering the mRNA 
for degradation. Since the reporter is translated from the same mRNA, its degradation would lead to 
a quick loss of expression of the fluorescence reporter, which therefore cannot be detected. 
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3.2.2. Establishment and optimisation of the CRISPR/Cas9-mediated genome 
engineering of the SMARCB1 locus in HEK293T cells using the generated CSS-
associated constructs 
When engineering HEK293T cells to express the mutated form of SMARCB1 associated with CSS, an 
enrichment of engineered cells by selection with zeocin was not possible. eGFP-positive HEK293T 
cells engineered to co-express the c.1091_1093del AGA SMARCB1 and the eGFP::ZeoR reporter died 
upon zeocin selection, maybe due to low expression levels of the resistance gene, which were 
insufficient to confer resistance to zeocin (Figure 8 depicts the genotype). Therefore, HEK293T cells 
engineered to express this mutant form of the SMARCB1 gene were enriched by flow cytometry and 
directly analysed for expression of the gene (Figure 24 and section 3.5.1). HEK293T were engineered 
using Cas9n plasmid #221 (mTagBFP reporter) and two HDR constructs inserting either an 
eGFP::ZeoR (plasmid #243or #253) or mKate2 (plasmid #318) reporter downstream of the native 
stop codon of the SMARCB1 gene upon CRISPR/Cas9n-mediated homology directed repair. Two 
samples, WT/WT (serves as control, HDR plasmids #243, #318) and CSS/WT (plasmids #253, 
#318) were isolated by FACS for expression analyses on the mRNA and protein level. Due to the 
tetraploidy of HEK293T cells, no conclusive results on the impact of the CSS-associated mutation 
c.1091_1093del AGA in exon 8 of the SMARCB1 gene on the transcription of eGFP and mKate-
associated alleles of SMARCB1 was obtained by RT-qPCR. SMARCB1 protein levels were reduced by 
3.8% in CSS/WT HEK293T cells compared to WT/WT HEK293T cells (Figure 24). 
 
Figure 24: Analysis of SMARCB1 protein levels in HEK293T cells engineered to simultaneously produce two SMARCB1 
proteins and one of two fluorescence reporters genomically linked by an IRES. For the WT/WT sample, HEK293T cells were 
transfected with Cas9n plasmid #221 and the two HDR constructs #243 (eGFP::ZeoR reporter) and #318 (mKate2 reporter). 
To obtain CSS/WT cells, HEK23T cells were transfected with plasmid #221 and the HDR constructs #253 
(c.1091_1093del AGA SMARCB1, eGFP::ZeoR reporter) and #318 (mKate2 reporter). 48 hours after transfection, the cells 
were detached and analysed by flow cytometry. 3-4x105 eGFP and mKate2 double positive cells of the mTagBFP positive 
population (reporter on gRNA and Cas9n plasmid #221) were sorted into a tube, collected at 200xg for three minutes and lysed 
in 70 µL of Lämmli buffer. Image analysis of the not-saturated images revealed that the protein bands detected showed a 3.8% 
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3.3. Establishment and optimisation of methods for CRISPR/Cas9-mediated genome 
engineering in hiPSCs 
Human induced pluripotent stem cell (hiPSC) lines differ in their growth rate, differentiation potential, 
and also ease of DNA transfer. In general, hiPSCs are difficult to transfect and especially the transfer 
of large plasmids – as necessary for CRISPR/Cas9-mediated genome engineering – is challenging. In 
the literature, electroporation of hiPSCs was reported to be highly effective in facilitating the transfer 
of large DNA fragments and thus CRISPR/Cas9-mediated genome engineering (Byrne, Mali et al. 
2014, Smith, Ye et al. 2016, Carlson-Stevermer and Saha 2017). During this work, different devices 
(Amaxa Nucleofector 2b, and 4D, Neon transfection system) and protocols for electroporation and 
nucleofection were tested. None of which was successful in generating hiPSCs expressing the reporter 
fluorescence gene co-encoded on the large gRNA and Cas9(n) plasmids indicating successful transfer 
of the plasmid into the cells.  
Thus, chemical transfection of the available hiPSC#33 line was evaluated. Transfection using 
Lipofectamine Stem reagent of Thermo Fisher was successful in efficiently transferring DNA of 
different sizes including gRNA and Cas9(n) plasmids of 9.8 kb. Naturally, the transfection efficiency 
declined with increasing plasmid size. For the large plasmids in this project, transfection efficiencies 
of approx. 10% could be achieved when transfecting hiPSC#33 seeded as single cells. Optimisation 
efforts like the application of the five-fold concentration of RevitaCell supplement for increasing the 
cells’ surface (Yen, Yin et al. 2014), reverse transfection and adaption of DNA amount did not yield 
any improvement regarding transfection efficiency. Furthermore, it was observed that transfection of 
hiPSC#33 with gRNA and Cas9(n) plasmids targeting the SMARCB1 gene was accompanied with 
lower transfection efficiencies (approx. 2% 48 hours post transfection, determined by FACS, data not 
shown) compared to transfection with gRNA and Cas9(n) plasmids targeting other genes like OTX2 
(OTX2-targeting plasmids kindly provided by Jana Frei). Additionally, more dead cells were observed 
in the SMARCB1-targeted condition 24 hours after transfection compared to transfections with gRNA 
and Cas9(n) plasmids targeting other genes like OTX2 (data not shown, OTX2-targeting plasmids 
kindly provided by Jana Frei). 
Transfection of cells with Cas9-gRNA ribonucleoprotein complexes (Cas9/gRNA RNPs) was reported 
to reduce the off-target cleavage of Cas9 by a shorter activity period and to bypasses the need to 
transfect the large Cas9 and gRNA plasmids (Liang, Potter et al. 2015, Yu, Liang et al. 2016). Transfer 
of the Cas9/gRNA or Cas9n/gRNA RNPs was performed using the protein transfection reagent 
Lipofectamine CRISPRMAX (CMAX00001, Thermo Fisher) or Lipofectamine Stem reagent. In both 
experimental approaches the HDR construct #243 for the insertion of an IRES-linked eGFP::ZeoR-
loxP cassette downstream of the native stop codon of the SMARCB1 gene was co-transfected. Neither 
did the transfected hiPSCs show any eGFP signal 24 to 48 hours after transfection nor could they be 
enriched by zeocin selection. Due to high costs and the lack of suitable controls, the transfection of 
Cas9(n)/gRNA RNPs was not followed up further. 
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Based on the experiments described above, two critical factors were identified which needed to be 
optimised for CRISPR/Cas9-mediated genome engineering in hiPSC#33: the low transfection 
efficiency of large plasmids and the high rate of cell death accompanied with Cas9(n) targeting the 
SMARCB1 gene. The issue of the high rates of cell death was tackled by the overexpression of the 
dominant-negative form of p53 (p53DD). 
 
Overexpression of the dominant-negative form of p53 (p53DD) to tackle the issue of Cas9 
cleavage-induced cell death in hiPSCs 
With the optimisation of the transfection of human induced pluripotent stem cells, the hiPSC#33 cell 
line used appeared to be very sensitive to Cas9(n)-induced cleavage of DNA. Especially when 
transfected with gRNA and Cas9(n) plasmids targeting the genomic region of the SMARCB1 gene, 
the amount of floating dead cells was remarkably higher compared to cells transfected with gRNA and 
Cas9(n) plasmids targeting other genes like OTX2 (data not shown, OTX2-targeting plasmids kindly 
provided by Jana Frei). 
BAF complexes, in general, thus also the core component SMARCB1, are essential for the balance 
between cell proliferation and differentiation (Wilson and Roberts 2011). Loss of Smarcb1 also was 
shown to be embryonic lethal in mice (Klochendler-Yeivin, Fiette et al. 2000). Moreover, Cas9-induced 
double strand breaks were shown to be toxic for hiPSCs, and the toxic response was shown to be 
TP53-dependent. Considering the regulating role of the BAF complexes and the embryonic lethality 
upon loss of SMARCB1, the high rate of cell death and the low genome editing efficiency in hPSCs 
may be associated with effects of the DSBs and with the SMARCB1 gene locus itself on the cells. 
Overexpression of the dominant-negative form of the murine sequence of the tumour suppressor gene 
Tp53 (p53DD) was shown to increase survival and genome editing efficiencies in hPSCs (Ihry, 
Worringer et al. 2018). Thus, a p53DD-encoding plasmid was co-delivered with the Cas9 plasmids. 
For this purpose, codons 1 to 13 and 302 to 390 of the murine coding region of Tp53 were cloned into 
an episomal backbone (Bowman, Symonds et al. 1996, Hong, Takahashi et al. 2009, Ihry, Worringer 
et al. 2018). Similarly, the p53DD encoding sequence was amplified from murine cDNA from E14.5 
Smarcb1+/inv individual E516 using the overlap extension method (section 2.1.14) and cloned into the 
transposable backbone of plasmid #01 yielding pMTE-p53DD (plasmid #415). The detailed cloning 
steps are summarised in Figure 25.  
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Figure 25: Schematic overview of the cloning steps to generate the transposable plasmid #415 and the lentiviral plasmid #416 
for overexpression of p53DD. The p53DD sequence was PCR amplified from embryonal mouse cDNA of E14.5 Smarcb1+/inv 
individual E516 using the overlap extension method. For this purpose, fragment A comprising codons 1-13 of the mouse Tp53 
gene was amplified using primers #1479 and #1480. Fragment B comprising the codons 302-390 of the mouse Tp53 gene was 
amplified using primers #1481 and #1482. Fragment A and B were combined in a third PCR, and the complete p53DD sequence 
was amplified using primers #1479 and #1482. The complete p53DD sequence was cloned into transposable plasmid #01 via 
NheI and NotI restriction endonuclease cloning resulting in plasmid #415. Ef1α = human elongation factor 1α (Ef1α) core 
promoter and truncated intron upstream of the start codon of human Ef1α; BleoR = Bleomycin resistance gene confers 
resistance to antibiotics of the bleomycin family, e.g. zeocin; 3’UTR = 3’ untranslated region (Stojanova, Tu et al.) of the major 
beta-globin gene of Xenopus laevis. 
 
The cloned transposable plasmid for overexpression of p53DD (plasmid #415, 5.3 kb) was applied to 
test the effect of expression of the dominant-negative form of p53 on the survival of hiPSC#33 upon 
transfection. Since the p53DD plasmid #415 does not contain a fluorescence reporter gene which 
allowed to directly assess the transfection efficiency, the gRNA and mTagBFP encoding plasmid #310 
(5.4 kb, Figure 37) was used as a size-equivalent control. Furthermore, hiPSC#33 were also 
transfected with the SMARCB1-targeting gRNA and Cas9 plasmid #387 (eGFP reporter, 9.8 kb, 
Figure 38) alone or in combination with the p53DD plasmid. Figure 26 shows the flow cytometry 
analysis results of the effect of the expression of p53DD on the survival of hiPSC#33 upon transfection. 
As indicated by the amount of mTagBFP positive cells in gate P4 (Figure 26A, B), a transfection 
efficiency of 36.2% can be achieved for plasmids of around 5 kb size (2.5 µg of plasmid DNA). This 
percentage also remained stable when the cells were transfected with the same total amount of DNA 
but composed of even shares of two plasmids (e.g. #310 and #415, #380 and #415, 1.25 µg each, 
Figure 26C). Transfection of hiPSC#33 with the SMARCB1-targeting gRNA and Cas9 plasmid #387 
showed very low transfection efficiencies of 0.9% 48 hours after transfection. Co-transfection of 
plasmid #387 and #415 did neither result in a remarkable increase of transfection efficiency (1.1%) nor 
in cell survival when assessed with the dead cell stain SytoxRed (Figure 26C, D). 
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Figure 26: Flow cytometry analysis does not show a beneficial effect of the expression of p53DD on the survival of hiPSC#33 
upon transfection with Cas9 plasmids. (A) Survival of hiPSC#33 was assessed by flow cytometry analysis and cell staining 
with the dead cell stain SytoxRed (left panel, gate P1). In general, the survival of hiPSC#33 was low for all conditions analysed 
in FACS (around 50%). Transfection efficiency was quantified as the percentage of fluorescent cells of the surviving cells in 
gate P1 (mTagBFP for plasmids #310 and #380, eGFP for plasmid #387, gate P4 or P5, respectively, right panel). (B) Upon 
co-transfection of the control plasmid #310 with the p53DD plasmid #415, the survival of the cells was only slightly increased 
while the transfection efficiency quantified as the number of fluorescent cells remained similar despite reducing the amount of 
plasmid DNA of #310 by 50% (compare gates P1 and P4). (C) Evaluation of all conditions analysed by flow cytometry showed 
a remarkable decrease in transfection efficiency with the increase of plasmid size from approx. 35% for 5.4 kb plasmids to 
0.9% for the 9.8 kb SMARCB1-targeting gRNA and Cas9 plasmid #387 (solid bars). Co-transfection of the p53DD plasmid 
#415 while keeping the total amount of DNA transferred constant (1.25 µg each vs. 2.5 µg alone) only slightly decreased the 
number of fluorescent cells detected (striped bars). (D) Quantification of the survival showed a slight increase upon (co-) 
transfection of hiPSC#33 with the p53DD plasmid #415 for plasmids up to 7.4 kb in size but a slight decrease in survival of 
cells co-transfected with the SMARCB1-targeting gRNA and Cas9 plasmid #387. In A and B the FACS plots of the analysis of 
the transfection of hiPSC#33 with plasmid #310 and the effect of co-transfection of plasmid #415 are shown as representative 
images for the other conditions quantified in C and D. 
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3.4. Establishment and optimisation of methods for CRISPR/Cas9-mediated genome 
engineering in MCF10A cells 
The constructs established in sections 3.1 and 3.2 were also to be used to edit the genome of  MCF10A 
cells to analyse the gene expression of SMARCB1 and the co-expressed reporter genes on the mRNA 
level via RT-qPCR. The MCF10A cell line was chosen since it is an established cell line, diploid for 
chromosome 22, and less difficult to transfect than hiPSC (Marella, Malyavantham et al. 2009). In 
MCF10A cells both alleles of SMARCB1 were to be edited to co-express a fluorescent reporter. One 
allele in its wild-type form, while the other one either mutated with an AT/RT- or CSS-associated 
mutation. With this approach the hypothesis that heterozygous CSS-associated missense mutation of 
the SMARCB1 gene causes either only a mild reduction of the gene expression level or a mildly 
malfunctioning protein which does not trigger the intracellular compensation by the second unaffected 
allele of SMARCB1 should be tested. Likewise, it should be analysed if AT/RT-associated nonsense 
mutations of SMARCB1 completely ablate the gene expression from the affected allele, causing an 
increase of transcription from the unaffected allele to compensate for the loss of gene product in case 
of RTPS1.  
CRISPR/Cas9-mediated genome engineering in MCF10A cells requires an efficient transfer of the 
nuclease and gRNA plasmid, and a HDR construct for the introduction of a reporter insert. The most 
abundantly used method to deliver DNA into cells is transfection. The common transfection reagents 
PEI and Lipofectamine 3000 are widely used for the transfection of MCF10A cells and were tested to 
identify the method for the most efficient transfer of DNA. 
In a conservative approach for transfection (seeding of cells 24 hours prior to transfection) with 
plasmids of different sizes, no remarkable difference in transfection efficiency of MCF10A cells between 
PEI and Lipofectamine 3000 reagent was observed. For small plasmids (plasmid #376, 5.4 kb) 
20 to 40% of the transfected cells showed reporter gene expression. In contrast, the amount of reporter 
gene expressing cells decreased to a maximum of 10% for larger plasmids (e.g. plasmid #221, 9.8 kb, 
data not shown). The standard transfection approach was nonetheless tested for the generation of 
MCF10A SMARCB1 reporter cell lines, but transfected cells could not be enriched for cells that 
integrated the reporter cassette by antibiotic selection. Therefore, different optimisation approaches 
were pursued. First, the co-transfection of Cas9n/gRNA constructs with linearised HDR constructs 
was tested. The linearization of the HDR constructs was reported to increase the ratio of homologous 
recombination and thus the introduction of the reporter gene insert (Stuchbury and Munch 2010, Song 
and Stieger 2017). Upon transfection of MCF10A cells with linearised HDR constructs, most of the 
cells died maybe due to higher toxicity of linear DNA fragments in the cells. As an alternative 
transfection method, a reverse transfection was performed. For this purpose, single cells in suspension 
were mixed with the transfection mix and incubated at room temperature for up to 30 minutes before 
plating. The reverse transfection was performed using either PEI or Lipofectamine 3000 reagent, but 
the MCF10A cells were not efficiently transfected with either of the reagents. All means of transfection 
to transfer DNA for CRISPR/Cas9-mediated genome editing mentioned above were tested with both, 
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Cas9 nickase and wildtype Cas9 nuclease plasmids. Seemingly, the chemical transfection is not the 
method of choice for the CRISPR/Cas9(n) engineering of MCF10A cells. Therefore, electroporation 
using the Amaxa Nucleofector 2b device in combination with a self-made electroporation buffer was 
tested (section 2.3.6). Based on the recommendations of Lonza for the optimisation of an 
electroporation setup, eleven different programmes were tested (A-020, T-020, T-030, X-001, X-005, 
L-029, D-023, S-005, T-013, W-001, U-017) for the transfer of a 9.5 kb plasmid (plasmid #273, mKate2 
reporter). The different programmes had different effects on the MCF10A cells regarding the toxicity, 
but none resulted in a successful transfection of the cells, since they did not show fluorescence reporter 
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3.5. Loss-of-function mutations in SMARCB1 de-regulate expression of Hes genes in 
murine neural stem and in HEK293T cells 
A mouse model recapitulating neurodevelopmental features of the human CSS was established in the 
Stem Cell and Developmental Biology group at the Technical University of Darmstadt. In these mice 
(Smarcb1+/inv NesCre+/- mice, referred to as mutant), heterozygous inactivation of the Smarcb1 gene 
occurs by inversion of the floxed region of Smarcb1 exon 1 upon expression of the Cre recombinase 
under the control of the rat nestin promoter starting around embryonic day (E) 10.5 (Roberts, Leroux 
et al. 2002, Filatova, Rey et al. 2019). Targeted cells are mainly radial glial cells (RGCs). RGCs are 
neural stem cells which are only transiently present during neural development (Gotz and Barde 2005, 
Filatova, Rey et al. 2019). Aside from various structural deviations from the Smarcb1+/inv NesCre-/- 
control mice, Smarcb1 mutant mice also exhibit a diminished RGC population. At E14.5 thinned layers 
of RGCs in the ventricular zone lining the lateral ventricles, as well as of intermediate progenitors in 
the subventricular zone, and of early-born cortical neurons were detected. Additionally, a decrease in 
neurosphere (NSP)-forming capacity of NSCs and NPCs in cultures from E15.5 mutant brain tissues 
was observed. Neurospheres (NSPs) are three-dimensional floating spheroid cell clusters that arise 
from NSP-forming cells, which can be both NSCs or NPCs, isolated from the mammalian CNS (Jensen 
and Parmar 2006, Singec, Knoth et al. 2006, Pastrana, Silva-Vargas et al. 2011). Upon in vitro 
cultivation, the heterogeneity of NSPs increases and aside from proliferative, NSP-forming NSCs and 
NPCs also post-mitotic neurons and glia cells can be found within one sphere (Jensen and Parmar 
2006). Nonetheless, NSP culture can be applied as a functional assay and is a useful tool to analyse 
proliferation, self-renewal capacity, and multipotency of the NSP-forming NSCs and NPCs over serial 
clonal passages (Jensen and Parmar 2006). Different lines of reasoning were followed to determine the 
underlying cause for the reduced number of RGCs in Smarcb1 mutant mouse brains (section 4.3). 
 
3.5.1. Loss-of-function mutations in SMARCB1 de-regulate expression of Hes genes in 
E14.5 mouse brain samples and in HEK293T cells 
Engineered HEK293T cells generated in this project carrying the CSS-associated SMARCB1 mutation 
c.1091_1093del AGA were analysed for changes in HES1 and HES5 gene expression. HEK293T cells 
were transfected with the plasmids encoding the CRISPR/Cas9 machinery for the editing of the region 
flanking the stop codon of the SMARCB1 gene and with two HDR constructs for insertion of an eGFP 
and mKate2 reporter downstream of exon 9 of the SMARCB1 gene. Equivalent to the mouse control 
samples, HEK293T control cells termed WT/WT were engineered using two HDR constructs 
without mutation in the SMARCB1 gene and either an eGFP or a mKate2 reporter (plasmids #243 
and #318). The engineered mutant HEK293T cell population termed CSS/WT was obtained by 
transfecting one HDR construct without mutation in the SMARCB1 sequence (plasmid #318, mKate2 
reporter) and a second HDR construct to introduce the CSS-associated mutation c.1091_1093del AGA 
in exon 8 of the SMARCB1 gene (plasmid #253, eGFP reporter). 60 hours after transfection, the 
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HEK293T cells were subjected to flow cytometry analysis. The desired WT/WT or CSS/WT 
populations were identified by expression of the eGFP and mKate2 reporter genes. Therefore, eGFP 
and mKate2 double positive cells in the population of Cas9n/gRNA expressing cells (BFP positive) 
were sorted via FACS into lysis buffer for RT-qPCR analysis of HES1 and HES5 gene expression 
(Figure 27A). In HEK293T cells, HES1 expression could not be detected, but the expression of HES5 
was significantly reduced by 50% (Figure 27B). 
 
Figure 27: RT-qPCR expression analysis of sorted HEK293T cells which were CRISPR/Cas9-engineered to express one 
c.1091_1093del AGA mutated allele of the SMARCB1 gene show a significant reduction in HES5 transcript abundance 
compared to control cells. (A) HEK293T cells were transfected with Cas9n/gRNA plasmid #221 and the SMARCB1 e9 wildtype 
HDR constructs #243 (eGFP::ZeoR) and #318 (mKate2) or SMARCB1 e9 wildtype HDR construct #318 (mKate2) and the 
SMARCB1 CSS e9 HDR construct #253 (eGFP::ZeoR). A sample blot of the FACS experiment is shown. (B) The sorted and 
lysed cells were directly used for cDNA synthesis. Depicted are the RQ means of two independent sorts of HEK293T WT/WT 
and CSS/WT cells. N = 2, statistical tests were performed on the original replicates of the sorts combined, normal distribution 
was not given for the control samples; thus, a Wilcoxon signed rank test was performed. * p < 0.05. 
 
Based on the findings of reduced HES5 expression in these HEK293T cells and in the developing glial 
wedge position at the medial walls of the lateral ventricles by RNA in situ hybridisation in E15.5 
mutant brain sections in Filatova, Rey et al. (2019), RT-qPCR analyses of Hes1 and Hes5 expression 
in E14.5 mice brain samples were conducted (primers #1123 and #1124, amplicon 113 bp, and #1268 
and #1269, amplicon 186 bp, respectively). The location of differential expression of Hes5 in the 
developing brain is small and difficult to isolate. Moreover, the changes in expression of Hes5 were 
only observed in the neural progenitor population lining the lateral ventricles. Thus, brain samples of 
different regions, i.e. forebrain and hemispheres, were analysed when applicable. Due to the affected 
population, RT-qPCR results were normalised to the Nestin gene (primers #1306 and #1307, amplicon 
86 bp). Nestin (Nes) served as a reference gene in this context since it is described to be expressed in 
all RGCs at a similar level (Gotz and Barde 2005) and since the microcephaly phenotype of the mutant 
mice precluded the use of conventional reference genes such as the TATA box-binding protein (Tbp). 
In all samples analysed, regardless of brain region, the expression of Hes1 was significantly increased 
by 20 to 40% in mutant compared to control RGCs at E14.5 (Figure 28). For the expression of Hes5 
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in Nes positive cells, the analyses were less distinct. In E14.5 forebrain samples a decrease in Hes5 
expression in these cells of up to 26% was observed, but this trend was only significant for one litter 
(Figure 28A, B). In E14.5 hemisphere samples, the expression of Hes5 in Nes positive cells remained 
similar in control and mutant individuals (Figure 28A). Summarising, the data obtained for mutant 
E14.5 forebrain samples corresponded with the results of the RNA in situ hybridisation experiments 
shown in Filatova, Rey et al. (2019). The increase in Hes1 expression in Nes positive cells during these 
stages of development was not observed in RNA in situ hybridisations of brain sections.  
 
Figure 28: RT-qPCR analysis of Hes1 and Hes5 in control and mutant brain samples of E14.5 mice. (A) In forebrain samples 
of E14.5 mouse embryos of litter A, a significant reduction in the expression of Hes5 normalised to Nestin (Nes) expression 
levels of mutant compared to control samples was observed alongside a significant increase of Hes1 transcripts. The increase 
in Hes1 transcript abundance was also true for the matching hemisphere samples. (B) For E14.5 litter B, only forebrain samples 
were available. Similar to (A) a significant increase in Hes1 transcripts relative to Nestin expression levels of mutant compared 
to control samples was observed while expression of Hes5 did not differ significantly between mutant and control samples. 
Control = Smarcb1+/inv NesCre-/-, mutant = Smarcb1+/inv NesCre+/-. N = 4 per group, except for mutant E14.5 litter B 
where n = 3. Normal distribution of the results was confirmed with the Anderson-Darling test. The results were analysed by a 
two-sided, unpaired Student’s t-test. * p < 0.05, ** p < 0.01, *** p > 0.0001.   
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3.5.2. Cloning and lentiviral packaging of murine Hes5-IRES-mKate2 overexpression 
and IRES-mKate2 control plasmids for the transduction of murine neural stem cells 
The murine Hes5 overexpression construct was generated by linking the complete coding sequence of 
Hes5 and the mKate2 fluorescent reporter via an IRES. A construct containing only IRES-mKate2 but 
no Hes5 coding sequence served as a control for the effect of the integration of the lentiviral genome 
itself. Based on the first set of lentiviral plasmids (plasmids #372-375, Figure 39), the cassette for 
overexpression of Hes5-IRES-mKate2 and the IRES-mKate2 control cassette were introduced into the 
lentiviral backbone plasmid #258 via blunt end cloning (Figure 29). This new set of Hes5-IRES-
mKate2 overexpression and IRES-mKate2 control plasmids was based on the same lentiviral backbone 
as the Cre recombinase plasmid #258 and its Venus control counterpart plasmid #340 which were 
selected to inverse the loxP-flanked exon 1 of the Smarcb1 gene in E42 NSP-forming cells. The 
lentiviral plasmids were packed into lentiviral particles using packaging plasmid #438 (pCD- NL/BH) 
and VSV- G envelope plasmid #257 (pMD2.G) as described in section 2.3.7. 
 
Figure 29: Schematic overview of the molecular cloning steps to generate the lentiviral plasmid for overexpression of murine 
Hes5 co-expressed with a mKate2 reporter (plasmid #406) and a suitable mKate2 reporter control plasmid (plasmid #407) from 
plasmids #258, #372, and #374 via blunted DNA ends. 
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3.5.3. Establishment and optimisation of methods to overexpress Hes5 in murine NSCs 
In general, lentiviral particles are generated by transfecting HEK293T cells with a lentiviral 
packaging and envelope plasmid with the transfer plasmid coding for the gene(s) of interest to be 
packed into the viral particle. Consequently, after transfection of the HEK293T cells, the medium has 
to be changed to the growth medium of the cells which will be transduced with the produced viruses. 
For most cell types to be transduced and most transfer plasmids, this approach is suitable. For the 
transduction of E42 neurospheres (NSPs) of E15.5 Smarcb1+/inv NesCre-/- mice, this approach was not 
successful for all applied plasmids.  
The aim was to transduce these spheres with a Cre recombinase carrying lentivirus to generate the 
Smarcb1 mutation in the cells, namely a Cre-mediated inversion of exon1, and simultaneously transduce 
the cells with a virus carrying a Hes5 overexpression cassette. Hence to test the hypothesis if 
overexpression of Hes5 can rescue the loss of the sphere forming ability that occurs upon Cre 
recombination in Smarcb1+/inv NesCre+/- neural stem cells as seen in Filatova, Rey et al. (2019). 
Transduction of E42 NSPs with VenusCre expressing lentiviral particles and the matching control 
(transfer plasmids #258, and #340 respectively) was successful with the conventional transduction 
approach without concentration (section 2.3.7). Therefore, the lentiviral Hes5-IRES-mKate2 
overexpression and IRES-mKate2 control transfer plasmids in a pLenti-UbC backbone were generated 
(plasmids #373, #375). Virus production in HEK293T cells and control transduction of HEK293T 
cells was efficient, but the viral particles generated repeatedly failed to generate mKate2-positive E42 
NSP-forming cells. After different optimisation attempts regarding experimental timing, setup, and 
ratio of co-transfected helper plasmids, another set of Hes5 overexpression and control transfer 
plasmids was cloned using the lentiviral backbone of the VenusCre plasmid (plasmids #406, #407). 
While lentiviral particles with the Hes5 overexpression cassette were infectious using the standard 
procedure, the matching mKate2 control viral particles failed to generate mKate2-positive E42 NSP-
forming cells. Tests in HEK293T cells revealed that the transfer plasmid was intact and was 
successfully packed into infectious lentiviral particles. Upon further experiments, it became apparent, 
that these particles were only generated efficiently by HEK293T cells if they were cultured in 
HEK293T growth medium but not when the medium was changed to the NSP growth medium 
(NSPM) after the transfection. The necessity of HEK293T medium for the efficient production of 
lentiviral particles restricted the direct use of the virus containing supernatant for transduction of E42 
NSPs. 
Alternative strategies were devised to transduce NSPs without the need of concentration since the 
viral titer produced was sufficient. As a result, transduction of E42 NSPs in 1 mL of NSPM 
supplemented with EGF and bFGF to match the final volume of the transduction with 500 µL to 1 mL 
of virus containing supernatant from HEK293T medium was tested. 24 hours after transduction the 
cells showed mKate2 expression but all spheres had attached and could not be detached to form spheres 
again, indicating a differentiating influence of the residual components of the HEK293T growth 
medium on the NSP-forming cells. Henceforth, a method for medium exchange of the virus containing 
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supernatant prior to transduction of the NSPs was required. The best means to achieve a medium-
independent system is centrifugation of the virus containing supernatant and re-constitution of the 
pelleted viral particles in an appropriate buffer or medium. Ultracentrifugation was chosen to pellet 
the viral particles. Re-constitution of the pellet in DMEM/F12 and 1% BSA followed by transduction 
of HEK293T and E42 NSPs compared to the non-concentrated HEK293T growth medium based virus 
containing supernatant revealed a decrease in infection rate for the ultracentrifuged Hes5 
overexpression particles compared to an equivalent volume of unconcentrated supernatant. E42 NSP-
forming cells and HEK293T cells transduced with the matching control particles in concentrated virus 
preparations still did not show reporter expression. Transduction of HEK293T cells with 
unconcentrated virus-containing supernatant showed expression of the mKate2 reporter, as seen 
before at a much lower intensity compared to the Hes5-IRES-mKate2 transduced cells. Therefore, the 
concentration of lentiviral particles as described by Jiang, Hua et al. (2015) was applied. In this 
protocol, concentration of lentiviral particles is achieved by centrifugation at 10,000 xg over a 10% 
sucrose cushion. Thereby, reducing the centrifugal forces and damaging potential applied to the viral 
particles. In this final experimental setup, all four required lentiviral particles (from plasmids #258, 
#340, #406, #407) carrying the VenusCre and Hes5-IRES-mKate2 expression systems as well as the 
respective controls were generated and concentrated (Figure 30). Transduction of E42 NSPs with 
combinations of the concentrated virus containing suspension resulted in spheres expressing Venus 
and mKate2 simultaneously (Figure 30B). Unfortunately, the transduced cells did not survive the first 
dissociation after transduction, and thus were not applicable for flow cytometry analysis and sort. 
Nonetheless, the transduction of E42 NSPs with the VenusCre and Hes5-IRES-mKate2 expression 
systems was established in a growth medium-independent approach. This will allow to test the 
hypothesis if overexpression of Hes5 can rescue the impaired sphere-forming ability of Smarcb1+/inv 
murine neural stem cells. 
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Figure 30: LV concentration over a 10% sucrose cushion facilitates transduction of E42 NSPs. (A) E42 NSPs were separately 
transduced with lentiviral particles generated from plasmids #258, #340, #406, #407. 48 hours after transduction, the NSP-
forming cells showed reporter signals indicating successful transduction. Volumes of virus suspension used for transduction of 
E42 NSPs: #258 50 µL, #340 200 µL, #406 100 µL, #407 200 µL. (B) Transduction of E42 NSPs with combinations of the 
four LVs was successful in generating spheres expressing both reporter genes. For the combination #258 + #406, a lot of debris 
exhibiting mKate2 signals was present. Double positive spheres were thus marked by white arrow heads. Scale bars represent 
50 µm.  
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4. Discussion 
 
4.1. Establishment and optimisation of methods and constructs for CRISPR/Cas9-
mediated genome engineering of the SMARCB1 gene locus in human cell lines  
In this thesis, a reporter system for the co-expression of two to three genes encoding fluorescent 
proteins and the human tumour suppressor gene SMARCB1 was designed.  
This reporter system, which is depicted in Figure 7, includes the introduction of a loxP-PuroR-P2A-
mTagBFP2-T2A cassette upstream of the native start codon and either an IRES-eGFP::ZeoR-loxP or 
an IRES-mKate2-loxP reporter cassette downstream of the stop codon of the SMARCB1 gene using 
the CRISPR/Cas9 technology. This system should allow a controlled homozygous or heterozygous 
deletion of the SMARCB1 gene, as seen in AT/RTs, via Cre recombination. Heterozygous deletion of 
the gene in combination with point mutations of the SMARCB1 gene found in AT/RT patients should 
facilitate the establishment of cell lines with different AT/RT-associated genotypes. The introduction 
of two HDR constructs with different fluorescence reporter cassettes, one with a SMARCB1 wildtype 
sequence and one encoding for the CSS-associated mutation c.1091_1093del AGA, was used as a two-
colour reporter system in human cell lines. These multi-colour reporter systems should allow not only 
the rapid identification of recombined cells by the expression of the fluorescence reporter genes which 
would be time and cost intensive if the insertion of a loxP site alone had to be verified, but also indicates 
the deletion of either marked allele of SMARCB1 by loss of the fluorescence signal upon Cre 
recombination. Moreover, the insertion of the fluorescence reporters facilitates the discrimination 
between the two SMARCB1 alleles. Therefore, differences in the gene expression of SMARCB1 from 
either allele should be detectable by RT-qPCR analysis of the fluorescence genes’ transcripts even 
though the sequence differences in the coding sequence of SMARCB1 are too subtle to be recognised 
by primers. Extensive testing of each component was performed in HEK293T cells resulting in a 
preliminary cell system in which the SMARCB1 gene was co-expressed with eGFP::ZeoR and mKate2-
T2A-BSD reporter cassettes downstream of its native stop codon. In addition, HEK293T cells 
expressing the mKate2-T2A-BSD cassette linked to one allele of the SMARCB1 gene in combination 
with the introduction of the CSS-associated mutation c.1091_1093del AGA and an eGFP::ZeoR 
reporter cassette were generated. With these two HEK293T cell systems, preliminary analyses of the 
effect of this mutation on the SMARCB1 gene expression were conducted (sections 3.5 and 4.3). 
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4.1.1. Transfer of large constructs into hiPSC#33 and re-evaluation of the HDR constructs 
Genome editing of the hiPSC cell line #33 proved to be very challenging. Despite extensive testing of 
diverse DNA transfer methods ranging from transfection of plasmid DNA, over transfection of pre-
assembled Cas9/gRNA ribonucleoprotein complexes, to electroporation the CRISPR/Cas9-mediated 
gene editing to insert the approx. 1.7 kb IRES-reporter cassettes downstream of the native stop codon 
of the SMARCB1 gene was not successful. Due to the large insert size and the comparably long 
homology arms selected25, transfection efficiency not only of the 9.8 kb Cas9(n) and gRNA plasmid 
but also of the >7 kb HDR constructs was very low (Figure 26). Independent of the method or device 
the reported transfection efficiencies of up to 70% could not be achieved (Moore, Atze et al. 2010, Ran, 
Hsu et al. 2013, Byrne, Mali et al. 2014, Renaud, Boix et al. 2016).  
A possible approach to overcome the poor DNA transfer efficiency could be use of integrase-defective 
lentiviral particles (IDLVs) as transduction is also reported to be highly effective in DNA transfer into 
hiPSCs (Lombardo, Genovese et al. 2007, Banasik and McCray 2010). IDLVs are generated with a 
packaging plasmid which carries an inactivating point-mutation in the viral integrase gene. Thus, 
these viral particles will not randomly integrate the transferred genes into the genome of the infected 
cell but targeted genome engineering can take place by expression of the CRIPSR/Cas9 machinery 
from the delivered nucleic acid. Nonetheless, extensive cell death as seen for transfection of hiPSC#33 
most likely will also be an issue when transducing hiPSC#33 with IDLVs encoding for the 
CRISPR/Cas9-genome engineering machinery due to the long-lasting expression of the Cas9/gRNA 
ribonucleic complexes and thus, the high number of DSBs in the genome. The issue of extensive cell 
death was tackled in this thesis by the application of the Rho-associated kinase inhibitor mix RevitaCell 
of Thermo Fisher and the overexpression of the dominant negative form of p53 (p53DD) (Bowman, 
Symonds et al. 1996, Ohgushi, Matsumura et al. 2010, Ihry, Worringer et al. 2018). The latter 
approach was reported to inhibit the TP53-dependent toxic response to Cas9-induced DSBs in hiPSCs 
(Ihry, Worringer et al. 2018). Even though a transfection efficiency of the p53DD encoding plasmid 
of over 30% can be assumed based on the transfection of an equivalently sized reporter plasmid, no 
positive effect on cell survival was observed by flow cytometry analysis (Figure 26). Therefore, the 
applied system for CRISPR/Cas9-mediated genome engineering has to be further optimised. 
Adjustments on the basis of the system should be considered to achieve the goal of a multi-colour 
reporter system which is co-expressed with the SMARCB1 gene and will allow the controlled removal 
of one or two SMARCB1 alleles by Cre recombination. First, re-evaluation and more extensive testing 
of the transfection of Cas9(n) RNPs could be implemented. The use of RNPs has different advantages. 
The half-life of these complexes and thus the Cas9-mediated cleavage activity is in the range of hours 
rather than weeks as for transfection of Cas9 and gRNA encoding plasmids and was reported to achieve 
indel insertion rates of 55 to 85% (Liang, Potter et al. 2015, Yu, Liang et al. 2016). This feature reduces 
the rate of off-target cleavage as well as the total load of double strand breaks in the genome of hPSCs 
 
25https://www.addgene.org/crispr/zhang/faq/?gclid=Cj0KCQjwhtT1BRCiARIsAGlY51K0IZOZg2ywnBeaudJsDZdSeAN8Qm0jKveeUf
m6YrLGoWNa5mM4-0EaAsi6EALw_wcB, May 15, 2020 
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(Liang, Potter et al. 2015). Both are considered to be beneficial in enhancing cell survival upon Cas9-
cleavage of the genome. Additionally, the process of protein transfection using Lipofectamine Stem 
reagent was also observed to be less stressful for the cells compared to other methods like 
electroporation or transduction. One point regarding successful establishment and deployment of the 
transfection of Cas9/gRNA RNPs into hiPSCs is that there is no direct control of the functionality of 
this method in other cell lines. Transfer of Cas9/gRNA RNPs into readily transfected cell lines like 
HEK293T cells has to be performed with Lipofectamine CRISPRMAX which has been optimised for 
transfer of RNPs while transfer of the RNPs into hPSCs is most effective using Lipofectamine Stem 
reagent. The Lipofectamine Stem reagent was specifically developed for the transfection of hPSCs but 
is ineffective in transfecting DNA or protein into other cells lines (personal communication with Tim 
Wiese, Thermo Fisher and26). Also, a size equivalent and visibly observable control for the transfer 
efficiency of the RNPs is required. Cas9 is a large protein of approx. 160 kDa. This is a protein size 
which is not met by the fluorophores (e.g. protein size of eGFP: 26.9 kDa27). Additionally, the selected 
fluorescent control protein should be purchasable at low costs or should be synthesised and purified 
in-house with a comparable purity to the commercial Cas9 protein.  
Second, the size of the HDR constructs necessary for the mediation of homologous repair and insertion 
of the reporter cassette and/or mutation of the genomic sequence could be re-considered. The 
recommendations of the Zhang laboratory on HDR construct design state that longer homologous 
sequences reduce the risk of unspecific integration at random sites in the genome, but also recommend 
homology arms of 800 bp at most (Ran, Hsu et al. 2013). These 800 bp homology arms were also 
reported to be sufficient for the insertions of DNA sequences of 1 kb.28 In this project, homology arms 
of >1.6 kb were designed for the insertion of a >1.7 kb insert. This resulted in larger HDR constructs 
and reduced transfection efficiencies, thus lower chances for homology directed repair in Cas9-
transfected cells due to the absence of a suitable repair template. The optimal length of the homology 
arms for efficient CRISPR/Cas9 genome editing differs and often is not disclosed in the publications 
on the generated hPSC reporter cell lines (Yu, Liu et al. 2015, Zhang, Termglinchan et al. 2019). 
Therefore, shorter homology arms should be considered for the generation of the SMARCB1 reporter 
hiPSC line to overcome the discussed disadvantages of homology arms >1.6 kb. Re-evaluation of the 
design of the HDR constructs should also be considered, e.g. the IRES-GFP knock-in strategy as 
described by He, Tan et al. (2016) may be a convenient strategy to generate the SMARCB1 reporter 
cell line. In this strategy, reporter insertion was achieved either by NHEJ-mediated knock-in alone or 
by a combination of NHEJ and HDR. In both cases knock-in frequencies were higher as for the 
conventional HDR approach. Following the experimental design of He, Tan et al. (2016), IRES-
reporter cassette donor templates with gRNA target sites derived from prokaryotic sequences (sg-A) 
 
26 https://www.thermofisher.com/de/en/home/brands/product-brand/lipofectamine/lipofectamine-stem-transfection-reagent.html, 
May 16, 2020 
27 https://www.fpbase.org/protein/egfp/, May 16, 2020 
28https://www.addgene.org/crispr/zhang/faq/?gclid=Cj0KCQjwhtT1BRCiARIsAGlY51K0IZOZg2ywnBeaudJsDZdSeAN8Qm0jKveeUf
m6YrLGoWNa5mM4-0EaAsi6EALw_wcB, May 14, 2020 
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5’ and 3’ of the cassette have to be designed. This so-called double-cut donor template does not contain 
homologous sequences and reporter knock-in will be achieved by NHEJ alone. Co-transfection of the 
Cas9, a gRNA targeting the 3’ UTR of the SMARCB1 gene, and sg-A will lead to cleavage of the 
genome and the generation of an IRES-reporter fragment, which will be integrated into the genome 
at the Cas9 cleavage site via conventional NHEJ. Alternatively, a repair donor containing a 
5’ homology arm (left homology arm) containing the same gRNA target sequence as the genome and 
a standard 3’ homology arm (right homology arm) should be designed to facilitate reporter knock-in 
via the combination of NHEJ due to Cas9 cleavage in the 5’ homology arm and HDR by homologous 
sequences of the 3’ homology arm. In both scenarios, knock-in frequencies are expected to be 
considerably higher compared to a classical HDR approach. This NHEJ-mediated knock-in strategy 
was reported to show low off-target integration even though the NHEJ-based repair may facilitate off-
target reporter integration at higher rates compared to the homology-dependent HDR mechanism. 
Establishment of this method for the knock-in of reporter cassettes will also be beneficial for the 
generation of other hiPSC reporter lines, especially when the reporter cassette is to be integrated 
adjacent to silenced genes (He, Tan et al. 2016). 
Zhang, Li et al. (2017) reported a similar knock-in method to He, Tan et al. (2016). They achieved high 
rates of precise editing in hiPSCs using a double cut donor with 600 bp homology arms flanking the 
up to 2 kb insert at two genomic loci. In this study, the double cut HDR donor showed a 2.5-fold 
increase in editing efficiency compared to a circular HDR donor with the same length of homology 
arms. The design of the double cut HDR donor in Zhang, Li et al. (2017) requires the addition of the 
gRNA target sequence including the PAM site that is used to target the genome 3’ and 5’ of the left 
and right homology arm, respectively. Thereby, the Cas9/gRNA complex targeting the genomic locus 
also cleaves the HL-insert-HR cassette from its plasmid backbone facilitating precise insertion possibly 
by the non-canonical HDR pathway of single strand annealing (SSA) (Zhang, Li et al. 2017). 
Further enhancement of successful insertion of e.g. reporter cassettes can be achieved by applying the 
β3-adrenergic receptor agonist L755507 or brefeldin A which inhibits the intracellular protein 
transport from the endoplasmic reticulum to the Golgi apparatus. Both components have been 
reported to enhance the insertion of a GFP reporter gene via homologous directed repair in 
CRISPR/Cas9-mediated genome engineering approaches (Yu, Liu et al. 2015). Zhang, Li et al. (2017) 
report an increase of editing efficiency of 80% in hiPSCs when boosting the insert integration by 
adding the cell-cycle synchronising agent nocodazole in combination with CCND1 (cyclin D1). Both 
components increase the number of cells in S/G2/M phases when HDR is efficient while 
simultaneously decreasing the number of cells in G0/G1 phase when only NHEJ is responsible for 
DSB repair (Zhang, Li et al. 2017).  
Combining both, the Cas9 delivery optimisation and the design optimisation of the HDR constructs 
should increase the cell survival, the number of cells transfected with both the CRISPR/Cas9 plasmid 
and the HDR construct, and therefore the chance of generating genome-engineered hiPSCs. 
Additionally, and independent of the HDR construct strategy, enhancement of repair pathways 
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supporting the integration of the insert by supplementation of small molecules or other agents should 
be implemented. 
 
4.1.2. Transfer of large constructs into MCF10A cells 
Aside from the designed AT/RT and CSS cell models based on hiPSC#33, the generated 
CRISPR/Cas9 plasmids were also to be used for the generation of genetically modified MCF10 cells 
with reporter genes co-expressed with the SMARCB1 gene. This MCF10A cell system was pursued 
for two reasons: to allow the analysis of SMARCB1 gene expression changes associated with different 
mutations of the SMARCB1 gene which are found in the context of different diseases, and to determine 
if cellular mechanisms exist that control the expression of the SMARCB1 gene as this could explain 
the different disease-associated cell fates upon different SMARCB1 mutations in a near-diploid cell line 
(Marella, Malyavantham et al. 2009). To address these two issues, both alleles of the SMARCB1 gene 
were to be engineered so that a co-expression with either eGFP and mKate2 fluorescence genes occurs. 
The co-expression of the reporters should enable the indirect assessment of the expression of the linked 
SMARCB1 allele and thus allow to examine differences in expression level of each allele upon specific 
changes in the gene’s genomic sequence. Upon mono-allelic inactivation of the Smarcb1 gene in mice, 
the transcript levels of Smarcb1 have been reported to remain at nearly equivalent levels compared to 
Smarcb1 wildtype tissues due to a positive and negative regulation of the Smarcb1 promoter by the 
amount of protein present (Guidi, Veal et al. 2004).  Inversion of exon 1 of the Smarcb1 gene leading 
to a CSS-associated phenotype in mice resulted in a reduction of Smarcb1 mRNA levels by 30% 
compared to control animals. These results indicate a partial loss-of-function of the Smarcb1 protein 
upon inversion of exon 1 which does not sufficiently trigger the compensatory mechanisms to restore 
Smarcb1 transcript levels equivalent to the control group (Filatova, Rey et al. 2019). In 
Smarcb1+/inv NesCre+/- mice the CSS-associated phenotype of brain abnormalities was assigned to the 
partial loss-of-function of the resulting protein. The analyses of different cell lines with the CSS-
associated SMARCB1+/1091_1093del AGA genotype by Valencia, Collings et al. (2019) confirmed that 
the de-regulation of various developmental processes and the resulting cell morphology cause a loss 
of interaction between the SMARCB1 protein with the acidic patch of the nucleosome. This results in 
an impairment of the chromatin remodelling activity of the BAF complexes (Valencia, Collings et al. 
2019, He, Wu et al. 2020). Using MCF10A cells engineered according to the two-colour system 
designed in this thesis, a detailed analysis of the transcription rate of each allele of SMARCB1 would 
be possible. By the introduction of different disease-associated SMARCB1 mutations in conjunction 
with this two-colour reporter system, direct detection and assessment of the transcription driven from 
both alleles, the wildtype and affected SMARCB1 allele, would be possible. Understanding the 
consequences of different SMARCB1 mutations on the transcript levels of mutant alleles may 
contribute to better understand why some of the heterozygous mutations predispose to tumours, while 
others result in CSS (section 4.1).  
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The proposed selectable fluorescence reporter insertions downstream of the native stop codon of the 
SMARCB1 gene, also in combination with the CSS-associated missense mutation c.1091_1093del AGA 
in exon 8 or the AT/RT-associated nonsense mutation c.1148del C in exon 9 of the gene, were 
successfully tested in HEK293T cells (Biegel 2006, Kordes, Gesk et al. 2010, Diets, Prescott et al. 
2019). Genome engineering of the SMARCB1 gene in MCF10A cells was more challenging compared 
to HEK293T cells and also than anticipated. The transfer of DNA proved to be similarly inefficient as 
for hiPSC#33. Despite several optimisation efforts regarding the transfection of the MCF10A cells, 
successfully engineered cells could not be obtained. The use of IDLVs to transfer the Cas9 and gRNA 
expression cassette as well as the HDR template as suggested for hiPSCs (section 4.1.1) should be 
considered.  
Engineering of HEK293T and MCF10A cells to co-express a mTagBFP2 reporter gene directly 
upstream of the native start codon of the SMARCB1 gene, also in combination with alteration of the 
genomic sequence exon 1 of the gene to contain mutations associated with RTPS1, was to be achieved 
(Eaton, Tooke et al. 2011). Insertion of the upstream PuroR-mTagBFP2 reporter cassette was more 
challenging compared to the insertion of the reporter cassette downstream of the native stop codon of 
the SMARCB1 gene since the left homology arm necessary for homologous directed repair had to 
contain native SMARCB1 promoter sequences. These sequences resulted in expression of the reporter 
genes directly from the HDR plasmid, even before directed insertion into the genome. Therefore, the 
addition of a selectable marker was strongly required. A prolonged puromycin selection period was 
applied to ensure the enrichment of cells which had incorporated the reporter cassette at its correct 
site and all transfected plasmid DNA was lost. This was applied at the expense of an increased 
possibility of random integration. However, random integration of the reporter at sites with low 
homology to the 3’ and 5’ homology arm sequences of the HDR construct is a very rare event. Due to 
the HDR design, random integration will most probably lead to an out of frame insertion of the 2A 
linked reporter cassette and thus a shift of the open reading frame preventing expression of functional 
fluorescent proteins. When keeping the wildtype sequence of exon 1 of the SMARCB1 gene, this 
approach was successful. The single-cut HDR constructs as discussed above (section 4.1.1) may help 
solve the issue of pre-integration expression of the reporter and resistance genes. With this HDR 
construct, the upstream junction of genomic DNA and HDR construct would be achieved by NHEJ 
and does not require a 5’ left homology arm, thus removing the native SMARCB1 promoter sequences 
from the original HDR construct and diminishing expression of the reporter and resistance gene prior 
to integration (He, Tan et al. 2016). 
Upon insertion of either the c.20_43delins T or the c.93G>C mutation into exon 1 of the SMARCB1 
gene which are both associated with the RTPS1 (Eaton, Tooke et al. 2011), the expression of 
SMARCB1 and the inserted reporter gene from the mutated allele should be lost. In case of 
c.20_43delins T, expression of the fluorescence reporter would be lost due to a frameshift resulting in 
pre-mature stop codons. When mutating c.93G>C, the splice site at the start of intron 1 is affected 
causing loss of the mutant transcript either by alteration of splicing or enhanced decay of the mRNA 
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(Bacci, Sestini et al. 2010). Enrichment of successfully engineered cells would not be possible since 
there would be no directly visible indicator to discriminate wildtype from engineered cells. To solve 
this issue, cells engineered to homozygously express the wildtype form of SMARCB1 linked to the 
reporter, thus expressing mTagBFP2 should be used as starting material to introduce the RTPS1-
associated mutations c.20_43delins T and c.93G>C in exon 1 of the SMARCB1 gene via single-stranded 
oligonucleotide HDR templates in a second round of CRISPR/Cas9-mediated genome engineering. 
The use of single-stranded oligonucleotides (ssODN) as repair templates has been reported to be 
highly efficient in the genome editing of small indels and small insertions of up to 100 bp in length, 
which is sufficient for the insertion of the RTPS1 associated mutations c.20_43delins T and c.93G>C 
into the SMARCB1 gene (Renaud, Boix et al. 2016, Xu, Gao et al. 2018). Successfully engineered cells 
could be identified by weakening or loss of mTagBFP2 expression and therefore be enriched by FACS. 
Genotyping of the cells would verify if the mutation was introduced hetero- or homozygously. 
Alternatively, a first model co-expressing each SMARCB1 allele with one fluorescence gene 
(e.g. mTagBFP2 and mKate2) could be used. With the resulting MCF10A cells expressing 
mTagBFP2 and SMARCB1 in a wildtype or mutated genetic background, the differences in expression 
from each allele could be determined.  
  
 
4 Discussion       100 
4.2. The designed multi-colour strategies for the CRISPR/Cas9-mediated genome 
engineering in comparison to other cellular modelling approaches at the SMARCB1 
locus 
In principle, targeted CRISPR/Cas9-mediated indel mutation of the SMARCB1 gene is possible as was 
shown by Terada, Jo et al. (2019) and Valencia, Collings et al. (2019). The genome engineering 
strategies applied in these publications are discussed and compared to the proposed multi-colour 
strategy in the following. 
 
4.2.1. The designed three-colour reporter strategy in comparison to another cellular 
AT/RT model  
Terada, Jo et al. (2019) generated hiPSC models with a complete loss of SMARCB1 gene expression 
by disrupting the gene in exon 5 resulting in absence of the SMARCB1 protein. However, they 
disrupted the SMARCB1 gene by random indels in exon 5 arising from NHEJ-mediated DSB repair 
upon Cas9 cleavage (Terada, Jo et al. 2019). Thus, the approach chosen by Terada, Jo et al. (2019) is 
considerably less complex compared to the designed three-colour reporter strategy with HDR 
constructs for the insertion of promoterless reporter cassettes of >1 kb size, since no HDR constructs 
were necessary for the introduction of random indels in exon 5 of the SMARCB1 gene. The SMARCB1 
knock-out hiPSC-model of Terada, Jo et al. (2019) revealed that tumours arising from hiPSCSMARCB1-
/-;TP53-/-, hiPSCSMARCB1- /-, and SMARCB1-deficient neural progenitor-like cells with forced 
overexpression of reprogramming factors (OSKM-NPLCSMARCB1-/-;TP53-/-) show the same histology 
and gene expression signature as aggressive rhabdoid tumours of the brain. This was not the case for 
tumours arising from NPLCSMARCB1-/-;TP53-/-. Thus, the results and the identification of the ESC-
like gene expression signature in the hiPSCSMARCB1-/-;TP53-/--derived tumours but not the 
NPLCSMARCB1- /- ;TP53-/- tumours further defined the most likely cell type of origin responsible for 
the growth of AT/RTs in children to be a neural progenitor or neural stem cell with an ESC-like gene 
expression profile, e.g. induced by overexpression of c-MYC (Wong, Liu et al. 2008, Johann, Erkek et 
al. 2016, Poli, Fagnocchi et al. 2018, Terada, Jo et al. 2019, Vladoiu, El-Hamamy et al. 2019). Based on 
these results, a pluripotent cell, which is more immature than a neural progenitor cell, is hypothesised 
to be the cell of origin of AT/RTs. This differs from results of mouse models which indicated that 
neural progenitor cells which lost the Smarcb1 protein to represent the origin of AT/RT-like tumours 
(Bouffard, Sandberg et al. 2004, Deisch, Raisanen et al. 2011, Ng, Martinez et al. 2015, Han, Richer et 
al. 2016). Even though there is a hiPSC line with AT/RT-associated loss of SMARCB1 available, the 
hiPSC model designed here is supplementary or even superior to it in many aspects. In the in vitro 
model generated by Terada, Jo et al. (2019), both alleles of the SMARCB1 gene are disrupted in hiPSC, 
the earliest developmental stage in vitro. This allows analyses of the AT/RT development in vitro, but 
may not mimic the situation in vivo as neural stem cell pools are depleted in the developing brain by 
differentiation. The constitutional loss of both SMARCB1 alleles and thus the complete loss of the 
SMARCB1 protein in hiPSC may also lead to different cellular consequences (i.e. gene expression 
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patterns and epigenetic alterations) than a sequential or simultaneous loss of function of the two 
SMARCB1 alleles in NSCs/NPCs. In the hiPSC model designed in this thesis, the generation of 
homozygous and, most importantly, heterozygous deletion of the SMARCB1 gene is facilitated. This 
allows the study of early stages of tumour development as well as of states of tumour predisposition. 
When evaluating the hypotheses based on the results obtained with SMARCB1-/- hiPSCs by Terada, 
Jo et al. (2019), which exhibit a seemingly normal differentiation behaviour, it has to be taken into 
consideration, that SMARCB1 gene expression was reported to be indispensable for self-renewal and 
neuronal differentiation in hESCs (Langer, Ward et al. 2019), which appears to be different for the 
SMARCB1-/- hiPSCs. 
Also, the genetic status seen in most patients suffering from an AT/RT differs from the homozygous 
disruption of the gene in exon 5 as established by Terada, Jo et al. (2019). Many AT/RT cases show 
large deletions at Chr.22q11 often comprising the complete coding sequence of the SMARCB1 gene 
or single base deletions in exon 5 or 9 of the SMARCB1 gene (Figure 3) (Versteege, Sevenet et al. 
1998, Biegel, Zhou et al. 1999, Rousseau-Merck, Versteege et al. 1999, Biegel, Fogelgren et al. 2000, 
Biegel, Kalpana et al. 2002, Biegel 2006, Jackson, Sievert et al. 2009, Bourdeaut, Lequin et al. 2011, 
Fruhwald, Hasselblatt et al. 2019). Moreover, the established SMARCB1-/- hiPSC model does not 
reproduce the genetic situation observed in patients with heterozygous germline mutations in the 
SMARCB1 gene. These patients are prone to develop rhabdoid tumours of the brain, kidney, or soft 
tissues due to a second hit affecting the intact allele of the SMARCB1 gene thus causing complete loss 
of gene expression of SMARCB1 (Sevenet, Sheridan et al. 1999, Sredni and Tomita 2015). In patients 
affected by the rhabdoid tumour predisposition syndrome 1 (RTPS1), therapeutic options for AT/RTs 
may exhibit negative effects also on all cells affected by the germline mutation of the SMARCB1 gene, 
a situation which necessitates a careful consideration. For future therapy options it is also of utmost 
importance to model the tumours’ different genetic background present in patients to possibly re-
construct the three molecular subgroups of AT/RTs identified in patients which are associated with 
different prognoses and to rule out possible negative effects of the future treatment or drug.  (Torchia, 
Picard et al. 2015, Johann, Erkek et al. 2016, Fruhwald, Hasselblatt et al. 2019, Ho, Johann et al. 2020) 
Most patients suffering from AT/RTs are young children or infants, who are highly susceptible for 
complications related with aggressive therapies as chemotherapy or radiation (Rorke, Packer et al. 
1996, Burger, Yu et al. 1998, Biegel, Zhou et al. 1999, Hilden, Meerbaum et al. 2004). Using the diverse 
models designed here, tumours arising from cells with inactivation of the SMARCB1 gene at very 
specific developmental stages or in a specific genetic background allow the analysis of cellular 
mechanisms to cope with the loss of this essential gene. Furthermore, the tumours could be evaluated 
for differences in their gene expression signature, aggressiveness, and susceptibility to different 
therapy options, thus being able to reflect the heterogeneity in tumour details seen in AT/RT patients 
(Birks, Donson et al. 2011, Torchia, Picard et al. 2015, Johann, Erkek et al. 2016, Vitte, Gao et al. 
2017). Also, the testing of a therapy that effectively eliminates tumour cells with biallelic SMARCB1 
loss-of-function which does not affect all other cells in the body of RTPS1 patients carrying 
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heterozygous germline SMARCB1 mutations would be possible with the cellular systems proposed in 
this thesis. The designed cellular tumour models may also play an important role in identifying new 
potential therapeutic targets or establishing already hypothesised ones in AT/RT cells (Wang, 
Haswell et al. 2014, Terada, Jo et al. 2019). With these rhabdoid tumour models one might also be able 
to assess if the previously reported proteasome stress, overexpression of MEK/MELK, and EZH2 
found in AT/RT cells may be exploited by inhibitors of these components or systems in combination 
with e.g. low dose radiation which may provide a promising but less collaterally damaging therapy 
option for the treatment of infants and young children suffering from AT/RTs with and without 
RTPS1 (Wilson, Wang et al. 2010, Hertwig, Meyer et al. 2012, Wei, Goldfarb et al. 2014, Moreno and 
Kerl 2016, Meel, Guillen Navarro et al. 2020). 
 
4.2.2. The designed two-colour strategy in comparison to another cellular CSS model 
A two-colour hiPSC model with SMARCB1 gene mutations associated with CSS has the following 
advantages over the model published by Valencia, Collings et al. (2019): co-expression of two different 
fluorescence reporter genes with a wildtype and a mutant SMARCB1 allele allows an immediate and 
simple assessment of gene expression from these two alleles. The functional effect of the deletion of 
lysine residue 364 resulting from the c.1091_1093del AGA missense mutation in exon 8 of SMARCB1 
was analysed in Valencia, Collings et al. (2019) by synthesis of the mutant protein in HEK293T cells 
and CRISPR/Cas9-mediated genome engineering of hiPSC to heterozygously delete bases 1091 to 
1093 of the SMARCB1 gene via single oligonucleotides as HDR templates. Frequent mutations of the 
SMARCB1 gene associated with CSS are located in the highly conserved coiled-coil C-terminal domain 
(CTD) of the protein (Morozov, Yung et al. 1998, Diets, Prescott et al. 2019). The SMARCB1 CTD 
was shown to be an α-helical domain containing a dense region of basic, positively charged amino acids 
which binds to the nucleosomal acidic patch facilitating nucleosome remodelling and DNA accessibility 
(Valencia, Collings et al. 2019, Han, Reyes et al. 2020, He, Wu et al. 2020). Upon a CSS-associated 
single residue missense mutation as c.1091_1093del AGA, the α-helical organization is shifted and 
acidic residues within the CTD are repositioned to face the same direction as the basic cluster (Diets, 
Prescott et al. 2019). This shift decreases the charge potential of the positively charged cluster and 
diminishes its interaction with the nucleosomal acidic patch (Valencia, Collings et al. 2019). Analysis 
of hiPSCSMARCB1+/1091_1093del AGA revealed no difference of genome-wide BAF complex targeting 
and activating H3K27ac nucleosome marks to control hiPSC with wildtype SMARCB1 protein. 25% 
of the occupied sites presented decreased DNA accessibility, especially gene loci encoding for 
pluripotency factors with OCT, SOX, or NANOG motifs, underlining the importance of the BAF 
complex mediated chromatin remodeling for the maintenance of pluripotency (Singhal, Graumann et 
al. 2010, Langer, Ward et al. 2019). Upon Ngn2-induced neuronal differentiation of 
hiPSCSMARCB1+/1091_1093del AGA, the reduced DNA accessibility at loci associated with CSS or other 
ID syndromes manifested and developmental processes of organ systems affected in CSS or ID (i.e. 
nervous system, cardiac muscle, kidney, mesenchyme, endocrine system, cell fate commitment) were 
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identified to be impaired (Valencia, Collings et al. 2019). Morphologically, neurons differentiated from 
hiPSCSMARCB1+/1091_1093del AGA showed diminished neurite outgrowth and neuron count as well as 
fewer neuronal projections recapitulating deficits observed in patient-derived cellular models of 
developmental delay (Valencia, Collings et al. 2019) and this possibly relates to phenotypic changes 
observed in the CSS mouse model described by Filatova, Rey et al. (2019). 
The molecular mechanisms responsible for the phenotypic outcome of the inversion of exon 1 of the 
Smarcb1 gene in the mouse model published by Filatova, Rey et al. (2019) are not fully understood yet. 
The inversion of exon 1 of the Smarcb1 coding sequence likely leads to an absence of this transcript, as 
reduced transcript levels were observed when applying primers binding in exons further downstream 
of exon 1. The reduction in transcript abundance may have a similar effect on the generation of DNA 
accessibility at loci essential for nervous system development as the c.1091_1093del AGA missense 
mutation in the C-terminal α-helix of the SMARCB1 gene accounting for the observed de-regulation 
of gene expression in the affected RGCs leading to the characteristic thin corpus callosum and 
hyperplastic choroid plexus as well as microcephaly in the CSS mouse model and CSS patients 
(Filatova, Rey et al. 2019). 
Combining all the aspects and variants of the cell models designed in this thesis, a detailed 
representation of the genetic background observed in patients with RTPS1, CSS, and de novo loss of 
SMARCB1 gene expression could be achieved. By this, a direct and informative comparison of the 
effect of each mutation on the expression of both SMARCB1 alleles would be possible. The comparison 
of the anticipated hiPSC line carrying the CSS-associated SMARCB1 mutation c.1091_1093del AGA 
with an additional hiPSC line carrying an inversion of exon 1 of the SMARCB1 gene in long term 
differentiation studies will reveal the differences and similarities of affected developmental processes 
and could help to further understand the role of SMARCB1 protein in maintaining the structural and 
functional integrity of the BAF complex. 
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4.3. Loss-of-function mutations in SMARCB1 de-regulate expression of Hes genes  
The RT-qPCR analysis of Hes gene expression levels in mouse brain tissue and HEK293T samples 
was based on results obtained with the established CSS-mouse model (Filatova, Rey et al. 2019). A 
diminished radial glial cell (RGC) population in Smarcb1+/inv NesCre+/- mutant mice observed by 
Filatova, Rey et al. (2019) can have different causes. One may be the premature differentiation of RGCs, 
resulting in depletion of the neural progenitor (NPC) pool. Others could include cell death or decreased 
expansion of the NPCs. Many genes and pathways are involved in the regulation of the maintenance 
and expansion of the NPC pool and the gene expression of some possible pathways was explored in 
mouse brain samples (data not disclosed). Mutant mouse models of these genes show similarities to 
the established CSS-recapitulating mouse model, e.g. regarding the diminished neurosphere (NSP) 
forming ability of cells isolated from Smarcb1+/inv NesCre+/- mutant mice and the microcephaly 
observed in the CSS-recapitulating mouse model as well as in CSS patients (Coffin and Siris 1970, 
Filatova, Rey et al. 2019) but de-regulation of genes involved in these pathways could not be observed 
in RT-qPCR analyses of mouse brain tissue. A reduction of Hes5 transcript levels was found in brain 
sections of mutant Smarcb1+/inv NesCre+/- mice in the area of the glial wedge RGC population lining 
the lateral ventricle compared to Smarcb1+/inv NesCre-/- control mice at E15.5 (Filatova, Rey et al. 
2019). This reduction in Hes5 gene expression explains certain midline alterations in these animals. 
Reduced Hes5 mRNA levels were also seen in RT-qPCR analyses of one litter of E14.5 mouse forebrain 
samples, when normalizing the cT values to the expression of the Nestin gene, which is expressed in 
RGCs. Reduced expression of Hes5 in the RGCs in the glial wedge region lining at the ventricular 
surface might contribute to premature loss of RGC identity, and thus reduced cell numbers in the glial 
wedge guide post region as seen by a reduction in glial fibrillary acidic protein (GFAP)-positive cells 
in this area in Smarcb1+/inv NesCre+/- mutant brain sections (Filatova, Rey et al. 2019). The reduction 
in GFAP-positive cells in this guide post region impairs the correct guidance of corpus callosum axons 
resulting in no axons crossing the midline in Smarcb1+/inv NesCre+/- mutant brains (Shu and Richards 
2001, Filatova, Rey et al. 2019). Due to the fact that the area of differential expression of Hes5 is small 
and randomly distributed when sectioning the brain for RNA isolation, it might be explained why this 
trend was not detected for all samples analysed.  
RT-qPCR analysis of Hes1 gene expression revealed an increase of Hes1 mRNA in mutant, compared 
to control mouse brain samples at E14.5. Conversely, overexpression of the Hes1 gene in NSCs was 
reported to repress differentiation and maintain NSC identity, even promoting proliferation of NSCs 
(Kageyama, Ohtsuka et al. 2008). Persistent high expression of the Hes1 gene was observed in non-
neurogenic boundary cells at early developmental stages (Baek, Hatakeyama et al. 2006). Nonetheless, 
the increase of Hes1 transcripts observed in Nestin expressing parts of brain tissue samples has to be 
evaluated carefully regarding its influence on neural development. RNA in situ hybridisations of E15.5 
brain sections did not reveal an increase in Hes1 mRNA levels in mutant compared to control brains. 
Moreover, Nestin is not only expressed in RGCs but also in the developing endothelial cells of brain 
vasculature (Mokry and Nemecek 1998, Mokry and Nemecek 1999, Suzuki, Namiki et al. 2010). Also, 
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Hes1 was reported to be a key transducer of Notch signalling in the developing vasculature of the brain 
(Kitagawa, Hojo et al. 2013).  
Interestingly, HEK293T cells, genetically engineered to express at least one c.1091_1093del AGA 
mutated allele of SMARCB1, show a significant reduction in HES5 mRNA transcripts compared to 
HEK293T cells expressing only wildtype alleles of SMARCB1. The CSS-associated alterations in 
SMARCB1 protein function seem to not trigger any compensatory mechanism to prevent the altered 
protein’s effect on gene expression of HES5, even though one intact allele of the Smarcb1 gene was 
reported to be sufficient to sustain Smarcb1 protein levels in mice (Guidi, Veal et al. 2004). 
To further investigate the role and mechanism of the Hes gene de-regulation in mouse neural 
stem/progenitor cells (NSCs/NPCs) upon CSS-associated inversion of exon 1 of the Smarcb1 gene, an 
in vitro model was to be established. NSCs and NPCs isolated from Smarcb1+/inv NesCre+/- mutant 
mice do not proliferate and cannot be cultured in vitro (Filatova, Rey et al. 2019). For this reason, 
transduction of NSP-forming cells established from Smarcb1+/inv NesCre-/- control mice with 
lentiviral particles transferring a constitutionally expressed Cre recombinase and a Venus reporter 
gene with and without a Hes5 overexpression cassette was established to overcome the shortage of 
mutant NSCs and to test the hypothesis if overexpression of Hes5 can rescue the growth arrest 
observed upon inversion of exon 1 of the Smarcb1 gene in NSP-forming cells. Therefore, the 
transduction of NSPs with lentiviral particles which were concentrated over a 10% sucrose cushion 
was established (Jiang, Hua et al. 2015). Co-transduction of NSPs with VenusCre and Hes5 
overexpression-facilitating lentiviral particles was successful in generating Venus and mKate2 double 
positive NSP-forming cells. However, these NSP-forming cells could not be maintained in culture for 
flow cytometry analysis. Based on these preliminary results, an optimised workflow with flow 
cytometry analysis 48 hours post transduction followed by sphere growth assay analyses is required 
to test if overexpression of the Hes5 gene can rescue the sphere forming ability of Smarcb1+/inv mutant 
NSP-forming cells. This should facilitate comprehensive analyses of the functional effects of the CSS-
associated partial loss of Smarcb1 function in these cells. 
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5. Outlook 
 
Mutations in the tumour suppressor gene SMARCB1 are associated with different disease states and 
types. Biallelic loss of SMARCB1 function due to truncating or nonsense mutations can cause 
malignant tumours of the brain with characteristic histology and a stem cell-like expression profile 
while heterozygous missense mutations or in-frame deletions of the SMARCB1 gene are associated 
with developmental defects (Versteege, Sevenet et al. 1998, Biegel, Tan et al. 2002, Tsurusaki, 
Okamoto et al. 2012). In this thesis, diverse genome engineering constructs were designed, tested, and 
applied with the aim of establishing cellular disease models by introducing SMARCB1 mutations 
present in human patients into human cell lines. With cellular disease models like these, the 
understanding of the biologic consequences of different mutations of the SMARCB1 gene can be 
analysed. This may help to gain a better molecular understanding of the associated disease states and 
types, and could aid in the development of new treatment approaches.  
Especially for patients affected by AT/RTs, sophisticated models recapitulating the molecular 
heterogeneity of these tumours may lead to the identification of specific and potential therapeutic 
targets which could ultimately result in advanced treatment strategies improving the survival rate of 
AT/RT patients while reducing the overall negative consequences of intensive cancer treatment in 
children (Butler and Haser 2006, Ho, Johann et al. 2020). In vitro cell models alone will not suffice to 
develop these therapeutic strategies, but the combination of the cell models with orthotopic xenograft 
transplantation could provide a platform to determine the effect of multimodal treatments on AT/RTs 
of the different subgroups.  
The multi-colour cellular AT/RT model that should allow the controlled homo- and heterozygous 
inactivation of the SMARCB1 gene as proposed in this thesis would also supplement the model 
established by Terada, Jo et al. (2019). Their model only recapitulates a simultaneous biallelic 
inactivation of the SMARCB1 gene by indels in exon 5 while the genetic reality of RTPS1 patients 
with a predisposition for AT/RTs due to a congenital monoallelic inactivation of the SMARCB1 gene 
present in the germline of these patients, cannot be recapitulated. Therefore, also the effect of potential 
AT/RT therapies on cells exhibiting a heterozygous loss of the SMARCB1 gene cannot be analysed 
but may be of importance for treatment decisions. Therapeutic agents which also negatively impact 
cells with a monoallelic loss of SMARCB1 may not be applicable for RTPS1 patients since most to all 
of their bodies’ cells would react to the therapy resulting in a systemic detrimental effect of the 
treatment. This could be analysed pre-clinically with the heterozygous SMARCB1 knock-out model 
proposed here. Additionally, the proposed multi-colour approach of a cellular model for AT/RTs 
facilitates the sequential inactivation of the SMARCB1 gene. Either by the combination of an 
inactivating point mutation of the SMARCB1 gene with a second floxed allele or by controlled, 
sequential inactivation of both floxed alleles by Cre recombinase. For the latter approach, a 
sophisticated approach e.g. with a tamoxifen-inducible Cre recombinase or Cre recombinase under the 
control of promoters of developmentally differentially expressed genes has to be applied. 
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7.1.1. List of oligonucleotides 
Table 46 contains all oligonucleotides and the respective annealing temperatures used for cloning or 
RT-qPCR. The primer numbers refer to the numbers the primers were given in the primer database 
of the Stem Cell and Developmental Biology group at the Technical University of Darmstadt. 
Table 46: List of oligonucleotides used for cloning or RT-qPCR analyses in this thesis. TAnnealing indicated the temperature used 
in the annealing step of PCR. Temperatures linked by “+” indicate the use of a 2-cycle PCR, “or” indicates if more than one 
annealing temperature can be used for PCR. The numbers refer to the identification numbers the primers were given in the 
primer database of the Stem Cell and Developmental Biology group at the Technical University of Darmstadt. 
# NAME SEQUENCE 5’→3’ TANNEALING  
299 CSS us BssSaI Fwd ttttttCACGAGGTACCCCTGGCCCTGTG 56° C 
300 gRNA C3- FWD CACCGATCATTGCGGCGGCAGAGGC - 
301 gRNA C3- REV AAACGCCTCTGCCGCCGCAATGATC - 
302 gRNA C3+ FWD CACCGTGGCGCTGAGCAAGACCTTC - 
303 gRNA C3+ REV AAACGAAGGTCTTGCTCAGCGCCAC - 
305 sgRNA_D1+_Fwr CACCGACGGAGCATCTCAGAAGATT - 
306 sgRNA_D1+_Rev AAACAATCTTCTGAGATGCTCCGTC - 
307 sgRNA_D1/2-_Fwr CACCGTTACCAGGCCGGGGCCGTGT - 
308 sgRNA_D1/2-_Rev AAACACACGGCCCCGGCCTGGTAAC - 
309 sgRNA_D2+_Fwr CACCGCCATCAGCACACGGCTCCCA - 
310 sgRNA_D2+_Rev AAACTGGGAGCCGTGTGCTGATGGC - 
311 sgRNA_D3+_Fwr CACCGTAACCAGCCCATCAGCACA - 
312 sgRNA_D3+_Rev AAACTGTGCTGATGGGCTGGTTAC - 
313 sgRNA_D3-_Fwr CACCGGCAAGACGCCTCATCCGCC - 
314 sgRNA_D3-_Rev AAACGGCGGATGAGGCGTCTTGCC - 
315 Upstream-hArm_Fwr * ttttttTATAAGAGCCTAGGGAGAGCCAAGT 59° C 




tttttCCTCGAGCCAGCCCATCAGCACACG 60° C 
318 Downstream-hArm_Rev CATGTGAATTCTTCATTGCCGAGGTTCCTAC 60° C 
666 
Multiplex CRISPR Step2 
Fwr 
GCCTTTTGCTGGCCTTTTGCTC 61° C 
667 
Multiplex CRISPR step2 
Rev 
CGGGCCATTTACCGTAAGTTATGTAACG 61° C 
668 mTagBFP AvrII Fwr ttttTCCTAGGATGAGCGAGCTGATTAAGGAGA 56 + 72° C 
669 mTagBFP ClaI Rev ttttTATCGATTTAATTAAGCTTGTGCCCCAGT 59 or 56 + 72° C 
743 
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745 













787 DsRed-AvrII-fwd TATTCCTAGGATGGCCTCCTCCGAGG 54° C 
801 dsRedExpress ClaI REV tttttATCGATCTAGAGCGGCCGCTTCAG 54 or 50 + 60° C 
887 
HL PAM mut rev (Ihry, 










889 HR rev (XbaI) TATTTCTAGATTCATTGCCGAGGTTCCTACC 59° C 
890 IRES SalI fwd TATTGTCGACTAACCCCTCTCCCTCC 50 or 58 + 60° C 
891 IRES NcoI rev TATTCCATGGTTGTGGCCATATTATCATCG 58° C 





















980 ClaI GFP::ZeoR FWD tttttATCGATATGGTGAGCAAGGGC 50 + 57° C 































1034 hTBP-fw1 CTTGTGCTCACCCACCAAC 54-58° C 
1035 hTBP-rev2 CTGCTCTGACTTTAGCACCTG 54-58° C 
1062 ClaI mCardinal FWD tttttATCGATATGGTGAGCAAGGGCGAGG 54 + 61° C 
1063 mCardinal NcoI REV ttttCCATGGttcCTTGTACAGCTCGTCC 54 + 61° C 
1064 mCardinal ClaI REV tttttATCGATttaCTTGTACAGCTCGTCCATGCC 58 + 60° C 
1104 ClaI mKate2 fwd tttttATCGATATGGTGAGCGAGCTGATTAAGG 57 + 59° C 
1105 NcoI mKate2 rev ttttCCATGGTCTGTGCCCCAGTTTGCTAG 57 + 59° C 
1106 NcoI mKate2 fwd ttttCCATGGATGGTGAGCGAGCTGATTAAGG 57 + 61° C 
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1107 ClaI mKate2 rev tttttATCGATTCATCTGTGCCCCAGTTTGCTAG 57 + 61° C 
1123 Hes1_fw_e3 TGTGAAGCACCTCCGGAAC 60° C 
1124 Hes1_rev_e4 TCACCTCGTTCATGCACTC 54 or 60° C 
1137 NcoI mKate2 fwd_corr ttttCCATGGTGAGCGAGCTGATTAAGG 60° C 
1139 
hHES1 fwd_4 (Weng et 
al, e2/3) 
TGAAGAAAGATAGCTCGCGGC 54° C 
1205 Hes5 fwd_2 GCCCCAAAGAGAAAAACCGAC 58° C 
1206 Hes5 rev_2 GACGAAGGCTTTGCTGTGCT 58° C 
1207 TagBFP2 ClaI fwd ttttATCGATATGGTGTCTAAGGGCGAAGAG 59° C 
1208 TagBFP2 NcoI rev tttCCATGGATTAAGCTTGTGCCCCA 54 + 60° C 
1268 mHes5 fwd GAGAAAAACCGACTGCGGAAGCC 60° C 
1269 mHes5 rev GGCGAAGGCTTTGCTGTGTTTC 60° C 
1285 IRES PspXI fwd ttttttACtcgagCCCCTCTCCCTCC 50 + 61° C 
1306 Nes fwd_3 GAACAGAGATTGGAAGGCCGC 60° C 
1307 Nes rev_3 CTTCTCCTGCTCCAGGGCTTC 60° C 
1308 mKate2 XbaI rev tttttttCTAGATCATCTGTGCCCCAGTTTGCTAG 50 + 61° C 
1309 ATRT 1148delC SalI rev ttttGTCGACTTACCAGGCCGGGCCGTG 59° C 
1314 E1 c.93GC HR rev CCCGGGCTACgTCGGAGCCGATC 59° C 
1315 E1 c.93GC HR fwd GATCGGCTCCGAcGTAGCCCGGG 59° C 
1381 























1438 PuroR Acc65I rev ttttttGGTACCGGCACCGGGCTTGCGGG 66° C 
1439 TagBFP2 AvrII fwd tttCCTAGGATGGTGTCTAAGGGCGAAG 54 + 60° C 
1440 BSD EcoRI fwd ttttGAATTCATGGCCAAGCCTTTGTC 54 + 56° C 
1441 BSD EcoRI rev ttttGAATTCTAGACCCGGGATAACTTC 54 + 56° C 
1479 p53 NheI fwd tttgctagcATGACTGCCATGGAGGAGTC 50 + 60° C 
1480 p53DD rev GGCAGCGCTCTCTTGAGGCTGATATCCG 50 + 60° C 
1481 p53DD fwd CGGATATCAGCCTCAAGAGAGCGCTGCC 50 + 60° C 
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7.1.2. List of restriction endonucleases 
Table 47 contains the NEB restrictions endonucleases used for cloning in this thesis, including their 
concentration, optimal reaction buffer, reaction temperature, and if applicable inactivation conditions.  
Table 47: Restriction Endonucleases used for cloning in this thesis. Conc., U/mL abbreviates the concentration of the enzyme 













10.000 NEB 3.1 37° C 20 minutes at 65° C 
AgeI-HF 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
AvrII 
 
5.000 CutSmart 37° C - 
BamHI-HF 
 
20.000 CutSmart 37° C - 
BbsI-HF 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
BbvCI 
 
2.000 CutSmart 37° C - 
BsaI-HF 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
BsrGI-HF 
 
20.000 CutSmart 37° C 20 minutes at 80° C 
BssSαI 
 
10.000 CutSmart 37° C - 
BstBI 
 
20.000 CutSmart 65° C - 
ClaI 
 
10.000 CutSmart 37° C 20 minutes at 65° C 
EcoRI-HF 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
EcoRV-HF 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
HindIII-HF 
 
20.000 CutSmart 37° C 20 minutes at 80° C 
NcoI-HF 
 
20.000 CutSmart 37° C 20 minutes at 80° C 
NdeI 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
NheI-HF 
 
20.000 CutSmart 37° C 20 minutes at 80° C 
NotI-HF 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
PacI 
 
10.000 CutSmart 37° C 20 minutes at 65° C 
PciI 
 
10.000 NEB 3.1 37° C 20 minutes at 80° C 
PsiI-v2 
 
10.000 CutSmart 37° C 20 minutes at 65° C 
PspXI 
 
5.000 CutSmart 37° C - 
SalI-HF 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
SmaI 
 
20.000 CutSmart 25° C 20 minutes at 65° C 
XbaI 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
XhoI 
 
20.000 CutSmart 37° C 20 minutes at 65° C 
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7.1.3. Guide RNA positioning within the genomic sequence of SMARCB1 
 
Figure 31: Schematic overview of the positioning of the gRNA pairs selected to target the sequences adjacent to the stop codon 
of the SMARCB1 gene. (A) gRNA and complementary genomic sequences as well as the corresponding protospacer adjacent 
motifs (PAM, black boxes), and Cas9 cleavage site (black arrow heads) are depicted on the genomic sequence of exon 9 and 
the 3’ UTR of the SMARCB1 gene. (B) Indication of the gRNA sequences in the genomic sequence of SMARCB1 and the silent 
point mutations of the PAM sites included in the HDR construct and inserted following CRISPR/Cas9-mediated genome 




Figure 32: Schematic overview of the positioning of the gRNA pair selected to target the sequences adjacent to the start codon 
of the SMARCB1 gene. (A) gRNA and complementary genomic sequences as well as the corresponding protospacer adjacent 
motifs (PAM, black boxes), and Cas9 cleavage site (black arrow heads) are depicted on the genomic sequence of the 5’ UTR 
and exon 1 of the SMARCB1 gene. (B) Indication of the gRNA sequences in the genomic sequence of SMARCB1 and the silent 
point mutations of the PAM sites included in the HDR construct and inserted following CRISPR/Cas9-mediated genome 
engineering of the SMARCB1 gene (red letters) 
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7.1.4. Graphical overview of all constructs generated for the CRISPR/Cas9-mediated 
genome engineering of the human SMARCB1 locus 
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Figure 33: Genealogy of HDR constructs cloned to insert an IRES-fluorescent reporter cassette downstream of exon 9 of the 
SMARCB1 gene. The first intermediate plasmid #227 was generated by combining PCR amplified IRES2 sequence (from 
plasmid #128 using primers #890 and #891) and eGFP::ZeoR-loxP cassette (from plasmid #83 using primers #892 and #893) 
via SalI, NcoI, and HindIII restriction endonuclease recognition sites in plasmid #80. The sequences homologous to the 
genomic DNA sequences up- and downstream of the Stop codon of the SMARCB1 gene were amplified from gDNA of 
hiPSC#33 using primers #315 and #887 (left homology arm), #888 and #889 (right homology arm). Cloning via PsiI and SalI 
(left homology arm) or EcoRI and XbaI (right homology arm) generated the SMARCB1 e9 HDR construct #243. Plasmid #243 
served as the starting point to exchange the reporter cassette for different fluorophores. An IRES-dsRedExpress2 cassette was 
amplified from plasmid #128 (primers #890 and #801) and cloned into #243 via SalI and ClaI restriction endonuclease 
recognition sites resulting in plasmid #254. The IRES-mCardinal cassette was amplified from plasmid #272 (primers #890 and 
#1064) and cloned into #243 via SalI and ClaI. The exchange of eGFP::ZeoR for mKate2 was achieved by PCR amplifying the 
mKate2 sequence from plasmid #311 (primers #1106 and #1107), and cloning it into plasmid #227 to obtain an intermediate. 
The IRES-mKate2 cassette was then cut from the intermediate via SalI and ClaI and cloned into #243 to generate plasmid #318. 
Addition of a blasticidin resistance cassette (BSD) was accomplished by first cloning mKate2 (PCR amplification, primers 
#1105 and #110) and a downstream T2A sequence (oligonucleotides #982 and #983) via NcoI and EcoRI into plasmid #227 
resulting in plasmid #385. Secondly, the BSD-loxP cassette was amplified from plasmid #355 (primers #1440 and #1441) and 
cloned into intermediate #385 via EcoRI and XbaI. Finally, the complete selectable reporter cassette of IRES-mKate2-T2A-
BSD-loxP was cloned into plasmid #318 via SalI and EcoRV/SmaI. The left homology arm covers the sequence of the NCBI 
reference genome NG_009303.1 positions 50,538 to 52,218. The right homology arm covers the sequence of NCBI reference 
genome NG_009303.1 positions 52,219 to 53,787, directly adjacent. 
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Figure 34: Genealogy of the cloning of SMARCB1 e1 HDR constructs with different fluorescence reporter cassettes with and 
without the AT/RT-associated mutations c.20_43delins T or c93G>C in exon 1 of the SMARCB1 gene. For the generation of 
the first intermediate #250, a loxP site (oligonucleotides #978 and #979), the PCR amplified eGFP::ZeoR cassette (from #243, 
primers #980 and #981), and a T2A sequence (oligonucleotides #982 and #983) were cloned into plasmid #80 step by step. 
The right homology arm containing sequences homologous to the DNA sequences downstream of the start codon of SMARCB1 
was PCR amplified from gRNA of hiPSC#33 (primers #987 and #988) and cloned into #250 via EcoRI and PciI restriction 
endonuclease digestion. Due to cloning issues, the left homology arm, homologous to the genomic sequences upstream of the 
start codon of SMARCB1, was PCR amplified from hiPSC#33 gDNA (primers #984 and #985) and cloned into #80 via TA 
cloning. The left homology arm was then transferred to the intermediate already containing the HR via PsiI and PspXI resulting 
in plasmid #273. The eGFP::ZeoR reporter cassette was subsequently exchanged for mCardinal (from plasmid #129, primers 
#1062 and #1063), mKate2 (from plasmid #311, primers #1104 and #1105), or mTagBFP2 (from plasmid #338, primers #1207 
and #1208) via ClaI and NcoI restriction endonuclease digestion resulting in plasmids #278, #316, and #346 respectively. The 
mutated homology arms were PCR amplified from plasmid #346. For c.93G>C HR, the overlap extension method was applied 
(section 2.1.14) using primers #1207 (A), #1314 (B), #1315 (C), and #988 (D). The final PCR product was cloned into plasmid 
#346 via EcoRI and PciI. The c.20_43delins T mutation in exon 1 of SMARCB1 was introduced via PCR from plasmid #346 
using the primers #1207 and #1381. The PCR product was cloned into plasmid #346 via EcoRI and PciI. The left homology 
arm covers the sequence of the NCBI reference genome NG_009303.1 positions 3,737 to 5,207. The right homology arm covers 
the sequence of NCBI reference genome NG_009303.1 positions 5,208 to 6,848, directly adjacent. 
 
7 Appendix       125 
 
Figure 35: Schematic overview of the cloning of the SMARCB1 e1 HDR constructs carrying the Puromycin resistance (PuroR)- 
mTagBFP2 selectable reporter cassette with or without the AT/RT-associated germline mutations c.20_43delins T, or c.93G>C 
in exon 1 of the SMARCB1 gene starting from plasmids #226 and #346. An intermediate was generated by insertion of PCR 
amplified PuroR gene (from plasmid #263, primers #1437, #1438) and a P2A sequence (oligonucleotides #1435, #1436) via 
PsiI, Acc65, and AvrII. Completion of the selectable reporter cassette was achieved by PCR amplification of mTagBFP2 (from 
plasmid #346, primers #1439, #1208) and AvrII/NcoI restriction endonuclease recognition sites. The complete PuroR-P2A-
mTagBFP2 cassette was transferred to plasmid #346 via ClaI and NcoI restriction endonuclease digestion resulting in 
SMARCB1 e1 HDR #380. ClaI EcoRI restriction endonuclease digestion was used to transfer the whole reporter cassette and 
generate the HDR constructs containing the mutated HRs c.20_43delins T ( from #378 from #378) and c.93G>C ( from #379 
from #379). The left homology arm covers the sequence of the NCBI reference genome NG_009303.1 positions 3,737 to 5,207. 
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Figure 36: Schematic overview of the cloning of the gRNA and Cas9 multiplex plasmids which facilitate the co-expression of 
Cas9 and different fluorophores as reporters. The original eGFP::ZeoR reporter cassette on plasmid #120 was exchanged for 
mCardinal from plasmid #126 via AvrII and ClaI/BstBI cloning (plasmid #216). mTagBFP was amplified from plasmid #215 
(primers #668 and #669) and cloned into plasmid #120 via AvrII and ClaI overhangs resulting in gRNA and Cas9 plasmid 
#218. Enhancement of the self-cleavage of the T2A peptide linking the Cas9 and fluorophore open reading frame was achieved 
by exchange of the original T2A sequence for one with a 5’ GSG linker (oligonucleotides #745 and #746) via BbvCI and AvrII 
restriction endonuclease sites. The resulting gRNA and Cas9 plasmids encoding either mCardinal (plasmid #217) or mTagBFP 
(plasmid #219) were used for the finalization with gRNA sequences targeting the tumour suppressor gene SMARCB1. To 
complete the set of reporters to choose from, mTagBFP was exchanged for dsRedExpress (PCR amplification from plasmid 
#128 with oligonucleotides #787 and #801) yielding plasmid #220. 
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Figure 37: Schematic overview of the deletion of the Cas9n open reading frame from gRNA and Cas9n plasmid #221 via AgeI 
and AvrII restriction endonuclease digestion, followed by blunting of the cohesive DNA ends, and blunt-end ligation. Finally 





Figure 38: Schematic overview of the cloning steps to generate the gRNA and Cas9 nuclease plasmids #387, #388, and #408. 
Golden Gate cloning using BbsI was utilised to insert the antisense gRNA of pair D3 targeting the region directly upstream of the 
stop codon of the SMARCB1 gene into Cas9 nuclease plasmids #07 (eGFP::ZeoR reporter) and #03 (PuroR reporter) yielding 
plasmids #387 (eGFP::ZeoR reporter) and #388 (PuroR reporter) respectively. Via AgeI and EcoRV digestion, the sequence of 
Cas9n containing the RuvC domain inactivating mutation D10A (base 26 A to C transversion) in Cas9n plasmid #221 was 
exchanged for the wildtype sequence obtained from plasmid #387. 
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7.1.5. Graphical overview of the cloning of the original lentiviral Hes5-IRES-mKate2 
plasmid for overexpression of Hes5 
 
Figure 39: Schematic overview of the cloning steps leading to the original set of lentiviral Hes5-IRES-mKate2 plasmids for 
overexpression of Hes5. The sequence of Hes5 was amplified from embryonic mouse cDNA and cloned into pENTR (plasmid 
#174) to generate the plasmid #351. PCR amplification of the IRES-mKate2 cassette (from plasmid #318, oligonucleotides 
#1285 and #1308) and cloning into plasmid #351 via XhoI/PspXI and XbaI restriction endonuclease recognition sites resulted 
in the pENTR plasmid #372. Removal of the Hes5 sequence was achieved by BamHI and XhoI cleavage followed by end 
blunting and ligation (plasmid #374). The LR reaction of the gateway cloning then transferred the gene cassette to be expressed 
into pLenti6-UbC (plasmid #160), generating the lentiviral Hes5 plasmid #373 and its corresponding control plasmid #375. 
Abbreviations: UbC = human ubiquitin C promoter, LTR = long terminal repeat 
 
7.1.6. Information of plasmids generated or used in this thesis 
In Table 48 relevant information is given to all plasmids generated or used in this work. For the 
sequences (SnapGene and FASTA format) please refer to the electronic storage device attached to the 
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Table 48: Summary and short description of all plasmids generated or used in this thesis. 
# PLASMID NAME DESCRIPTION 
1 338pMTE-Oz Transposable backbone vector 
3 pSpCas9(Sekeres, Riggs et al.)-2A-Puro (PX459) V2.0 Basic Cas9/gRNA expression vector, Puromycine resistance cassette T2A-linked 
7 V3 (PX459-Cas9(BB)-2A-EGFPZeo) V55L T2A Glu-Asp Basic Cas9/gRNA expression vector, eGFP::ZeoR cassette T2A-linked 
80 pBluescript  II SK (+)  Bluescript backbone, multiple cloning site in lacZ gene 
83 pBS_PuroR_EGFP+ZeoR Basis vector for cloning of plasmid #226 
110 pCl-VSVG Lentiviral VSV-G envelope gene to facilitate generation of lentiviral particles 
111 psPAX2 Lentiviral packaging plasmid 
120 pX330A_D10A-eGFPZeo-1x2 Basic Cas9n/gRNA pair expression vector, eGFP::ZeoR cassette T2A-linked 
128 pCMMP-IRES-dsRedExpress source of dsRedExpress2 sequence 
131 pX330A_D10A-1x2 Basic Cas9n/gRNA pair expression vector from CRISPR/Cas9 Assembly System Kit 
#1000000055, Addgene 
160 pLenti6 UbC empty lentiviral backbone vector for Gateway Cloning 
174 pENTR4 empty donor backbone vector for Gateway Cloning 
215 EpiC BFP-Cs2l GFP source of mTagBFP sequence, kind gift of Rolf Marschalek, Frankfurt am Main 
216 pX330A_D10A-mCardinal-1x2 Basic Cas9n/gRNA pair expression vector, mCardinal reporter T2A-linked 
217 pX330A_D10A-mCardinal-1x2 GSG-T2A Basic Cas9n/gRNA pair expression vector, mCardinal reporter T2A-linked, optimised T2A 
sequence with Gly-Ser-Gly linker 
218 pX330A_D10A-BFP-1x2 Basic Cas9n/gRNA pair expression vector, mTagBFP reporter T2- linked 
219 pX330A_D10A-BFP-1x2 GSG-T2A Basic Cas9n/gRNA pair expression vector, mTagBFP reporter T2A-linked, optimised T2A 
sequence with Gly-Ser-Gly linker 
220 pX330A_D10A-dsRed-1x2 GSG-T2A Basic Cas9n/gRNA pair expression vector, dsRedExpress reporter T2A-linked, optimised 
T2A sequence with Gly-Ser-Gly linker 
221 pX330A_D10A-mTagBFP gRNA pair D1 (SMARCB1 Cas9n gRNA E9 
pair D1) 
Cas9n/gRNA pair D1 expression vector targeting exon 9 of the coding region of the human 
SMARCB1 gene, mTagBFP reporter T2A-linked 
222 pX330A_D10A-mTagBFP gRNA pair D2 (SMARCB1 Cas9n gRNA E9 
pair D2) 
Cas9n/gRNA pair D2 expression vector targeting exon 9 of the coding region of the human 
SMARCB1 gene, MTagBFP reporter T2A-linked 
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223 pX330A_D10A-mTagBFP gRNA pair D3 (SMARCB1 Cas9n gRNA E9 
pair D3) 
Cas9n/gRNA pair D3 expression vector targeting exon 9 of the coding region of the human 
SMARCB1 gene, MTagBFP reporter T2A-linked 
225 pX330A_D10A-dsRedExpress gRNA pair C3 (SMARCB1 Cas9n gRNA 
E1 pair C3) 
Cas9n/gRNA pair C3 expression vector targeting exon 1 of the coding region of the human 
SMARCB1 gene, dsRedExpress reporter T2A-linked 
226 pBS_HL-T2A-eGFPZeoR-loxP-HR (SMARCB1 HDR E9 T2A-
eGFPZeoR-loxP) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
227 pBS_IRES-eGFPZeoR-loxP Basic vector for the cloning of HDR constructs with eGFP::ZeoR reporter insert 
243 pBS_HL-IRES-eGFPZeoR-loxP-HR (SMARCB1 HDR E9 IRES-
eGFPZeoR-loxP 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
253 pBS-HL-IRES-eGFPZeoR-loxP-HR CSS (SMARCB1 HDR E9 CSS 
c.1091-1093delAGA) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene introducing the CSS-associated mutation c.1091-1093delAGA in exon 8 of 
the human SMARCB1 gene 
254 pBS_HL-IRES-dsRedExpress-HR (SMARCB1 HDR E9 IRES-
dsRedExpress) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
255 pBS_HL-IRES-dsRedExpress-loxP-HR (SMARCB1 HDR E9 IRES-
dsRedExpress-loxP) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
256 pX330A_D10A-mTagBFP gRNA pair C3 (SMARCB1 Cas9n gRNA E1 
pair C3) 
Cas9n/gRNA pair C3 expression vector targeting exon 1 of the coding region of the human 
SMARCB1 gene, MTagBFP reporter T2A-linked 
257 pMD2.G VSV-G envelope plasmid 
258 pS-IcKVenus-Cre-WRPE Lentiviral plasmid for expression of the VenusCre fusion gene under control of the human 
SFFV promoter 
272 pBS_HL-IRES-mCardinal-HR (SMARCB1 HDR E9 IRES-mCardinal) HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
273 pBS_E1HL-loxP-GFPZeoR–T2A-E1HR (SMARCB1 HDR E1 loxP-
mCardinal-T2A) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene 
277 pBS_HL-IRES-mCardinal-loxP-HR (SMARCB1 HDR E9 IRES-
mCardinal-loxP) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
278 pBS_E1HL-loxP-mCardinal–T2A-E1HR (SMARCB1 HDR E1 loxP-
mCardinal-T2A) 
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279 pBS_E1HL-mCardinal–T2A-E1HR (SMARCB1 HDR E1 mCardinal-
T2A) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene 
282 pBS_HL-IRES-mCardinal-loxP-HR CSS (SMARCB1 HDR E9 CSS 
IRES-mCardinal-loxP) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
309 pX330A-mTagBFP gRNA C3 SMARCB1 E1 gRNA pair C3 plasmid, gRNA sequences targeting exon 1 of the human SMARCB1 gene, 
mTagBFP reporter T2A-linked 
310 pX330A-mTagBFP SMARCB1 E9 gRNA pair D1 gRNA pair D1 plasmid, gRNA sequences targeting exon 9 of the human SMARCB1 gene, 
mTagBFP reporter T2A-linked 
311 pmKate-Hyg-N1  source of mKate2 sequence, only mKate2 sequenced, kind gift of Johannes Fels, UKE 
Münster 
316 pBS_E1HL-loxP-mKate2-T2A-E1HR (SMARCB1 HDR E1 loxP-
mKate-T2A) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene 
317 pBS_E1HL-mKate2-T2A-E1HR (SMARCB1 HDR E1 mKate-T2A) HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene 
318 pBS_HL-IRES-mKate2-loxP-HR (SMARCB1 E9 HDR IRES-mKate2-
loxP) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
319 pBS_HL-IRES-mKate2-HR (SMARCB1 E9 HDR IRES-mKate2) HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene 
339 pX330A_D10A-mCardinal gRNA pair D1 (SMARCB1 Cas9n gRNA E9 
pair D1) 
Cas9n/gRNA pair D1 expression vector targeting exon 9 of the coding region of the human 
SMARCB1 gene, mCardinal reporter T2A-linked 
340 pS_IcK-Venus Lentiviral expression vector of Venus reporter under control of the human SFFV promoter 
346 pBS_E1HL-loxP-mTagBFP2-T2A-E1HR (SMARCB1 HDR E1 loxP-
mTagBFP2-T2A) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene 
355 EMX2 HDR T2A TagBFP2 Blasticidin source of the blasticidin resistance gene (BSD) sequence 
363 pBS-HL c.1148delC-IRES-eGFPZeoR-loxP-HR (ATRT E9 HDR 
c.1148delC) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene introducing the AT/RT-associated point-mutation c.1148delC 
372 pENTR4_mHes5-IRES-mKate2 Donor vector with Hes5-IRES-mKate2 cassette for Gateway Cloning 
373 pLenti-UbC-mHes5-IRES-mKate2 Lentiviral expression vector of the Hes5-IRES-mKate2 cassette under control of the human 
UbC promoter 
374 pENTR4_IRES-mKate2 Donor vector with IRES-mKate2 cassette for Gateway Cloning 
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375 pLenti-UbC-IRES-mKate2 Lentiviral expression vector of the IRES-mKate2 cassette under control of the human UbC 
promoter 
376 pMAX-GFP plasmid for GFP overexpression, positive control for transfection and electroporation, 
source: Lonza Nucleofector 4D kit 
378 pBS_E1HL-loxP-mTagBFP2-T2A-E1HR c.93G>C (SMARCB1 
AT/RT HDR E1 c.93G>C loxP-mTagBFP2-T2A) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene introducing the AT/RT-associated splice-site mutation c.93G>C 
379 pBS_E1HL-loxP-mTagBFP2-T2A-E1HR c.20_43delins T (SMARCB1 
AT/RT HDR E1 c.20_43delins T loxP-mTagBFP2-T2A) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene introducing the AT/RT-associated indel c.20_43delins T 
380 SMARCB1 E1 HDR loxP-PuroR-P2A-mTagBFP2-T2A HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene, final version 
381 SMARCB1 E1 HDR loxP-PuroR-P2A-mTagBFP2-T2A c.93G>C HDR construct for Cas9-mediated genome engineering upon cleavage in exon 1 of the human 
SMARCB1 gene introducing the AT/RT-associated splice-site mutation c.93G>C, final 
version 
382 SMARCB1 E1 HDR loxP-PuroR-P2A-mTagBFP2-T2A c.20_43delins T HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene introducing the AT/RT-associated indel c.20_43delins T, final version 
383 pBS_PuroR-P2A-eGFPZeoR-SMARCB1 E9HR Cloning intermediate for the final version of the SMARCB1 E1 HDR vectors 
384 pBS_PuroR-P2A-mTagBFP2 PuroR-P2A-mTagBFP cassette in pBluescript 
385 pBS_IRES-mKate2-T2A IRES-mKate2-T2A cassette in pBluescript 
386 SMARCB1 HDR E9 IRES-mKate2-T2A-BSD-loxP HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene, final version 
387 pX549 Cas9 GFPZeoR gRNA SMARCB1 E9 D3 antisense Cas9/gRNA D3 antisense expression vector targeting exon 9 of the human SMARCB1 gene, 
eGFP::ZeoR cassette T2A-linked 
388 pX549 Cas9 PuroR gRNA SMARCB1 E9 D3 antisense Cas9/gRNA D3 antisense expression vector targeting exon 9 of the human SMARCB1 gene, 
PuroR cassette T2A-linked 
406 pS_IcK Hes5-IRES-mKate2 Lentiviral expression vector of the Hes5-IRES-mKate2 cassette under the control of the 
human SFFV promoter 
407 pS_IcK IRES-mKate2 Lentiviral expression vector of the IRES-mKate2 cassette under the control of the human 
SFFV promoter 
408 pX330A Cas9 SMARCB1 E9 gRNA pair D1 Cas9/gRNA pair D1 expression vector targeting exon 9 of the human SMARCB1 gene, 
mTagBFP reporter T2A-linked 
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415 pMTE-p53DD Transposable expression vector of the dominant negative form of murine p53DD under the 
control of the human Ef1α promoter 
422 pBS_CSS HL-IRES-mKate2-T2A-BSD-loxP-HR (SMARCB1 E9 HDR 
CSS mKate2) 
HDR construct for Cas9-mediated genome engineering upon cleavage in exon 9 of the human 
SMARCB1 gene, introducing the CSS-associated mutation c.10911093delAGA in exon 8 of 
the SMARCB1 gene, final version 
438 pCD-NL-BH Lentiviral packaging plasmid 
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7.2. Publications 
Filatova, A., Rey, L.K., Lechler, M.B. et al. Mutations in SMARCB1 and in other Coffin–Siris 




Graduate College 1657 Radiation Biology of the German Research Foundation (Deutsche 
Forschungsgemeinschaft, DFG), April 2017 to May 2020.  
  
 
7.4. Contributions of others 
Elias Sellner cloned of pBS_T2A-eGFP::ZeoR-loxP (plasmid #83), and made a first draft of the design 
of gRNA sequences targeting the genomic region of the SMARCB1 gene’s stop codon before I started 
the project. 
 
Simon Rosowski generated the plasmids SMARCB1 CSS e9 HDR IRES-eGFP::ZeoR (plasmid #253) 
under my direct supervision. 
 
Debashmita Mukherjee helped in the cloning of the murine Hes5 overexpression and control constructs 
(plasmids #406, 407) under my direct supervision. 
 
Ulrike Hoppe removed the Cre recombinase gene sequence from plasmid #258 to generate the Venus 
encoding control plasmid #340 by instructions of Ulrike Nuber. 
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